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Executive summary 
The National Cervical Screening Programme (NCSP) has been highly successful in 
reducing the incidence of and mortality from cervical cancer. From 1991, when the 
NCSP commenced, to 2011, cervical cancer mortality declined from 6.2 to 2.4 per 
100,000 for all women, and from 13.0 to 5.4 per 100,000 for Māori women1. Between 
1996 and 2012, cervical cancer incidence declined from 10.5 to 6.2 per 100,000 for 
women of all ethnicities, and from 25.0 to 12.7 per 100,000 for Māori women (NSU 
2014a). 
 
The many high-quality achievements and initiatives of the NCSP, clinicians and staff 
working within the programme since its inception must be acknowledged. The NCSP is 
among the most successful cervical cancer screening programmes in the world, and 
this achievement would not have been possible without the dedication and commitment 
of many people. This commitment to ensuring New Zealand women have access to a 
high-quality cervical screening programme includes the regular, ongoing monitoring and 
evaluation of the programme’s performance as well as open and transparent reviews 
such as the one delivered with this report. The New Zealand Government and all staff 
working within the programme are to be congratulated. 
 
Highest-priority key issues and recommendations identified by the 
2015 Parliamentary Review Committee 
1. The incidence of and mortality from cervical cancer in Māori women are twice the 
incidence and mortality for women from all ethnicities. This inequity needs to be 
addressed with strategies that will remove barriers to accessing screening 
services. Including an additional measure of socio-economic status in the regular 
reporting on and monitoring of participation would enable a greater understanding 
of the barriers to screening among ethnic groups. 
2. Ongoing audit of the screening histories of women who develop cervical cancer is 
paramount. The underpinning rationale is that there are likely to be valuable 
lessons from these audits that would inform the implementation of quality 
improvement initiatives. 
3. Issues impeding the successful completion of the e-colposcopy project to enable 
electronic uploading of colposcopy data must be resolved as a priority. This must 
include working with providers who are responsible for uploading colposcopy 
reports to ensure the colposcopy forms are user-friendly and able to be 
transmitted in a timely manner. A comprehensive national intervention to resolve 
the barriers to the successful completion of the e-colposcopy project is essential to 
ensure complete data for women referred for colposcopy is captured on the 
National Cervical Screening Programme-Register (NCSP-R). It is recommended 
that an audit across all District Health Boards (DHBs) is undertaken by December 
2015 to ensure colposcopy data is being collected successfully. 
                                            
1
 Data provided by the NSU in 2015 
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4. High-quality screening programmes need to be supported by high-quality 
organisational structures, systems and processes. Continuing change processes 
and loss of corporate knowledge with staff turnovers have had major impacts on 
the organisational systems in the National Screening Unit (NSU) and NCSP. The 
NCSP has been stable for a good part of the past three years but it experienced 
significant change previously, and over recent months has again seen major 
senior management change with the resignation of personnel from the three most 
senior positions impacting the NCSP – the Group Manager, NSU; the Programme 
Manager, NCSP; and the Clinical Leader, NCSP. Particularly important within the 
NSU and the NCSP is the robustness of the clinical leadership structures. It is 
imperative that clinical leadership positions are at the forefront of the National 
Cervical Screening Programme and that these are sustained as its driving force. 
5. Internationally, clinical evidence has shown convincingly that primary human 
papillomavirus (HPV) screening can deliver greater gains in reducing morbidity 
and mortality from cervical cancer, and international cervical screening 
programmes are transitioning to new testing regimes and follow-up protocols. New 
Zealand must give priority to reviewing the evidence and developing 
recommendations to transition to a primary HPV screening protocol that will deliver 
a more effective and efficient programme for the investment. It is recommended 
the Ministry of Health requests the engagement of the National Health Committee 
to support the National Screening Unit in developing the business plan and 
recommendations for the design and implementation of the new model of care for 
cervical screening in New Zealand. This process must be appropriately resourced 
and funded. 
 
All key issues and recommendations identified by the Parliamentary 
Review Committee 2015 
Coverage, participation, equity and access 
A well-conceived, well-managed national cancer control programme lowers cancer 
incidence and mortality and improves the quality of life of cancer patients. Although 
coverage for all women is below the national target of 80%, the NCSP is to be 
congratulated for enabling access to screening for 76.4% of women aged 25–69 years 
over the most recently reported three-year period to December 2013. Participation rates 
in the cervical screening programme compare very favourably with participation rates in 
other developed countries that have organised cervical screening programmes. 
 
There is, however, room for improvement. The incidence of and mortality from cervical 
cancer in Māori women are twice the incidence and mortality for women from all 
ethnicities and this needs to be addressed with strategies that will remove barriers to 
accessing screening services. Although socio-economic status is an important 
determinant of health, the NCSP monitoring and annual reports do not currently capture 
this data. National recruitment strategies are also important and the NCSP should 
centrally coordinate at a national level a full range of health promotion and recruitment 
initiatives. A close and collaborative working relationship with the Māori Monitoring and 
Equity Group will be critical in achieving improved participation rates and reducing the 
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burden of the disease on the Māori population. This collaborative effort will include 
developing health promotion and recruitment strategies and working in partnership with 
the National Kaitiaki Group (NKG) to enable access to data in order to develop and 
appropriately target strategies. Providers need to offer training in cultural competency to 
health practitioners to support access to services by women from different cultural 
backgrounds. 
 
Given the wide variation in early re-screening rates, it is important for the cervical 
screening programme to regularly monitor and review performance on this indicator 
across DHBs to determine whether the variation is due to clinical practice that is not 
conforming with guidelines in those areas with high re-screen rates. The variation in 
timely follow-up outcomes suggests there may be barriers to accessing services, 
particularly for Pacific and Māori women. Timely follow-up after an abnormal test result 
is important. Overcoming barriers will be essential to reduce inequities. 
 
Monitoring and evaluation 
Comprehensive monitoring reports have been produced by the NCSP since 2004. 
These reports are now produced biannually by the University of New South Wales, 
Australia, against a suite of eight groups of monitoring indicators, including coverage, 
first screening events, withdrawal rates, early re-screening, laboratory indicators, follow-
up of women with high-grade cytology and no histology, colposcopy indicators and HPV 
tests. These reports provide ongoing monitoring against the programme’s process 
measures and indicator targets. 
 
Including an additional measure of socio-economic status in the regular reporting and 
monitoring of participation would enable a greater understanding of the barriers to 
screening. In addition, a watching brief on early re-screen rates will be important to 
ensure that early re-screening does not reduce the cost-effectiveness of the programme 
and that it does not limit access for women who are not participating in screening 
regularly. The ability to match data or record women’s HPV vaccination status on the 
NCSP-R is an essential body of work for the programme. 
 
Data on the accuracy of negative cytology reports in the most recent Monitoring Report 
showed a significant variance across laboratories. Close monitoring of this indicator is 
essential. Discussions with pathology experts to determine whether a quality 
intervention is required would be highly appropriate. 
 
The targets for timely follow-up for women with a high-grade cytology report to accepted 
referral and colposcopy visit have not been met. Moreover, the proportional over-
representation of Māori and Pacific women who are not accessing timely follow-up for 
treatment and management of suspicious high-grade abnormalities indicates barriers for 
these women in their ability to access services. Strategies to identify and address these 
issues are essential. 
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Complete data for the timeliness of women accessing colposcopy subsequent to 
persistent low-grade cytology or a low-grade cytology and positive HPV test was not 
available from the NCSP-R for the latest Monitoring Report. The e-colposcopy project 
has experienced interoperability challenges, with the result that the majority of providers 
are unable to upload colposcopy reports. A comprehensive national intervention to 
resolve these information technology issues is essential. 
 
Quality assurance 
The National Screening Unit has produced a draft document, released for consultation 
in December 2014, entitled National Screening Unit Quality Framework 2014: Delivering 
screening programmes (NSU 2014c). The core set of six principles is intended to 
provide a foundation for achieving the NSU’s strategic vision of high-quality, equitable 
and accessible screening programmes. Further, the NCSP Policies and Standards 
document provides agreed policies, guidelines and standards of practice for health 
professionals who provide cervical screening services (Ministry of Health 2014a). The 
NCSP also has well-established advisory group structures, including the Māori 
Monitoring and Equity Group, which can both support and inform the identification of 
issues and development of strategies that will assist in the achievement of its quality 
strategic vision. Engagement of these groups in the quality improvement initiatives for 
the programme will be critical to their success. 
 
Performance monitoring must inform the development and implementation of strategies 
that become part of the continuous quality improvement cycle. Monitoring and 
evaluation and the implementation of quality improvement strategies must be a 
collaborative process between the NCSP, DHBs, laboratories and the NCSP-R so that 
learnings can be shared and strategies implemented consistently across the country. 
Regular, ongoing meetings for monitoring and quality improvement should be scheduled 
shortly after the release of the biannual monitoring reports, and the agenda for these 
meetings should be informed by the monitoring report indicators. The actions and 
outcomes from these meetings would inform the development of, on an ongoing basis, 
a Quality Improvement Plan for the NCSP. 
 
Ongoing audit of the screening histories of women who develop cervical cancer is 
recommended. The underpinning rationale is that there are likely to be valuable lessons 
from these audits that would inform the implementation of quality improvement 
initiatives. It is essential that these audits occur regularly and include expert clinicians 
involved in the programme. Any identified system or process gaps or failures should be 
used to inform quality improvement strategies, and be incorporated into a quality 
improvement plan. 
 
The NCSP would be enhanced by the introduction of the Plan-Do-Check-Act (PDCA) 
cycle, particularly during the NCSP’s consideration of the biannual monitoring reports. It 
would likewise benefit from the implementation of a Quality Improvement Plan that 
informs the ongoing work plan for the programme. 
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Organisational and structural issues 
This Parliamentary Review Committee (PRC) 2015 acknowledges that challenges have 
consistently arisen in terms of organisation and structure. Five essential components 
are critical to the effectiveness of the programme: a central agency to lead and 
coordinate the screening pathway; clinical governance; infrastructure and systems to 
manage a screening programme; monitoring and evaluation; and the quality cycle. Each 
of these components must operate to a high standard for the programme to meet its 
objectives of providing the screening pathway for women in New Zealand. 
 
Currently the single most important issue facing the national screening programme in 
New Zealand is addressing the disparities and inequities that continue to challenge 
participation in the programme by Māori, Pacific and Asian women. 
 
High-quality screening programmes need to be supported by high-quality organisational 
structures, systems and processes. A common element of all programmes is the 
necessity for information systems that meet the specific requirements of screening. 
Within the confines of available resources, systems should be thoughtfully developed to 
be as user-friendly as possible. Continuing changes have had major impacts on the 
organisational systems in the NSU and NCSP, with staff turnovers making change 
necessary for the continuation of the NCSP. The NCSP has been stable for a good part 
of the past three years but it experienced significant change previously, and over recent 
months has again seen major senior management change with the resignation of 
personnel from the three most senior positions impacting the NCSP – the Group 
Manager, NSU; the Programme Manager, NCSP; and the Clinical Leader, NCSP. 
Particularly important within the NSU and the NCSP is the robustness of the clinical 
leadership structures. It is imperative that clinical leadership positions are at the 
forefront of the National Cervical Screening Programme and that these are sustained as 
its driving force. 
 
Within the organisation and structure of the NCSP, there needs to be greater focus on 
supporting equity in access to all elements of the screening pathway. Equity is 
important; in particular, achieving the target for participation by Māori women should be 
a priority, as should achieving the targets for Asian and Pacific women. The 
development of culturally appropriate information for Māori, Asian and Pacific people 
about HPV and screening should be a focus for the programme. 
 
Workforce issues 
The outstanding area of concern for the laboratory science workforce in the near future 
is the impact that HPV screening will have across this sector. 
 
With the changes in cervical screening internationally, the loss of cytology expertise of 
senior scientists and laboratory personnel has been a major challenge in the transition 
to primary HPV screening. There needs to be a planned approach to support 
cytologists, pathologists and laboratory scientists in order to sustain the programme 
until any changes in the screening regime are implemented. Change management 
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strategies, including education and re-training, will be critical in ensuring the workforce 
can be maintained until any transition occurs. 
 
Cultural competency is also important. The Foundation Course in Cultural Competency 
provides support to practitioners to build their understanding of cultural competency and 
health literacy in New Zealand, with a focus on improving Māori health outcomes. As 
the general Māori population increases, so too will the demand for a workforce that is 
sensitive to the needs of the Māori population. 
 
NCSP-Register 
The National Cervical Screening Programme-Register (NCSP-R) is the national 
database that stores screening and diagnostic test results for women who are enrolled 
in the NCSP. Having the ability to populate the NCSP-R with population-level data and 
issue invitations to all eligible women to screen would enable proactive approaches to 
unscreened and under-screened women. The current invitation process is dependent 
on general practice databases having a complete record of all women in their regions. 
 
The majority of issues with electronic transfer of colposcopy reports to the NCSP-R 
appear to be due to challenges with the interoperability of the operating systems. Timely 
access to and reporting of colposcopy findings is critical to the outcomes of the NCSP. 
Consistent feedback from screening providers was that the system is unable to match 
local health databases with the NCSP-R data to identify unscreened or under-screened 
women. This was a primary concern for identifying women from ethnic groups who are 
at greatest risk of developing cervical cancer. 
 
The 2011 Parliamentary Review Committee Report identified concerns that colposcopy 
and test results could be inconsistent with those recorded on the Register. The NCSP-R 
audit in 2014 did not include a random audit of coding on the NCSP-R and correlation 
with laboratory and colposcopy records. This quality assurance intervention should be 
considered for future audits. 
 
The issue, action and outcome of complaints, regarding either the NCSP-R or the 
programme as a whole, must have robust follow-up processes. Complaints from 
consumers regarding the screening programme need to be regularly reviewed and 
monitored, and a summary report provided to the NCSP Advisory Group. Reports from 
the NCSP-R to providers are a valuable quality improvement opportunity to enable 
personal performance benchmarking and monitoring. Reporting back to providers on 
their outcome data should form part of the continuous feedback cycle for quality 
improvement, and should be a focus for the NCSP into the future. 
 
Māori women are over-represented in cervical cancer statistics, and under-represented 
in cervical screening participation. The mechanisms for applying to NKG for data appear 
to be an impediment to improving the health outcomes and reducing cervical cancer 
incidence and mortality for Māori women. 
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There are currently no links with the HPV immunisation data. The full benefit of 
immunisation will not be realised for many years, until entire generations of girls and 
women have been vaccinated. However, monitoring of the vaccinated cohort and 
evaluating their screening results will inform any future decisions regarding both the 
vaccination and the screening programmes. 
 
Ethnicity data 
New Zealand holds a unique position in the international health sector arena regarding 
the protection of research information that belongs to its indigenous people. For the 
NCSP, information concerning Māori women’s cervical screening data is deliberately 
and purposefully guarded by legislation, which has enabled the establishment of the 
National Kaitiaki Group. The NKG’s task is to consider applications for the release of 
Māori women’s data from the NCSP-R. 
 
An audit of the NCSP-R confirmed that relationships and governance, quality 
improvement, value for money and IT systems for the Register (and therefore women’s 
data, including that of Māori women) were well managed. The NSU and NCSP continue 
to voice their frustration with both the past relationship with the NKG, and the process 
for obtaining access to Māori women’s data from the Register. 
 
All of the Ministry of Health’s monitoring reports analyse data by ethnic groups, 
including Māori, Pacific, Asian and European/Other. Current analysis from the NCSP-R 
data (at March 2014) recorded ethnicity codes for approximately 98.4% of the 
1.4 million women on the NCSP-R. The NCSP is continuing work to improve the 
accuracy of ethnicity recording on the Register (NSU 2014b). 
 
In New Zealand, ethnicity is an important dimension of health inequities. Māori and 
Pacific people experience lower life expectancy and health disadvantage across most 
mortality and morbidity indicators compared with Europeans, as well as socio-economic 
disadvantage in areas such as housing, education, income and employment. Ethnic 
inequalities between Māori and non-Māori are the most consistent and compelling 
inequities in health and need to be addressed. Planning for primary HPV screening is 
seen as a critical opportunity to improve cervical screening coverage for Māori women. 
 
Independent service providers (ISPs) have found it challenging to identify unscreened 
women in their areas, particularly Māori women, who have a higher cervical cancer rate 
than the other priority groups. Strategies to enable identification of unscreened and 
under-screened women should be investigated in collaboration with general practices 
and ISPs. 
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Colposcopy 
Colposcopy services in New Zealand are contracted to DHBs, where the service is 
usually part of a gynaecological or women’s health service. Colposcopy is also provided 
by gynaecologists working in private practice. 
 
Medical practitioners and nurses wanting to practice colposcopy in New Zealand must 
first have obtained Colposcopy Quality Improvement Program (C-QuIP) certification. 
Colposcopy indicators already collected in the NCSP-R colposcopy data should be 
included in the next C-QuIP accreditation cycle. It is important to analyse and report on 
complete data sets from colposcopy services to promote best practice, emphasising 
safety and quality. 
 
National colposcopy meetings should take place annually to improve networking of 
DHBs and information sharing. 
 
Human papillomavirus and cervical cancer 
The New Zealand Government needs to be confident the New Zealand Cervical 
Screening Programme is delivering maximum benefit for New Zealand women in 
reducing morbidity and mortality attributable to cervical cancer. It needs to be confident 
that the programme’s design and delivery is comparable with international best practice, 
and is effective, cost-effective and efficient in achieving the programme’s objectives and 
in view of the Government’s investment in the initiative. 
 
Clinical evidence has shown convincingly that primary HPV screening can deliver 
greater gains in reducing morbidity and mortality from cervical cancer. Internationally, 
national screening programmes are transitioning to new testing regimes and follow-up 
protocols. New Zealand must give priority to reviewing the evidence and developing 
recommendations to transition to a primary HPV screening protocol that will deliver a 
more effective and efficient programme for the investment. 
 
The assessment and future recommendations must include a strategy for ensuring 
every woman’s HPV vaccination status is captured as part of her screening history. This 
may be achieved through data linkage with the HPV Immunisation Register, or through 
an alternative methodology for direct capture of the woman’s HPV vaccination status on 
the NCSP-R. 
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Summary of recommendations 
Coverage, participation, equity and access 
1. Ongoing strategies are needed to address the disparities among priority groups in 
terms of participation and retention in the programme. Improved follow-up is 
needed after abnormal screening results. 
2. The provision of funding for free smears is a commendable initiative, but the 
amount of funding, and consequently coverage, is limited. There need to be clear 
strategies to ensure that access to free smears is appropriately targeted to the 
women in highest need. To improve coverage for high-priority women, the cost of 
smears must not be a barrier. 
3. Cultural competency is vitally important and ongoing education is needed to 
ensure that smear takers are attuned to cultural sensitivities. ISPs play a vital role 
in supporting local communities and providing access to cervical screening. Any 
changes to funding for cervical screening for ISPs should be carefully evaluated in 
terms of the consequences. DHBs and primary health organisations (PHOs) 
should be supported to work closely with ISPs to facilitate access to screening for 
unscreened and under-screened women. 
4. Ongoing HPV education campaigns are important to increase awareness and 
knowledge among the general population and among health care providers. Such 
campaigns are of particular importance prior to any introduction of primary HPV 
screening. 
5. It is recommended that NCSP and NKG work closely together to facilitate more 
timely and ongoing access to Māori data.2 
6. The NSU and NCSP must continue to work to meet the priorities of the New 
Zealand Cancer Strategy and achieve 80% coverage for all women of all ethnic 
groups. 
 
Monitoring and evaluation 
7. There should be more stringent monitoring of the quality of colposcopy. 
8. Regular reporting and monitoring of participation by a measure of socio-economic 
status should be considered as an additional monitoring indicator to ensure 
equitable access by all disadvantaged groups. 
9. Monitoring Indicator 2 (First screening events) has no monitoring target at this 
time. The NCSP should review whether targets could be implemented for this 
indicator to enable closer monitoring of the distribution of first screening events by 
ethnicity and socio-economic status. 
                                            
2
 See also Chapter 8: NCSP-Register and Chapter 9: Ethnicity data. 
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10. Early re-screen rates vary significantly by DHB. The NCSP should investigate to 
understand whether these are chance anomalies or whether training or 
interventions are required to ensure clinical compliance with NCSP screening 
guidelines. 
11. It will be important for the NCSP to determine if the decline in the proportion of 
samples reported as high-grade squamous intraepithelial lesions (HSIL) for 
women in the age cohorts of < 20 and 20–24 years is consistent with an effect of 
HPV vaccination. The ability to match data or record women’s HPV vaccination 
status on the NCSP-R is an essential body of work for the programme. 
12. There is significant variance across laboratories for Indicator 5.3, which monitors 
the accuracy of negative cytology. Close monitoring of this indicator is essential. It 
would be highly appropriate to review and discuss these findings with pathology 
experts to determine whether a quality intervention is required. 
13. The proportion of women who did not have a follow-up test reported within 90 days 
after a high-grade cytological abnormality varied significantly across DHBs. It also 
varied by ethnicity, with 24.4% of Pacific women and 14.8% of Māori women not 
having a follow-up test within an appropriate timeframe. The NCSP should 
investigate the barriers to attendance that are preventing timely investigations and 
treatment, and develop strategies to improve outcomes for these women. 
14. A comprehensive national intervention to resolve the barriers for the successful 
implementation of the e-colposcopy project is essential to ensure complete data 
for women referred for colposcopy is captured on the Register. 
 
Quality assurance 
15. Regular, ongoing meetings for monitoring and quality improvement should be 
scheduled shortly after the release of each of the biannual monitoring reports. The 
agendas for these meetings should be informed by the monitoring report indicators 
in particular areas where targets have not been achieved. The actions and 
outcomes from the meetings would inform the development of a Quality 
Improvement Plan for the NCSP. 
16. The development of specific Quality Improvement Plans must be a collaborative 
process between the NCSP and the relevant partners in the screening programme 
– DHBs, primary health care providers, laboratories, the Register – so that 
strategies are implemented consistently across the country. 
17. Regular, ongoing audit of the screening histories of all women who develop 
cervical cancer is essential. The knowledge gained from these audits must be 
used to inform quality improvement of the programme. 
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18. Complaints and feedback from consumers of the screening programme received 
by the Health and Disability Commissioner, the Register and the NSU must be 
reviewed regularly and also be used to inform quality improvement strategies. A 
process for the NCSP to review complaints received at the provider level should 
be developed so the NCSP has an understanding of issues for the programme at 
the point of service delivery. 
 
Organisational and structural issues 
19. NCSP must address the variable achievement of the target rate of 80% for Māori, 
Pacific and Asian women by producing Action Plans for each of the priority groups 
that can demonstrate progressive reduction in disparities for each of these groups. 
20. NCSP regional portfolio managers must continue to demonstrate improvements in 
coordination with providers through at least one planned national meeting each 
year and through ongoing, regional face-to-face meetings with local service 
leaders for the cervical screening programme in the regions. 
21. High-quality screening programmes need to be supported by high-quality 
organisational structures, systems and processes. The NCSP has been stable for 
a good part of the past three years but it experienced significant change 
previously, and over recent months has again seen major senior management 
change with the resignation of personnel from the three most senior positions 
impacting the NCSP. 
22. Particularly important within the NSU and the NCSP is the robustness of the 
clinical leadership structures. It is imperative that clinical leadership positions are 
at the forefront of the National Cervical Screening Programme and that these are 
sustained as its driving force. 
23. Information about HPV must be appropriately provided to the NCSP priority 
groups: Māori, Pacific and Asian people. The NCSP must work collaboratively with 
the HPV Immunisation team within the Ministry of Health to ensure consistent and 
supportive messaging for both HPV vaccination and primary screening/testing 
programmes is achieved for these groups. 
 
Workforce issues 
24. In light of momentous changes in cervical screening in other countries, it is likely 
that New Zealand’s NCSP will also move towards primary HPV screening. It is 
therefore advised that a planned process be developed over the next two years 
(2015 to 2017) to support the laboratory workforce to identify pathways and/or 
professional development programmes that assist staff to transition into other 
areas of work and future career pathways. This process will need to be supported 
by a specific communication and consultation plan that is appropriately developed 
with the laboratory workforce. 
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25. The NCSP must ensure online courses are regularly updated and access is 
improved to online training for primary care workers, including practice nurses, 
midwives, registered nurses, enrolled nurses and general practitioners. It is noted 
that District Health Board contracts also require DHBs to provide annual smear-
taker updates. 
26. The NCSP can learn much from the many successful examples of reducing 
disparities across the health sector. This learning must be continually 
demonstrated and supported by actions the NCSP takes to ensure the flexible but 
targeted use of funds in future contracts, such as those for services to support 
screening, and the Very Low Cost Access funds. 
27. The NCSP must ensure, for those District Health Boards that are not achieving the 
target rate of 80% for each of the NCSP’s priority groups, the DHBs have well-
planned programmes to avoid increasing their inequalities.3 
 
NCSP-Register 
28. Strong strategic governance and IT expertise within the Ministry are needed to 
enable informed decisions regarding future HPV screening, data linkage with the 
National Immunisation Register, and the subsequent redesign of the NCSP-R and 
its functions that will be required. 
29. Decisions regarding the future directions of cervical screening must be 
strategically planned. Realistic and achievable timeframes and resourcing are 
needed so that robust registry systems can be developed to support any revised 
screening pathway. 
30. Issues impeding the successful completion of the e-colposcopy project to enable 
electronic uploading of colposcopy data must be resolved as a priority. This must 
include working with providers who are responsible for uploading colposcopy 
reports to ensure the colposcopy forms are user-friendly and able to be 
transmitted in a timely manner. A comprehensive national intervention to resolve 
the barriers to the successful completion of the e-colposcopy project is essential to 
ensure complete data for women referred for colposcopy is captured on the 
NCSP-R. It is recommended that an audit across all DHBs is undertaken by 
December 2015 to ensure colposcopy data is successfully being uploaded to the 
NCSP-R. 
31. Achieving the ability to populate the NCSP-R with population data and issue 
invitations to all eligible women to screen should be a strategic priority for the 
NCSP to investigate. 
32. It is noted the NCSP-R audit in 2014 did not include a random audit of coding on 
the NCSP-R and correlation with laboratory records. This quality assurance 
intervention should be considered for future audits. 
                                            
3
 See also Chapter 6: Organisational and structural issues. 
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33. The issue, action and outcome of complaints, regarding either the NCSP-R or the 
programme as a whole, need to be regularly reviewed and monitored, and a 
summary report provided to the NCSP Advisory Group, so that any trends can be 
identified and addressed. 
34. A focus for the NCSP into the future should be reporting back to providers and 
reviewing the data and outcomes, in collaboration with lead clinical providers from 
DHBs, as part of a continuous feedback cycle for quality improvement. 
35. It is strongly recommended the NCSP and NKG work in partnership to identify 
more streamlined processes that minimise the burdens the current processes for 
accessing data place on both parties. 
36. Any future planning for the NCSP-R must include options for linking the HPV 
Immunisation Register data with women’s cervical screening history on the 
NCSP-R, so that a woman’s vaccination status forms part of her cervical screening 
history. 
37. The NCSP must ensure processes are in place to monitor compliance with the 
legislative requirement for all colposcopy clinics, including the private clinics, to 
send their colposcopy data to the NCSP-R. 
 
Ethnicity data 
38. The PRC is encouraged by the progress made between the NCSP and the NKG in 
order to provide timely and accurate reporting information on Māori women. There 
is further room for NCSP and NKG to continue to strive to improve relationships.4 
39. The NSU, NCSP portfolio managers and DHB managers need to collaborate with 
ISPs and PHOs (general practices) regarding data sharing between the agencies 
to identify unscreened women in the regions. It is emphasised that this issue is 
related to reducing disparities for priority women and Māori women in particular. It 
is recommended that, as a result of this collaboration, NCSP and NSU should 
issue clear guidelines on sharing client data between agencies. 
40. NCSP should ensure that DHBs provide Action Plans for each of the priority 
groups. In particular, DHBs should develop an annual Pacific Action Plan and an 
annual Asian Action Plan to address inequities and disparities in cervical 
screening for each of these priority groups.5 
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 See also recommendation 35. 
5
 See also recommendation 19. 
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Colposcopy 
41. There is an urgent need to ensure that colposcopy data in the NCSP-R is 
complete. The NCSP can facilitate this process by making available e-colposcopy 
to all DHB colposcopy clinics.6 
42. The NCSP should ensure that colposcopy data submitted from the private sector 
fully complies with the Health Act 1956.7 
43. Data held on the NCSP-R that is received from colposcopy services should be 
analysed annually to support practitioners in their quality improvement.8 
44. The NCSP and the Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists will need to address the discrepancy between the C-QuIP and 
NCSP colposcopy standards. This recommendation is to ensure New Zealand 
colposcopists accredited by C-QuIP meet the same standards as those required 
by the NCSP. 
 
Human papillomavirus and cervical cancer 
45. New Zealand must give priority to reviewing international evidence and developing 
a process for the introduction and implementation of a revised contemporary best-
practice screening programme that will realise further improvements in reducing 
morbidity and mortality attributable to cervical cancer and its precursors. Evidence 
shows that a screening protocol employing primary HPV screening with partial 
HPV genotyping will result in the greatest reductions in incidence and mortality 
from cervical cancer. 
46. It is recommended the Ministry of Health requests the engagement of the National 
Health Committee to support the National Screening Unit in developing the 
business plan and recommendations for the design and implementation of the new 
model of care for cervical screening in New Zealand. This process must be 
appropriately resourced and funded. 
47. Within the existing programme, the benefits of HPV triage for LSIL cytology should 
be reviewed. 
48. Within current screening guidelines, the use of HPV tests by clinicians should be 
monitored. Feedback from this monitoring should be provided to non-compliant 
clinicians to improve practice. 
49. As per recommendations in Chapter 8: NCSP-Register, to enable monitoring and 
evaluation of the effectiveness and cost-effectiveness of the HPV Immunisation 
Programme, it is necessary to develop strategies to capture and record a woman’s 
                                            
6
 See also recommendation 30. 
7
 See also recommendation 37. 
8
 See also recommendation 34. 
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HPV vaccination status with her screening history, or data linkage with the 
National Immunisation Register.9 
50. In reviewing evidence for a revised screening protocol, consideration should be 
given to screening options that would encourage participation by unscreened and 
under-screened women. Self-sampling has been identified as a strategy to reduce 
inequities and barriers for women at highest risk who are not screening, or not 
screening regularly. 
 
                                            
9
 See also recommendation 36. 
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Chapter 1: 
Introduction and methods 
Overview 
The National Cervical Screening Programme (NCSP) Parliamentary Review Committee 
is a ministerial review committee established under the Health Act 1956, as amended 
by the Health (National Cervical Screening Programme) Amendment Act 2004 
(Part 4A). 
 
According to the Health Amendment Act, the Minister must at least once every three 
years establish a review committee of up to three persons to review: 
 the operation of the National Cervical Screening Programme 
 evaluation activities of the kind described in section 112T of the Act that have been 
carried out, or that are proposed to be carried out.10 
 
According to the legislation, the focus of the Review Committee must be the continuous 
quality improvement of components of the NCSP, with a view to reducing the incidence 
and mortality rates of cervical cancer. 
 
In November 2014, the New Zealand Minister of Health appointed Dr Jeffrey HJ Tan, 
MBBS, MRCOG, FRANZCOG (Australia), Ms Gail Ward, Dip App Sc (Med Rad), Dip 
Prac Mgt, Grad Cert PSM (Australia) and Ms Linda H Thompson, RN, ADN (New 
Zealand) to undertake an independent review of the New Zealand NCSP. The Minister 
requested that the Review Committee present a written report of this review by June 
2015, which the Minister would subsequently present to the New Zealand Legislature 
and would later publish and distribute to interested parties. The Review Committee has 
summarised its findings and recommendations in this report to the Minister of Health. 
 
Table 1.1 briefly describes the role and contributions of members of the Review 
Committee. 
 
                                            
10
 Section 112T: Meaning of evaluate 
(1) For the purposes of this Part, evaluate means to monitor and assess the service delivery and outcomes of 
the NCSP so as to promote the fulfilment of its objectives by determining whether there are any systemic 
issues to address within the programme or quality improvements that may be made to it. 
(2) An evaluation may, from time to time, include a review of, and an investigation into, the cases of – 
(a) any woman who is enrolled in the NCSP (whether or not she has developed any cervical cancer); and 
(b) any woman who has developed any cervical cancer (whether or not she is enrolled in the NCSP); and 
(c) any deceased persons to whom paragraph (a) or paragraph (b) applied at the time of death. 
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Table 1.1: Parliamentary Review Committee responsibilities 
Title Name Key responsibilities and lead areas 
Committee 
Chair 
Dr Jeffrey Tan  Liaise with stakeholders on the project’s scope. 
 Finalise the review scope. 
 Develop the review framework. 
 Identify key informants and other information-gathering requirements. 
 Analyse and document findings and develop recommendations. 
 Take responsibility for the following review areas: colposcopy, HPV 
and cervical cancer, future directions – technology and research. 
Committee 
Member 
Ms Gail Ward  Contribute to the review’s design and implementation. 
 Identify key informants and other information-gathering requirements. 
 Analyse and document findings and develop recommendations. 
 Take responsibility for the following review areas: coverage, 
participation, equity and access, monitoring and evaluation, quality 
assurance, the NCSP-R, HPV primary screening, and future 
directions – screening. 
Committee 
Member 
Ms Linda Thompson  Contribute to the review’s design and implementation. 
 Identify key informants and other information-gathering requirements. 
 Analyse and document findings and develop recommendations. 
 Take responsibility for the following review areas: organisational and 
structural issues, workforce issues, ethnicity data, and future 
directions – management. 
 
Background 
History of cervical screening in New Zealand 
In June 1987, Sylvia Cartwright, an Auckland District Court Judge, was appointed by the 
then Minister of Health Michael Bassett to conduct an inquiry into allegations concerning 
the treatment of cervical cancer at the National Women’s Hospital and other related 
matters. The report of the Committee of Inquiry was released on 5 August 1988 and 
provided a detailed analysis of the evidence presented, as well as the key findings and 
recommendations (Cartwright 1988). One of the key recommendations was to establish 
a National Cervical Screening Programme in New Zealand, and in 1990 the NCSP was 
established in 14 Area Health Boards. 
 
The next major inquiry into cervical screening occurred in May 1999, when the then 
Health Funding Authority began an investigation after concerns were raised about the 
reading of cervical smears by a community laboratory in the Tairawhiti region. Almost 
23,000 cervical cytology slides were re-read by a Sydney laboratory, and significant 
under-reporting of cervical smear abnormalities was found. The then Minister of Health 
immediately announced an inquiry, subsequently known as the Gisborne Cervical 
Screening Inquiry (CSI), would take place (Duffy et al 2001). The committee’s report 
presented 46 recommendations; subsequent reviews put forward 126 recommendations 
for programme improvements (see Table 1.2). More information about key events in the 
history of cervical screening in New Zealand is presented in Appendix A. 
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Table 1.2: Key events in the history of cervical screening in New Zealand 
1988 The Report of the Cervical Cancer Inquiry (Cartwright 1988) is published. It 
recommends the establishment of a National Cervical Screening Programme in New 
Zealand. 
1990 The NCSP is established in 14 Area Health Boards and is accountable to these boards. 
The Department of Health provides guidance and support. 
October 1999 An inquiry is launched to investigate the under-reporting of cervical smear abnormalities 
in the Gisborne region. 
April 2001 The Gisborne Cervical Screening Inquiry report is published (Duffy et al 2001). 
February 2002 The Office of the Auditor General (OAG) report is published (OAG 2002): this monitored 
the Gisborne recommendations. 
August 2003 A final report on the review of progress to implement the recommendations of the 
Gisborne CSI is published (McGoogan 2003). 
December 2003 The OAG’s second report, comprising a review of the CSI and other recommendations, 
is published (OAG 2003). 
July 2004 The Health (National Cervical Screening Programme) Amendment Act, section 112c, 
comes into force on 1 July 2004. The rest of the Act comes into force 12 months after 
the date on which it received royal assent. 
November 2004 The Cervical Cancer Audit Report is published (Cervical Cancer Audit and the University 
of Auckland 2004). 
May 2006 The Health and Disability Commissioner’s review of colposcopy services at Waitemata 
DHB is published (NSU 2006). 
June 2011 The Report of the Parliamentary Review Committee regarding the New Zealand Cervical 
Screening Programme is completed (Tan et al 2011). 
 
The National Cervical Screening Programme 
The National Cervical Screening Programme is part of the National Screening Unit 
(NSU) and is funded by the New Zealand Ministry of Health. The NCSP interfaces with 
District Health Boards (DHBs), with many services coordinated regionally. Cytology, 
histology and human papillomavirus (HPV) testing services are provided by both private 
and DHB laboratories across New Zealand by way of a tendering process and contracts 
with the NSU. 
 
NCSP-Register 
A key component of the programme is the National Cervical Screening Programme-
Register (NCSP-R), which enables access to information by those operating or 
evaluating the programme. Data contained within the Register includes every result 
reported to the NCSP from a screening or diagnostic test. Immunisation data is held in a 
separate register. Data linkage with the New Zealand Cancer Registry occurs at regular 
intervals as part of the cancer case review process. Laboratories have access to 
historical screening and pathology data from their own and other laboratories. 
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NCSP networks 
The NCSP Advisory Group connects the NCSP with stakeholders and partners. The 
NCSP also has a range of clinical networks and contracts with service providers. 
External monitoring is carried out by the NCSP Advisory Group with technical 
assistance provided by the University of New South Wales. Laboratory accreditation 
services are provided by International Accreditation New Zealand, a national 
organisation that offers accreditation services for the technical competence of 
laboratories and radiology services. Colposcopy audit services are provided by Health 
and Disability Auditing New Zealand. 
NCSP Policies and Standards 
Following the implementation of the NCSP in 1990, a series of Policies and Standards 
was developed for laboratories, smear takers who screen, colposcopists and 
information systems. Guidelines for cervical screening have also been developed. Since 
1990, there has been a decrease in both the incidence and mortality rates of cancer of 
the cervix, while participation in cervical screening in New Zealand has increased. 
 
Cervical cancer incidence and mortality in New Zealand 
Cancer incidence 
Cancer incidence is the annual rate of new registrations of invasive cervical cancer (per 
100,000 women in the New Zealand resident population at the end of that year) 
standardised to the World Health Organization (WHO) Standard Population according to 
Ahmad et al (2001). Cancer incidence data is available in the latest NSU Annual Report 
to 2012 (NSU 2014a). 
 
In 2012, there were 166 new diagnoses of cervical cancer, including 40 new diagnoses 
among Māori women. This is equivalent to an age-standardised rate (ASR) of 6.2 new 
diagnoses per 100,000 women in the general population and 12.7 per 100,000 for Māori 
women (NSU 2014a). 
 
Most cervical cancers were squamous (116 cases; 4.5 per 100,000 women ASR), with 
a smaller proportion comprising adenocarcinoma (26 cases; 1.0 per 100,000 women 
ASR), adenosquamous (one case; < 0.05 per 100,000 women ASR) or other cervical 
cancers (23 cases; 0.8 per 100,000 women ASR). 
 
Overall, between 1996 and 2012 cervical cancer incidence declined from 10.5 to 6.2 per 
100,000 for women of all ethnicities, and from 25.0 to 12.7 per 100,000 for Māori 
women. There was some variation in the incidence rates by ethnicity, as shown in 
Figure 1.1a, although the 95% confidence intervals were very wide. When Māori women 
were compared to all women (Figure 1.1b), incidence was higher among Māori women, 
although again confidence intervals were comparatively wide. 
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Cancer mortality 
The most recent mortality data available is for 2010. In 2010, there were 52 deaths due 
to cervical cancer, including eight deaths in Māori women. This is equivalent to an age-
standardised mortality rate of 1.7 per 100,000 women in the general population and 
3.3 per 100,000 for Māori women. 
 
Overall, between 1998 and 2010 cervical cancer mortality has declined from 3.2 to 
1.7 per 100,000 for women of all ethnicities, and from 10.3 to 3.3 per 100,000 for Māori 
women. However, incidence and mortality rates have not changed from 2006 to 2012. 
 
Figure 1.2 shows the age-standardised cervical cancer mortality rates from 2006 to 
2010 by ethnicity. As with the incidence data, the 95% confidence intervals are very 
wide. 
 
Figure 1.1: Age-standardised cervical cancer incidence rates, 2006 to 2012, by ethnicity 
a) All ethnic groups 
 
Note: Vertical bars represent 95% confidence intervals. 
Source: NCSP Annual Report 2012 (NSU 2014a) 
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b) Māori women, compared with all women 
 
Note: Vertical bars represent 95% confidence intervals. 
Source: NCSP Annual Report 2012 (NSU 2014a) 
 
Figure 1.2: Age-standardised cervical cancer mortality rates, 2006 to 2010, by ethnicity 
(all ethnic groups) 
 
Note: Vertical bars represent 95% confidence intervals. No deaths were recorded for Asian women in 2006. 
Source: NCSP Annual Report 2012 (NSU 2014a) 
 
  Report of the Parliamentary Review Committee 7 
 regarding the New Zealand Cervical Screening Programme 
Performance of the National Cervical Screening Programme 
Although screening coverage for all women is below the national coverage target of 
80%, the NCSP is to be congratulated for enabling access to screening for 76.4% of 
women aged 25–69 years over the most recently reported three-year period to 
December 2013. 
 
Of particular interest are the increases in coverage for Pacific and Asian women since 
Monitoring Report Number 34, which reports 2010 figures (NSU 2012a) – with a 7.7% 
improvement in coverage for Pacific women since 2010 and a 10.5% improvement for 
Asian women. There has been a 6.2% improvement in coverage for Māori women from 
2010 to 2013. Of note, coverage for European/Other women declined by 1.9% over that 
same period (see Chapter 3: Coverage, participation, equity and access). 
 
Although overall cervical cancer incidence and mortality rates have declined between 
1996 and 2012, there has been a plateau since 2006. We will need to consider if further 
substantial improvement can be expected from improving coverage in this current 
programme. The NCSP will achieve further success in the future through the benefits of 
HPV vaccination and if primary HPV screening is introduced. 
 
Methodology of the review process 
Review scope 
The statutory functions of the Review Committee were to: 
 prepare a review plan 
 ensure the plan applied the focus for continuous quality improvement referred to in 
section 112O(2) of the Health (National Cervical Screening Programme) Amendment 
Act 2004, and took into account the need for timeliness in the completion of the 
review 
 determine which issues were to be reviewed and the expected date of completion of 
the review. 
 
The review plan developed by the Review Committee was presented to the Minister of 
Health in November 2014. The Minister approved the plan on 10 December 2014. 
 
Broad areas for the review included: 
 coverage, participation, equity and access 
 monitoring and evaluation 
 quality assurance 
 organisational and structural issues 
 workforce issues 
 the NCSP-R 
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More detail about the areas reviewed is provided in Appendix B. 
 
Review objectives 
In accordance with section 112O(2) of the Health (National Cervical Screening 
Programme) Amendment Act 2004, the focus of the Review Committee was the 
continuous quality improvement of components of the NCSP, with a view to reducing 
the incidence and mortality rates of cervical cancer. Specific objectives involved 
addressing the following questions: 
 What progress has been made in implementing the previous recommendations of the 
Parliamentary Review Committee (Tan et al 2011)? 
 What are the key issues, challenges and risks to the programme? 
 How does the NCSP evaluate the programme and implement quality improvement 
initiatives? 
 What are the future issues that need to be considered by the NCSP? 
 
An effective cervical screening programme needs to be built on evidence-based 
guidelines and standards. Particular tools and resources are also needed to fulfil the 
requirements of the programme’s mandate. Accurate knowledge and awareness among 
both clinicians and the public are critical to the success of cervical screening. This 
knowledge will help ensure that participants are well informed throughout the process 
and understand the rationale for screening. All of these aspects of the programme have 
been considered in this review. 
Methodology overview 
Both qualitative and quantitative research methods were used by the Review 
Committee to gather information for this review. More specifically, its work involved the 
following: 
 A full literature review was carried out in relation to cervical cancer screening and 
related topics. 
 Relevant information was evaluated from peer-reviewed scientific literature, 
technology assessments, specific reports, standards documents, and guidelines from 
other jurisdictions. Evidence was collected from both New Zealand and international 
sources. 
 Findings from reviews, meta-analyses and randomised controlled trials were 
considered in the context of the entire spectrum of programme components and 
delivery of services. 
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 NCSP documentation was reviewed, including external audits, historical documents 
(see Table 1.2) and performance-related programme documents from the NSU and 
the NCSP. The NSU also facilitated access to a wide variety of documents required 
for key areas of the review. 
 Recommendations for best practice were assessed. 
 Interviews took place in February 2015 with interviewees and key informants. For the 
purposes of this report, an interviewee is defined as a participant interviewed by the 
PRC who is external to the Ministry of Health, including the advisory groups of the 
National Screening Unit and the National Cervical Screening Programme. A key 
informant is a key staff member from the Ministry of Health. Interviews took place 
either in person or by teleconference. A list of the individuals and groups who were 
interviewed is provided in Appendix C. To help identify priority themes, and to help 
elicit information from a variety of audiences about their experience and opinions in 
relation to interactions with the NCSP, a semi-structured interview guide was used. 
This is provided in Appendix D. 
 Written submissions were also received from partners, stakeholders and the public. 
This provided the opportunity for open feedback. A copy of the form used is provided 
in Appendix E. 
 The Parliamentary Review Committee also requested that the NCSP provide an 
update of progress towards the recommendations made following the previous 
review in 2011. This update is reported in Chapter 2 of this report. 
 
Parliamentary Review 2015 
This report follows on from a previous Parliamentary Review Committee Report (Tan 
et al 2011). The chapters that follow discuss in detail the various aspects of the cervical 
screening programme, and provide an update on progress towards achieving the 
recommendations made in that report. The final chapter provides suggestions on the 
future directions for the programme. 
 
This report is based on data that is publicly available. A full list of references is included 
at the end. The latest National Cervical Screening Programme Annual Report was 
produced for the year 2012 (NSU 2014a), and the latest Monitoring Report (Number 40) 
covered July to December 2013 (NSU 2014b). 
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Chapter 2: Update from the 2011 Parliamentary 
Review Committee recommendations 
1 Coverage, participation, equity, access and disease burden 
No. Parliamentary Review 
recommendation 
June 2011 
National Cervical Screening 
Programme (NCSP) update 
February 2015 
Comments in Parliamentary 
Review Committee Report 
2015 
1.1 A proactive campaign is needed, 
with targeted interventions to 
address disparities among ethnic 
groups in terms of participation, 
retention, and improved follow-up 
after abnormal screening results. 
This is ongoing, with 
communication campaigns 
targeted to Māori and Pacific 
women. 
The National Screening Unit 
(NSU) has run a tender process 
and appointed a new 
communications supplier. Social 
marketing initiatives will target 
priority groups and strengthen 
messaging in the Ministry of 
Health’s campaigns about human 
papillomavirus (HPV) 
immunisation. 
A campaign will be run for 
cervical screening awareness 
month in September 2015. 
Ongoing strategies are needed to 
address the disparities among 
priority groups in terms of 
participation and retention. 
Improved follow-up is needed 
after abnormal screening results. 
Further details are provided in 
Chapter 3: Coverage, 
participation, equity and access 
and Chapter 9: Ethnicity data. 
1.2 The Ministry of Health must 
explore options to fund Pap tests 
at a system level to reduce 
disparities in access. 
This has been completed. 
Currently the NSU contracts with 
District Health Boards (DHBs) 
and non-government 
organisations to provide 
approximately 38,600 free 
cervical smears per year to 
priority women. Priority group 
women can access free smears 
within the primary care setting or 
through Māori or Pacific health 
providers who work to help 
women to overcome barriers to 
access. Other options for 
provision of free cervical smears 
have been explored. No changes 
to the funding structure will be 
made at this time. 
The provision of funding for free 
smears is a commendable 
initiative, but the amount of 
funding and consequently 
coverage, is limited. There need 
to be clear strategies to ensure 
that access to free smears is 
appropriately targeted to the 
highest-need women. To improve 
coverage for high-priority women, 
the cost of smears must not be a 
barrier. 
Further details are provided in 
Chapter 3: Coverage, 
participation, equity and access. 
1.3 Improve screening participation 
by increasing the number of 
smear takers who are attuned to 
cultural sensitivities and the 
preferences of women with 
special needs. 
This is ongoing. Smear-taker 
training courses include a cultural 
awareness component and cover 
some issues for women with 
special needs. 
Cultural competency is vitally 
important and ongoing education 
is needed to ensure that smear 
takers are attuned to cultural 
sensitivities. It is important to 
provide local community support; 
it is recommended that 
independent service providers 
(ISPs) are funded to support local 
communities and that smear 
takers work closely with ISPs. 
Further details are provided in 
Chapter 3: Coverage, 
participation, equity and access. 
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No. Parliamentary Review 
recommendation 
June 2011 
National Cervical Screening 
Programme (NCSP) update 
February 2015 
Comments in Parliamentary 
Review Committee Report 
2015 
1.4 Undertake an HPV education 
campaign to increase awareness 
and accurate knowledge among 
the general population. (See also 
the two sections relating to HPV.) 
This is ongoing. The NCSP 
communication campaigns 
include education and awareness 
messages about HPV and this is 
being strengthened on the NSU 
website and as NSU goes 
forward with new social marketing 
initiatives. The NSU sees ongoing 
education as essential for new 
providers and women entering 
the cervical screening pathway. 
Ongoing HPV education 
campaigns are important to 
ensure increased awareness and 
knowledge among the general 
population and among health 
care providers. 
Further details are provided in 
Chapter 3: Coverage, 
participation, equity and access. 
1.5 Ensure continuity of monitoring, 
evaluation and reporting. This is 
best achieved through 
collaboration and improved 
partnerships with the academic 
community and/or the NCSP 
Advisory Group. NCSP must 
make concerted efforts to consult 
with partners and stakeholders 
and to complete and report on 
overall programme activities on a 
more regular basis, whether 
annually or biannually. 
This has been completed. The 
NCSP Advisory Group reviews 
and provides recommendations to 
the National Screening Unit in the 
NCSP monitoring reports. NCSP 
monitoring reports are sent to 
NCSP providers in draft for 
comment on errors or omissions. 
Continuity of monitoring, 
evaluation and reporting is 
essential for the clinical safety of 
participating women. The NCSP 
consults extensively with partners 
and stakeholders to ensure the 
delivery of a high-quality cervical 
screening programme. 
Since the last Parliamentary 
Review Committee Report (Tan 
et al 2011), comprehensive 
external monitoring reports have 
been produced biannually against 
a suite of eight groups of 
monitoring indicators. 
1.6 Extended reporting delays 
contribute to a loss of confidence 
in the programme and must be 
prevented in the future. 
This is ongoing. A business case 
and funding to establish NSU 
datamarts in the Ministry of 
Heath’s data warehouse have 
been approved. The NCSP 
datamart is expected to be 
operational towards the end of 
2015 and will enable timelier 
reporting. 
An interim solution has been put 
in place to ensure data is 
extracted from the National 
Cervical Screening Programme-
Register (NCSP-R) in a timely 
way so that ongoing biannual and 
annual monitoring is achievable. 
The biannual monitoring reports 
are addressing this issue. The 
challenge is ensuring that 
information gained through the 
monitoring reports is used for 
continuous quality improvement 
for the programme. 
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Comments in Parliamentary 
Review Committee Report 
2015 
2.1 The NSU should explore options 
for consolidating services related 
to cytology, histology and HPV-
DNA testing, which will ideally be 
centralised with, at most, one or 
two laboratories. Several 
laboratories have expressed a 
preference for a centralised 
national model. Others were not 
happy with the current regional 
structure because they were 
subsidising cytology services and 
this is not a sustainable business 
model. 
This has been completed. The 
NSU has explored options for 
consolidation of laboratory 
services. While HPV primary 
testing is being considered in the 
New Zealand context, the NSU 
considers it is not prudent to 
implement significant service 
change, which would be a short- 
to medium-term solution. This 
decision has been approved by 
the NSU Senior Management 
team. 
The NSU and NCSP have 
commenced policy work for a 
potentially major change to HPV 
primary testing in the National 
Cervical Screening Programme. 
2.2 It would be beneficial for the 
Ministry of Health to consolidate 
laboratory negotiations in one 
department external to the NSU. 
It makes sense for one Ministry 
section to assume responsibility 
for all discussions with laboratory 
executives/representatives 
regarding all lab services. 
Although the Ministry contact 
would need to seek input from 
clinical and lab experts within the 
NCSP about specific tests, 
contract and funding negotiations 
should be conducted outside the 
screening programme. 
It is not feasible at this time to 
move responsibility for laboratory 
negotiations into another part of 
the Ministry. No other area of the 
Ministry has the capability or 
capacity, as no other area in the 
Ministry is directly responsible for 
laboratory contracts. This 
decision has been approved by 
the NSU Senior Management 
team. 
NCSP laboratory contracts were 
successfully renegotiated by the 
NSU during 2014. 
This has been noted by the 
Parliamentary Review Committee 
(PRC) 2015. 
2.3 The NCSP should continue to 
conduct ongoing review of the 
screening histories of women who 
develop cervical cancer. 
This is ongoing. Reviews of 
cervical cancer cases are being 
undertaken and will continue as 
part of the NCSP work 
programme. 
Ongoing audit of the screening 
histories of women who develop 
cervical cancer is recommended. 
The underpinning rationale is that 
there are likely to be valuable 
lessons from these audits that 
would inform the implementation 
of quality improvement initiatives. 
Further details are provided in 
Chapter 5: Quality assurance. 
2.4 It is difficult to adopt a proactive 
approach in a programme when 
there are delays in the production 
of monitoring and evaluation 
efforts. The NCSP Annual Report 
has been delayed by more than 
three years. Since that delay, 
semi-annual monitoring reports 
have been produced by an 
Australian group. Numerous 
interviewees expressed concerns 
regarding unexplained delays and 
dissolution of the Independent 
Monitoring Group. Not everyone 
agrees that sourcing this function 
outside of New Zealand is the 
best approach, as many believe 
there is sufficient expertise within 
the country to perform this 
function. 
This has been completed. 
External monitoring reports are 
now up to date. The 2012 Annual 
Report has been published on the 
NSU website (NSU 2014a). This 
is now business as usual. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
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Comments in Parliamentary 
Review Committee Report 
2015 
2.5 External expert review is 
recommended every five years, 
rather than every three years. 
The proposal to move to a five-
year review was declined, and 
therefore the review will stay at 
three years at this time. 
This can be re-visited if five-
yearly screening comes in with 
primary HPV screening. It is 
noted the three-yearly review is a 
legislative requirement. Ongoing 
review of the programme is an 
important element of quality 
improvement. 
2.6 Secretariat support for future 
external reviews should be 
provided by Ministry of Health 
staff outside the NSU, and should 
have experience in providing 
executive assistance. 
The NSU has engaged 
contractors with experience in 
providing executive assistance to 
help coordinate the 2015 NCSP 
Parliamentary Review 
Committee. This review will be 
completed by June 2015. 
Secretariat support was provided 
by contracted staff. Due to 
difficulty securing contracted staff 
who were suitably qualified, the 
report-writing support for PRC 
was provided by an NSU staff 
member, but her work on the 
review was independent of the 
Ministry of Health. 
 
3 Organisational and structural issues 






Comments in Parliamentary 
Review Committee Report 
2015 
3.1 The NSU and NCSP must 
supplement clinical leadership 
capacity to include population 
health, public health and 
screening expertise as a matter of 
urgent priority. 
This has been completed. In 
January 2013 an NSU Clinical 
Director was appointed. The 
position of NCSP Clinical Leader 
has also been retained. Both post-
holders are public health 
physicians with population health, 
public health and screening 
expertise. A public health 
physician with applied 
epidemiology skills has also been 
appointed to lead the monitoring 
and evaluation analysis within the 
NSU’s Information, Quality and 
Equity team. An additional public 
health physician with a lead role in 
promoting achievement of equity 
for all NSU screening programmes 
has also been appointed. 
Additionally, a Clinical Governance 
Group was established in 2010. 
This group provides clinical, public 
health and strategic advice on 
screening practice, including 
monitoring and resourcing. 
It is imperative that clinical 
leadership positions are at the 
forefront of the National Cervical 
Screening Programme and that 
these are sustained as its driving 
force. 
It is crucial that the new 
incumbents, including the 
appointment to the clinical 
leadership position, are promptly 
oriented in their positions and that 
the new leadership team 
establishes strong regional 
coordination and communication 
across the national screening 
sector. 
Further details are provided in 
Chapter 6: Organisational and 
structural issues. 
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3.2 Regional coordination and 
communications need to be 
improved. The NSU and NCSP 
must provide the lead 
collaboratively for performance 
management and monitoring 
across all sectors to strengthen 
coordination and integration. 
Examples of key areas for 
collaborative discussions are 
contracting arrangements and 
incentives to improve delivery 
through funding innovation (eg, 
for coverage, screening, 
assessment and treatment 
services, and change 
management). 
Interviewees expressed 
significant concerns regarding the 
apparent isolation of the NCSP 
from other Ministry departments 
as well as from other partners 
and stakeholders, and also within 
the NSU itself. Such isolation has 
been manifested in a lack of 
appropriate consultation and 
limited communications with 
partners and stakeholders, 
combined with decision making 
that has excluded key partners. 
This is of great concern as 
communication and collaboration 
are essential for a successful 
screening programme, not only to 
ensure feedback and 
representation from all partners 
and stakeholders, but also to 
optimise the benefit of scarce 
resources, avoid duplication and 
provide meaningful services. 
This has been completed. The 
NSU continues to communicate 
with its stakeholders with the 
regular Screening Matters 
newsletter and an additional 
quarterly update to the sector with 
NCSP highlights and monitoring 
information. The NCSP has a 
quarterly teleconference attended 
by regional coordination services 
and non-government 
organisations. This teleconference 
focuses on sharing successes (eg, 
initiatives that increase coverage 
in priority groups), discussing 
current issues and developments, 
and connecting providers with 
each other. 
The NCSP became fully staffed in 
2013, and both senior portfolio 
managers have been undertaking 
a programme of visiting providers. 
The NCSP team has been 
supporting a number of quality 
improvement initiatives (eg, 
improving methods to identify 
unscreened women through a 
data matching process) being 
undertaken by DHBs and primary 
health organisations. 
The regional coordination section 
of the Policy and Quality 
Standards has been reviewed and 
updated standards were published 
in July 2014. Consultation with the 
sector has been an important part 
of the review of all NCSP Policies 
and Standards. This 
recommendation will continue 
under business as usual. 
NCSP and NSU have ongoing 
relationships with other areas of 
the Ministry, for example, with the 
Cancer team (and cancer 
networks) about the Cancer 
Control Strategy. The NCSP and 
the Immunisation team are 
building a strong relationship 
around HPV immunisation and 
cervical screening. An important 
focus of this relationship is to 
ensure messaging is consistent 
between and supportive of both 
programmes. 
NSU’s breast screening and 
cervical screening clinical leaders 
have a professional reporting line 
through the NSU’s Clinical 
Director to the Ministry’s Chief 
Medical Officer. 
While steps have been taken to 
improve regional coordination 
with providers, further strategies 
must be identified to rectify 
remaining issues of coordination 
and communication with regional 
providers. 
NCSP regional portfolio 
managers must continue to 
demonstrate improvements in 
regional coordination with 
providers through at least one 
planned national meeting per 
year and ongoing regional face-
to-face meetings with local 
service leaders for the cervical 
screening programme in the 
regions. 
Further details are provided in 
Chapter 6: Organisational and 
structural issues. 
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3.3 A whānau ora approach should 
be adopted. The NSU and NCSP 
need to broaden their scope of 
contract modelling to include the 
emerging whānau ora collectives, 
along with the primary/community 
health care independent service 
providers. These networks 
incorporate essential health 
initiatives that are already 
integrated with other social and 
educational programmes to 
demonstrate inclusiveness of 
whānau/family. The NCSP should 
drive this initiative with whānau 
ora and primary health care 
providers to increase 
opportunities for coverage and 
participation. (See also the 
‘Ethnicity data’ section.) 
This has been completed. The 
NSU is working closely across the 
Ministry’s integration programme, 
with a particular focus on primary 
care. 
The Clinical Director, along with 
the NCSP and BreastScreen 
Aotearoa programme managers, 
has worked with the Māori Health 
Business Unit to establish regular 
meetings. This allows participants 
to review progress against the 
Māori Health Plans and the 
whānau ora collective reports, 
and to discuss initiatives or policy 
developments. 
Addressing equity is important. In 
particular, the variable 
achievement of the 80% target for 
Māori, Pacific and Asian women 
is an outstanding disparity of this 
programme that must be 
eliminated. 
Information and appropriate 
messaging about HPV and 
changes to the NCSP are 
important to achieving effective 
and ongoing engagement of the 
priority groups for this 
programme. 
3.4 The NSU and NCSP must align 
their initiatives and work plan with 
the priorities and planning of the 
New Zealand Cancer Control 
Strategy. This will require 
improved consultation and 
coordination of all cancer 
screening programmes to achieve 
better alignment of strategies and 
services across the entire cancer 
continuum. 
This has been completed. 
Development of NSU work plans, 
initiatives and programmes is 
aligned to the Cancer Control 
Strategy, and its associated work 
plans. 
The NCSP is to be commended 
for having an 80% participation 
rate included as a target within 
the cancer control work plan. 
Ongoing strategies to achieve 
these targets across all DHBs for 
all cultural groups are essential. 
 
4 Workforce issues 






Comments in Parliamentary 
Review Committee Report 
2015 
4.1 As in other jurisdictions, 
professional associations that are 
linked to the Royal College of 
Pathologists of Australasia 
(RCPA) may be best positioned 
to administer quality standards for 
cytotechnicians, pathologists and 
screeners. Quality is closely 
aligned with professional 
education and can potentially be 
very difficult to ensure. It may not 
be appropriate for any one 
laboratory to assume 
responsibility. Professional 
colleges and associations tend to 
have greater credibility among 
their members and are more 
likely to require adherence to 
professional standards and a 
scope of practice. 
This has been completed. The 
laboratory training service is in 
place, and is being delivered to 
laboratories. 
The RCPA Quality Assurance 
Programme now administers the 
individual external quality 
assurance programme for all 
cytopathologists, cytoscientists 
and cytotechnicians screening 
and reporting cervical cytology 
samples. This commenced on 
1 July 2012. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
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4.2 To ensure equitable access in 
outlying, rural and under-serviced 
areas, the NSU and allied 
professional staff should consider 
alternative options for service 
delivery to improve screening 
access for vulnerable 
populations. Such options might 
include: 
 train-the-trainer approaches, 
or 
 training local health 
professionals to coach such 
populations in the use of self-
collected specimens. 
This is ongoing. The Ministry of 
Health has developed an online 
learning tool on HPV to support 
training opportunities for health 
professionals. This was released 
in January 2015. 
The introduction of self-collected 
specimens will be considered as 
part of any future policy 
development on HPV primary 
screening testing. 
Cervical screening information on 
the NSU website is regularly 
reviewed and updated.  
NCSP must ensure regular 
updates to online courses and 
improved access to online 
training for primary care workers 
such as practice nurses, 
midwives, registered nurses, 
enrolled nurses and general 
practitioners. 
Further details are provided in 
Chapter 7: Workforce issues. 
4.3 As cervical screening technology 
evolves, professional 
requirements will also change. 
Planning and strategies for such 
change are best achieved by 
participation and collaboration 
across all disciplines involved in 
the screening process. Given that 
there are significant financial and 
training implications of converting 
to any new standard or process, 
this type of collaboration and 
consultation is essential to map 
out the most efficient, efficacious 
and cost-effective screening 
programme. 
This is ongoing. The NSU, Health 
Workforce New Zealand and 
provider representatives meet to 
consider future planning, and how 
systems and technology will 
impact the screening workforce. 
Working groups are established 
as required to inform new 
standards or processes. 
The NSU recognises that there 
may be workforce impacts, 
particularly for the laboratory 
sector, if HPV primary screening 
is introduced. The NSU will work 
with the sector to ensure clear 
communication of any changes 
and will support a planned 
transition for providers and their 
workforce.  
The introduction of primary HPV 
screening is likely to have a 
significant impact on the 
laboratory workforce. This will 
precipitate the need to have a 
planned approach to support 
cytologists, pathologists and 
laboratory scientists to move or 
relocate to areas where their 
expertise is not lost to the sector. 
Well-designed and integrated 
education and training, together 
with ongoing competency 
assurance, will be vital to support 
change. It will also be important 
to ensure that service 
specifications, purchase 
agreements, funding 
arrangements and industrial 
arrangements do not 
unnecessarily impede this. 
4.4 Until such discussions and long-
term plans have been addressed 
at a system level, it is difficult to 
predict workforce demands, 
because the health system must 
first decide on the best approach 
for their population and existing 
infrastructure. 
This is ongoing, as above. See PRC comments in 
section 4.3. 
4.5 The HPV vaccination programme 
will decrease the burden of HPV-
related disease, in particular 
cervical abnormalities. This will 
have an impact on all elements of 
the collective prevention and 
screening workforce. Strategic 
planning and an integrated 
evaluation plan are essential to 
cope with this transition. (See 
also the ‘HPV vaccination’ 
section.) 
This is ongoing. Strategic 
workforce issues will be 
considered as part of the policy 
work on primary HPV screening. 
See PRC comments in 
section 4.3. 
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4.6 Laboratories must maintain the 
experience and expertise of their 
scientific workforce. 
This has been completed. The 
current laboratory training school 
contract for the gynaecological 
cytology, histology and HPV 
screening laboratory sector has 
been extended to December 
2017 to support the experience 
and expertise of the pathology 
and scientific workforce. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
 
5 Ethnicity data: quality, completeness and use 
No. Parliamentary Review 
recommendation June 2011 
NCSP update February 2015 Comments in Parliamentary 
Review Committee Report 2015 
5.1 The following strategies aim to 
increase and improve 
participation and retention. 
The NCSP has implemented a 
range of strategies to increase 
coverage for Māori, Pacific and 
other priority group women. 
These should be advanced and 
identified in a Priority Action Plan 
for increasing screening 
participation of the seldom and 
never screened. Evaluation of 
these efforts is essential. 
Provider contributions and 
innovations need to be explored 
through community consultation 
and collaboration to engage a 
range of Māori, Pacific and Asian 
providers in both primary health 
care and whānau ora collective 
arrangements. 
The NCSP needs to explore 
options for implementing 
commercially available options for 
self-collected specimens for HPV-
DNA testing (see also the section 
on HPV screening). 
This is ongoing. The NCSP DHB 
contract reporting templates have 
included reporting against actions 
in the Māori Health Plans from 
July 2014. 
See also recommendations 1.1, 
1.3, 3.2 and 3.3 above. 
The NSU is revising its Quality 
Framework and has consulted 
with a wide range of stakeholders 
as part of this process. 
The NSU is undertaking analysis 
to examine the issues in ethnicity 
data collection, and any potential 
solutions, across all screening 
programmes. 
Self-collected samples will be 
explored when work is 
undertaken to consider the role of 
HPV screening as the primary 
screening test in New Zealand. 
Current analysis from the 
NCSP-R data (at March 2014) 
recorded ethnicity codes for 
approximately 98.4% of the 1.4 
million women on the NCSP-R. 
The NCSP should monitor the 
completeness and accuracy of 
ethnicity data on the NCSP-R. 
The data shows persisting 
inequities in participation rates for 
cervical screening among Māori, 
Asian and Pacific women. This is 
considered a major concern for 
the NCSP and the sector, 
particularly in regard to Māori 
women. Planning for primary HPV 
screening is seen as a critical 
opportunity to improve cervical 
screening coverage for Māori 
women. 
Further details are provided in 
Chapter 9: Ethnicity data. 
 18 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
No. Parliamentary Review 
recommendation June 2011 
NCSP update February 2015 Comments in Parliamentary 
Review Committee Report 2015 
5.2 The following recommendations 
relate to the National Kaitiaki 
Group (NKG). 
In line with the recommendations 
of the legal reviewers, we believe 
this review is an opportunity to 
amend the Kaitiaki Regulations to 
achieve supportive and 
enhancing actions that uphold the 
respective roles and 
responsibilities of the National 
Kaitiaki Group and the NSU and 
NCSP. 
All major parties (ie, the NKG, 
and units of the Ministry of 
Health: the Māori Health 
Directorate, NSU and NCSP) 
must be involved in consultation 
to produce mutually agreeable 
protocols that clarify the 
relationship between the NKG 
and NCSP to access, use and 
disclose ‘protected information’. 
This is ongoing. The NKG 
Regulations have not been 
amended. However, the Māori 
Business Unit at the Ministry of 
Health, the NSU and the NKG are 
working together, to make the 
NKG process appropriate for 
allowing access to data and for 
protecting data that relates to 
Māori women. 
The NSU has undertaken a 
review of the process for NKG 
applications for Māori women’s 
data. Process improvements 
have been discussed and agreed 
with the NKG. The NKG is 
leading the work to develop a 
combined NSU and NKG 
application form for accessing 
and using Māori women’s cervical 
screening data. 
Issues encountered in regard to 
data access have highlighted that 
the process of obtaining 
information from NCSP-R is slow. 
This is mainly influenced by 
relationships between the NCSP 
and the NKG, which need to 
improve to bring about a process 
that ensures timely, ongoing 
access to important data and in 
this way enables ongoing 
monitoring and quality 
improvement of the programme. 
Further details are provided in 
Chapter 9: Ethnicity data. 
 
6 NCSP-Register 






Comments in Parliamentary 
Review Committee Report 
2015 
6.1 The NCSP must work with DHBs 
to ensure the integrity of 
colposcopy data supplied to the 
NCSP-Register. This is an urgent 
priority. 
This is ongoing. A large-scale 
project is underway to ensure that 
all DHB colposcopy clinics 
capture the required colposcopy 
data in a database, and that data 
is then transferred electronically 
to the NCSP-Register. This 
project is well underway with all 
DHBs working towards updating 
their databases and establishing 
electronic messaging to the 
NCSP-Register. All DHBs should 
have completed implementation 
within the 2015/16 financial year. 
See also recommendation 7.2 
below. 
Issues impeding the successful 
completion of the e-colposcopy 
project to enable electronic 
uploading of colposcopy data 
must be resolved as a priority. 
This must include working with 
providers who are responsible for 
uploading colposcopy reports to 
ensure the colposcopy forms are 
user-friendly and able to be 
transmitted in a timely manner. 
Further details are provided in 
Chapter 8: NCSP-Register. 
6.2 Longer wait times for colposcopy 
must be closely monitored by the 
NCSP, and efforts to resolve wait 
time issues with local service 
providers must be proactive for 
the preventive benefit of women 
with high-grade lesions. Timely 
assessment by clinicians and 
colposcopy is essential. 
This has been completed. 
Colposcopy wait times continue 
to be monitored using service 
monitoring data. The updated 
(July 2013) colposcopy standards 
have been implemented. These 
standards contain clear wait time 
indicators, which colposcopy 
providers will be measured 
against. 
Timely access to colposcopy for 
all women continues to be an 
unmet target. Strategies to 
eliminate barriers to accessing 
colposcopy services, particularly 
for Māori and Pacific women, 
must be an ongoing priority.  
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6.3 Colposcopy services must be 
supported to facilitate efficient 
electronic transfer of data. 
This has been completed. The 
NSU and DHBs are working 
closely together to support the 
electronic transfer of colposcopy 
data. This recommendation is 
business as usual. See also 
recommendation 6.1 above. 
It has been noted by the 
Parliamentary Review Committee 
2015 that this project is not 
complete. See recommendations 
in Chapter 8: NCSP-Register. 
6.4 Smear takers and NCSP service 
providers should continue to 
inform the public that screening 
data are included in the 
NCSP-Register and advise them 
of their withdrawal options. 
This has been completed. The 
information to support this 
message by smear takers and 
NCSP providers is available on 
the NSU website. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
6.5 Continuing dialogue is essential 
between the NCSP and NKG to 
resolve the persistent issue of 
access to Māori women’s 
aggregate data from the 
NCSP-Register. This will facilitate 
monitoring and evaluation; a 
standing agreement would be the 
preferred option. 
This is ongoing. See also 
recommendation 5.2 above. 
It is strongly recommended the 
NCSP seeks the advice of, and 
works in partnership with, the 
NKG to identify more streamlined 
processes that minimise the 
burdens the current processes for 
accessing data place on both 
parties. 
Further information is provided in 
Chapter 8: NCSP-Register. 
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7.1 The current round of 2010 audits 
should be made available to 
ensure that DHBs have 
addressed the shortcomings in 
the findings of the 2008 audit, 
when all DHBs were non-
compliant in several, or many, 
areas. 
This has been completed; the 
2010 audit findings were made 
available in a meeting held with 
DHB colposcopy providers in 
June 2012. All audit corrective 
actions and evidence provided by 
DHB colposcopy clinics to close 
out corrective actions are 
monitored by the NCSP portfolio 
managers, with input from the 
NCSP Clinical Leader. 
A new round of audits 
commenced in 2015 for all 
20 DHBs. 
7.2 There is an urgent need to ensure 
that colposcopy data in the 
NCSP-Register are complete and 
that colposcopy indicators are 
included in monitoring reports. 
This is ongoing. A project is well 
underway for all data in the 2013 
colposcopy standards to be 
electronically sent to the 
NCSP-Register. Full 
implementation is due to be 
completed in 2015/16. 
Colposcopy indicators have been 
included in monitoring reports 
since 2011. See also 
recommendations 6.1 and 6.2 
above. 
Electronic reporting from DHBs 
would reduce the likelihood of 
incomplete reporting of 
colposcopy to the NCSP-R. It is 
important to ensure e-colposcopy 
is functioning well in all DHB 
colposcopy clinics. 
Further details are provided in 
Chapter 4: Monitoring and 
evaluation, Chapter 8: 
NCSP-Register and Chapter 10: 
Colposcopy. 
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7.3 National colposcopy meetings 
should be re-convened to 
improve the networking of DHBs 
and information sharing, as the 
last meeting held was in 2008. 
This has been completed. The 
NCSP held national DHB 
colposcopy meetings in June 
2012 and November 2014. Also, 
the Australian Society for 
Colposcopy and Cervical 
Pathology Scientific Meeting in 
2013 was held in New Zealand. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
7.4 New Zealand supports the 
RANZCOG C-QuIP programme 
and ensures all health 
professionals performing 
colposcopy in New Zealand 
undergo a common pathway for 
accreditation/re-accreditation and 
participate in the audit 
programme. 
This recommendation has been 
implemented by including the 
Royal Australian and New 
Zealand College of Obstetricians 
and Gynaecologists (RANZCOG) 
Quality Improvement Programme 
in the NCSP colposcopy 
standards, and data being 
collected in the NCSP-Register. 
There is discrepancy between the 
C-QuIP and NCSP colposcopy 
standards that will need to be 
addressed by NCSP and 
RANZCOG. 
Further details are provided in 
Chapter 10: Colposcopy. 
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8.1 Effective, intensive and broad-
reaching education strategies are 
essential for the general public as 
well as health care providers to 
ensure awareness and accurate 
knowledge about this very 
common virus – human 
papillomavirus (HPV). The 
benefits from such a strategy are 
likely to translate to improved 
screening participation as well as 
vaccine uptake. 
This is ongoing. The 2012/13 
advertising campaign included a 
focus on HPV and this focus will 
remain in future education 
strategies. See also 
recommendations 1.1 and 5.1 
above. 
To support training opportunities, 
the Ministry of Health has 
developed an HPV online 
learning tool for health 
professionals. This tool was 
released in January 2015. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
8.2 Ongoing linkage among all 
immunisation, screening and 
cancer databases is essential to 
move forward with the integrated 
evaluation of primary and 
secondary prevention of 
HPV-related cancers. 
This is ongoing, with the process 
of reporting new cases of cervical 
cancer to the NCSP from the 
Cancer Registry continuing. 
Further work will be explored to 
improve data sharing between the 
NCSP-Register and the National 
Immunisation Register as part of 
the HPV primary screening policy 
work. 
As per recommendations in 
Chapter 8: NCSP-Register, to 
enable monitoring and evaluation 
of the effectiveness and cost-
effectiveness of the HPV 
Immunisation Programme, it is 
necessary to develop strategies 
to capture and record a woman’s 
HPV vaccination status with her 
screening history, or to link data 
with the Immunisation Register. 
8.3 All Ministry of Health departments 
responsible for education, 
prevention (immunisation), 
screening and cancer control 
strategies must be in regular 
communication with each other to 
develop consistent messages for 
effective planning and evaluation 
strategies. Working in isolation is 
not an option. 
This has been completed. 
Integration across the Ministry of 
Health has been incorporated into 
the NCSP work plan. See also 
recommendations 3.2, 3.3 and 
3.4 above. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
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8.4 All stakeholders need to embrace 
this new paradigm for the control 
of cervical and other HPV-related 
infections and cancers. It is 
apparent that many are still 
embedded in the old paradigm of 
singular screening, with little 
regard for the overall impact of 
HPV-related disease across the 
entire population. Both men and 
women are affected by HPV: this 
is truly an issue that affects 
society as a whole. 
This is ongoing. The NSU and the 
Immunisation teams are working 
with stakeholders to discuss all 
the evidence and alignment of the 
programme’s priorities in relation 
to HPV. 
New DHB reporting templates 
include the need for reporting on 
how regional coordination 
activities involve HPV 
immunisation providers. 
The current three-dose coverage 
in girls aged 12–13 years in New 
Zealand is 48–56%. The 
coverage is higher among the 
Māori and Pacific population. 
Efforts are needed to increase 
this coverage to levels achieved 
in countries like Australia and 
United Kingdom. 
Further details are provided in 
Chapter 11: Human 
papillomavirus (HPV) and cervical 
cancer. 
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9.1 NSU and NCSP need to more 
actively engage with, and 
broaden the scope of expertise 
on, their advisory boards. Given 
current and future challenges, 
advisory groups must be involved 
in the consultation processes 
noted above, with representation 
that is knowledgeable about 
traditional aspects of the 
screening pathway as well as 
immunisation and other HPV-
related cancers. The NCSP 
should position their programme 
in the context of the broader 
cancer control strategies. 
This has been completed. The 
NCSP has additional expertise on 
the NCSP Advisory Group with 
the appointment of a molecular 
scientist / biologist (with expertise 
in HPV) representative for the 
New Zealand Institute of Medical 
Laboratory Science. 
This has been noted by the 
Parliamentary Review Committee 
2015. 
 
 22 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Ongoing issues from recommendations identified in previous reviews 
The table below lists some of the recommendations from past reviews that were 
indicated as ongoing in the 2011 Parliamentary Review Committee Report (Tan et al 
2011). These are highlighted as they are issues spanning over a decade and have been 
reviewed by the PRC in 2015. 
 
1 Status of the Cervical Screening Inquiry (CSI) recommendations 
Ref Recommendation Status: January 2011 Further work 
required? 
1.12 Management of the National Cervical 
Screening Programme within the Ministry 
of Health 
The National Cervical Screening 
Programme must be managed within the 
Ministry of Health as a separate unit by a 
manager who has the power to contract 
directly with the providers of the 
programme on behalf of the Ministry. The 
programme’s delivery should not be reliant 
of the generic funding agreements the 
Ministry makes with providers of health 
services. For this purpose the unit will 
require its own budget. 
The NSU was established in July 2001 as 
a separate business unit with the delegated 
power to contract directly with providers of 
the programme. 
The NSU has subsequently been re-
integrated into the Ministry of Health. The 
NSU continues to contract directly with 
providers. 
The NSU has been part of the National 
Health Board since its introduction in 
November 2009. 
Yes – ongoing 
1.13 Manager of the National Cervical 
Screening Programme 
The National Cervical Screening 
Programme should be under the control of 
a second or third tier manager within the 
Ministry. The Manager of the unit should as 
a minimum hold specialist medical 
qualifications in public health or 
epidemiology. As a consequence of the 
programme’s link with the Cartwright 
Report it has always had a female national 
co-ordinator. 
In 2002 the NSU appointed a Programme 
Manager and Clinical Leader to jointly 
manage the programme at fourth tier. The 
Clinical Leader has specialist medical 
qualifications in public health. 
Restructuring the Ministry of Health placed 
the NSU into an operational group under 
National Services Purchasing. At this time 
the title of Clinical Leader was downgraded 
to Clinical Advisor. The change in title was 
not supported by the Group Manager of 
NSU. The subsequent restructuring of the 
Ministry of Health brought the NSU in 
under the National Health Board. 
Yes – ongoing 
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2 Status of Dr McGoogan’s recommendations 
Ref Recommendation (McGoogan 2001) Status/date Further work 
required? 
2.8 National Screening Unit organisational 
development (para 100) 
In addition to addressing the manpower 
resource issue in the NSU, consideration 
should be given to organisational 
development. 
The NSU was restructured in 2007 with the 
aim of providing greater leadership, clarity 
around decision making and increasing 
capacity for lateral teamwork and research 
and development. 
A subsequent review in 2009, resulted in 
additional performance management 
analysts joining the NCSP team, with the 
responsibility for managing the NCSP 
provider contracts with regional services, 
independent service providers, laboratories 
and DHB colposcopy services. 
At the same time, clinical leadership has 
been downgraded with the NCSP Clinical 
Leader now being a tier 6 (whereas the 
CSI recommendation was that the position 
be a second or third tier; see 
recommendation 1.13). Work is currently 
underway to restore the position to Clinical 
Director at a higher tier. 
Yes – ongoing 
2.10 Clinical audit 
More work must be done to develop and 
promote an understanding of clinical audit 
as an integral part of good quality 
healthcare delivery. Regular critical review 
of how well clinical care is being delivered 
is vital to improving the quality of health 
care. I suspect that the external audit 
suggested for the retrospective cancer 
audit has mistakenly been portrayed as 
similar to financial auditors checking up on 
one’s income tax returns and snooping into 
private matters. 
The retrospective cancer audit is not 
‘external’ in that sense. It simply means that 
experts will be commissioned to investigate 
and evaluate the information collected on 
behalf of the NSU. Women will be 
approached by nurses or trained healthcare 
professionals who will be sensitive to the 
local customs and cultural needs so that the 
full information about screening histories can 
be gathered, They are in effect functioning 
as part of the NCSP. As with all healthcare 
records, all information gathered will be 
handled with great sensitivity and kept 
confidential (para 105). 
There is no intention to repeat the audit 
published in 2004. However, audits of parts 
of the screening pathway are regularly 
undertaken (eg, laboratory and colposcopy 
units). Audits of individual cancer cases are 
also ongoing. An analysis of cases for 
2003 to 2006 has been published. It is 
intended to undertake further analysis as 
more cases accumulate. 
Yes – ongoing 
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3 Status of Dr McGoogan’s further recommendations 
Ref Recommendation (McGoogan 2003) Status/date Further work 
required? 
3.1 New cases of cervical cancer should not 
just be reviewed but be fully audited as 
soon as they arise (paragraph 27). 
I am also concerned that a decision has 
been made not to carry out a full audit of all 
new cases of cervical cancer as they are 
diagnosed. I highlighted this in my first 
report and on each of my subsequent 
visits. I understand that each case is now 
being ‘reviewed’ but not fully audited. I find 
the decision not to audit new cases as they 
arise, with the consent of women, 
incomprehensible. The woman’s 
gynaecologist could request her consent 
soon after diagnosis and the audit carried 
out contemporaneously. The results could 
be combined into anonymised annual 
reports or three yearly reports but any 
specific deficiencies identified could be 
remedied immediately. It is not best 
practice to carry out only periodic audits of 
women who develop cervical cancer. 
New cases of cervical cancer are reported 
to the NCSP on a monthly basis once they 
have been confirmed by the Cancer 
Registry. Cases have been reviewed over 
the four years 2003–2006. Case reviews 
include reviewing the entire screen history 
of each case and the histology report. Data 
are entered onto a spreadsheet and 
analysed after sufficient cases accumulate. 
These data have been published in the 
New Zealand Medical Journal. 
Periodic audit appears to be sufficient. 
However, even this has been criticised by 
some commentators as unnecessary. In 
spite of this, a decision was made to 
continue this work. 
Yes – ongoing 
3.7 The NSU, its clinical leadership, 
management structure and location within 
the Ministry of Health should be kept under 
critical review (main recommendation). 
See CSI recommendation 1.13. Yes – ongoing 
 
4 Status of the Auditor-General’s recommendations 
Ref Recommendation (OAG 2002, 2003) Status/date Further work 
required? 
4.2 Clinical Leader role 
Noted that Dr McGoogan highlights that the 
Clinical Director has a direct line 
management relationship to the National 
Screening Unit’s Manager who is not 
medically qualified. The Clinical Director is 
also not the direct line manager of any 
permanent staff. This structure runs the 
risk that the clinical input into the National 
Screening Unit could be sidelined and the 
Clinical Director excluded from decision 
making. Consider that it is important that 
this risk is acknowledged and appropriately 
managed. 
See also CSI recommendation 1.13. 
A review of the Clinical Advisor’s position is 
being undertaken, including a change of 
title to Clinical Director and positioning to 
align with the restructured Ministry of 
Health. This will acknowledge the 
accountability and responsibilities of the 
role. 
Yes – ongoing 
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5 Status of the Cervical Cancer Audit recommendations 
Ref Recommendation 
(Cervical Cancer Audit) 
Status/date Further work 
required? 
5.28 Future audits 
Prior to further audits of women with 
invasive cervical cancer, priority be given 
to implementation of other Audit 
recommendations described above. 
Implementation of the audit 
recommendations has been prioritised. 
Yes – ongoing 
5.29 Independent audits of women with cervical 
cancer. 
Following the implementation of changes in 
the National Cervical Screening 
Programme, further independent audits of 
women with cervical cancer should occur, 
although not more frequently than once 
every 10 years. This interval could be 
reviewed if there was compelling reason to 
do so. 
The data accumulated for the years 
2003–2006 produced through linkage with 
the Cancer Registry have been analysed 
and published. 
Yes – ongoing 
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Chapter 3: Coverage, participation, equity and access 
Overview 
A well-conceived, well-managed national cancer control programme lowers cancer 
incidence and mortality and improves the quality of life of cancer patients. An organised 
population-based national cancer screening programme is a public health intervention 
designed to prevent and reduce the number of cancer cases and deaths attributable to 
the disease, through the systematic and equitable implementation of evidence-based 
strategies for prevention, early detection, diagnosis and treatment. A comprehensive 
national cancer screening programme aims to reduce the burden of a disease in the 
community, evaluates the various ways for prevention and early detection of the 
disease and implements those that are the most cost-effective and beneficial for the 
largest part of the population. Its emphasis is on preventing cancers or detecting cases 
early so that they can be cured. An effective cancer screening programme targets the 
identified ‘at risk’ population as a whole, while seeking to address the needs of the 
different subgroups at risk (WHO 2006a). 
 
The principles for implementation and management of a successful national screening 
programme include the following (Australian Population Health Development Principal 
Committee, Screening Subcommittee 2008): 
 The programme has a detailed national management policy framework that defines 
the screening age range and screening interval, the follow-up tests for those with a 
positive screening test, clinical guidelines for treatment and management, and 
identification and management of high-risk groups. 
 The screening pathway must be clearly defined and based on the best available 
evidence. 
 The pathway must be efficient and cost-effective and maximise the utilisation of 
resources. 
 Screening to diagnosis must be delivered in a timely manner, minimising any harms 
of delayed diagnosis and treatment. 
 The resources required, including funding, workforce and supporting workforce 
infrastructure, must be sufficient to sustain the programme. 
 The governance and coordination of the programme, including data capture, 
invitation and follow-up protocols, must be clearly defined. 
 There must be high levels of participation by the target population and evidence-
based strategies for ensuring ongoing participation in the programme – including high 
levels of participation by ‘at risk’ and disadvantaged groups. 
 There must be equity in access to all elements of the screening pathway for all 
participants, and information to support participants in making informed choices 
about their participation, management and treatment. 
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 Stakeholders (including consumers) must be engaged in the ongoing oversight of the 
programme to ensure support for and ‘ownership’ of the programme by those 
involved in its delivery. 
 There must be a quality management framework that continually reviews and 
assesses the programme’s performance. 
 Governance and management, including clinical leadership, must be robust. 
 A formal approach to the ongoing monitoring and evaluation of the programme must 
be undertaken. 
 
Without an end-to-end systematic, organised approach, screening programmes will not 
be able to achieve significant reductions in morbidity and mortality from the identified 
disease, and will consequently not realise the community and population benefits. 
 
Current status 
For the purpose of this report, ‘coverage’ considers the capacity of the cervical 
screening programme to ensure equitable, timely, access to all elements of the 
screening pathway for eligible women (regardless of their socio-economic, cultural, 
ethnic, disability, rural or remote status) in order for the programme to achieve its stated 
objectives and performance indicators. Generally, coverage refers to the extent to which 
the screening programme covers the eligible population equitably. Participation rates 
describe the proportion of women in the eligible population attending screening. 
 
Although coverage for all women, and each priority group is below the national target of 
80%, the National Cervical Screening Programme (NCSP) is to be congratulated for 
enabling access to screening for 76.4% of women aged 25–69 years over the most 
recently reported three-year period to December 2013 (see Table 3.1). Over a five-year 
period, 90.4% of women in the target age group accessed cervical screening. 
Participation rates for the cervical screening programme compare very favourably with 
participation rates in other developed countries with organised cervical screening 
programmes. Cervical cancer incidence and screening participation from 1980 to 2003 
are shown in Figure 3.1. Figure 3.2 shows an updated analysis of cervical cancer 
incidence and coverage from 2001 to 2014. 
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Figure 3.1: Cervical cancer incidence and screening participation among women aged 
20–69 years from 1980 to 2003 
 
Source: NZHIS and NCSP-R, National Cervical Screening Programme, 2005 
 
Figure 3.2: Age-standardised cervical cancer incidence rates of women aged 20–69 years 
for 2001 to 2013* and NCSP rolling coverage of women aged 20–69 years in each 
36-month period ending 31 December from 2001 to 2014** 
 
Notes: ASR = age-standardised rate per 100,000 population standardised to the World Health Organization (WHO) 
World Standard Population. 
* 2012 and 2013 cancer data is provisional. 2014 cancer data is not yet available. 
** Coverage is for each three-year period ending 31 December of the year indicated. 
Source: Cervical cancer data – the New Zealand Cancer Registry; coverage data – National Screening Unit 
 
  Report of the Parliamentary Review Committee 29 
 regarding the New Zealand Cervical Screening Programme 
International participation rates for organised cervical cancer screening programmes 
vary widely for many reasons, including differences in target age groups, screening 
intervals and eligibility criteria. Although any comparisons should be undertaken with 
caution, in a 2009 Canadian report comparing international participation in cervical 
screening programmes, three-year participation rates of over 80% were reported for 
Finland, New Zealand and Denmark (Funen County). Participation rates of between 
70% and 80% were observed in Iceland, Norway, the United Kingdom, Belgium and 
Denmark (Copenhagen). Participation rates of between 60% and 70% were seen in the 
Netherlands, Australia and Chile. In Sweden, participation rates ranged between 50% 
and 70%, and in Italy 36.7% of women were screened (Public Health Agency of Canada 
2009). 
 
In the National Cervical Screening Programme Monitoring Report Number 40 (NSU 
2014b), the hysterectomy-adjusted participation rate for women aged 25–69 years for 
the three years ending December 2013 was 76.4%. This was a slight increase of 1.2% 
on Monitoring Report Number 34; the 2010 rate was 75.2% (NSU 2012a), which was 
also the rate at the time of the 2011 Parliamentary Review (Tan et al 2011). The 
coverage for Māori, Pacific and Asian women has increased since the previous 
Parliamentary Review; however, participation by ethnic groups continues to fall well 
short of the 80% targets. Table 3.1 shows the three-year participation rates by ethnicity. 
 
Table 3.1: Percentage of women screened by ethnicity 
Ethnicity % screened in 3 years to 2013 % screened in 3 years to 2010 
Māori 62.6 56.4 
Pacific 68.6 60.9 
Asian 64.8 54.3 
European/Other 81.9 83.8 
Total 76.4 75.2 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Figure 3.3 below shows the percentage of women aged 25–69 years screened in the 
previous three years, by year and ethnicity. Figure 3.4 shows the percentage of women 
screened by ethnicity for each year. 
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Figure 3.3: Percentage* of women aged 25–69 years screened in the previous three 
years, 2008 to 2012, by year and ethnicity 
 
Note: Attendance is within the three year period ending on 31 December of the year Note: Attendance is within the 
three-year period ending on 31 December of the year indicated.* As a percentage of the hysterectomy-adjusted 
population in that age group and year, based on projections from 2006 Census population to the end of the relevant 
calendar year and hysterectomy prevalence estimates relating to the end of the relevant calendar year. 
Source: NCSP Annual Report 2012 (NSU 2014a) 
 
Figure 3.4: Percentage* of women aged 25–69 years screened in the previous three 
years, 2008 to 2012, by ethnicity 
 
Note: * As a percentage of the hysterectomy-adjusted population in that age group and year, based on projections 
from 2006 Census population to the end of the relevant calendar year and hysterectomy prevalence estimates 
relating to the end of the relevant calendar year. 
Source: NCSP Annual Report 2012 (NSU 2014a) 
 
Hysterectomy-adjusted five-year participation rates were 90.4% for all women aged 
25–69 years, compared with 87.8% in 2010. Five-year participation was 77.2% for 
Māori women, 86.7% for Pacific women, 76.4% for Asian women, and 95.9% for 
European/Other women. Figure 3.5 shows five-year coverage by ethnicity. 
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Of particular interest are the increases in coverage for Pacific and Asian women since 
Monitoring Report Number 34, which reports 2010 figures (NSU 2012a): coverage for 
Pacific women improved by 7.7% and for Asian women by 10.5% since 2010. There 
has been a 6.2% improvement in coverage for Māori women from 2010–2013. Of note, 
coverage for European/Other women declined by 1.9% over that same period 
(2010–2013). 
 
There are no readily available explanations, supporting data or rationale for these 
significant changes in participation coverage, particularly for Pacific and Asian women. 
However, feedback and interviews with stakeholders and National Screening Unit 
(NSU) staff during this Parliamentary Review provided some anecdotal insight that may 
enable the development of some hypotheses to help understand these improvements 
for participation among three ethnic groups and the slight decline among 
European/Other women. 
 
Figure 3.5: Five-year coverage by ethnicity (women screened in the five years prior to 
31 December 2013, as a proportion of hysterectomy-adjusted female population) 
 
Note: Coverage calculated using population projection for 31 December 2013 based on 2006 Census data. 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Anecdotal evidence from District Health Board (DHB) cervical screening providers 
suggests that marketing campaigns and the incentives implemented to encourage 
providers to achieve the 80% coverage targets for all demographic groups in their 
region may have played a significant role in the improvements in participation. Four 
DHBs have exceeded the overall 80% target for the three-year period ending December 
2013 – Hawke’s Bay (81.4%), Marlborough (81.7%), Taranaki (86.6%) and Wairarapa 
(82.5%). Two further DHBs – Capital & Coast (79.3%) and Southern (79.8%) – fell only 
marginally short of achieving the 80% target. Although the numbers of women within 
some ethnic groups are very small in some DHBs, it is worth noting that Wairarapa was 
the only DHB to have achieved the target of 80% coverage for Māori women, and 
indeed across all cultural groups. Six DHBs achieved the 80% target for Pacific women 
and nine achieved the target for Asian women. 
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It has also been suggested that the 1.9% decline in coverage for European/Other 
women may relate to a belief among young women who have had a human 
papillomavirus (HPV) vaccination that they do not need to screen (HPV vaccination and 
the interdependency with participation are covered in Chapter 11: Human 
papillomavirus and cervical cancer). The percentage of women aged under 30 years 
who participate in the programme has declined slightly between the 2011 and 2013 
monitoring reports; however, this factor alone is unlikely to explain the drop in coverage 
for European/Other women. Figure 3.6 shows the trends in three-year coverage by 
DHB. Table 3.2 shows coverage by DHB. 
 
Figure 3.6: Trends in three-year coverage by DHB (women aged 25–69 years screened in 
the previous three years, as a proportion of hysterectomy-adjusted female population) 
 
Note: Coverage calculated using population projection at the end date shown, based on 2006 Census data. 
Target 80%. 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
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Table 3.2: Coverage by DHB (women aged 25–69 years screened in the three years prior 
to 31 December 2013, hysterectomy-adjusted) 
DHB Hysterectomy-
adjusted population 
Women screened in the last 3 years 
Number Percentage 
Auckland 133,680 101,910 76.2 
Bay of Plenty 54,372 42,768 78.7 
Canterbury 132,874 98,219 73.9 
Capital & Coast 82,231 65,188 79.3 
Counties Manukau 129,590 90,073 69.5 
Hawke’s Bay 38,617 31,439 81.4 
Hutt Valley 36,629 28,574 78.0 
Lakes 25,929 20,355 78.5 
Mid Central 41,262 31,127 75.4 
Nelson Marlborough 36,265 29,627 81.7 
Northland 39,546 29,703 75.1 
South Canterbury 13,641 10,585 77.6 
Southern 76,446 60,967 79.8 
Tairawhiti 11,455 8,822 77.0 
Taranaki 26,979 23,355 86.6 
Waikato 91,231 70,213 77.0 
Wairarapa 9,832 8,113 82.5 
Waitemata 147,023 110,997 75.5 
West Coast 8,238 6,382 77.5 
Whanganui 15,076 11,349 75.3 
Total 1,150,916 879,766 76.4 
Note: Excludes 33 women for whom DHB could not be determined. 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Screening programmes require an organised, systematic approach to recruitment to 
ensure all population groups have equitable access to screening. This may require 
targeted interventions for groups at highest risk and/or greatest disadvantage. The 
recent ‘Support to Screening Services Review’ undertaken by the NSU may consider 
changes to the funding arrangements for support to services for disadvantaged women. 
Concern has been expressed by Māori independent service providers (ISPs), who are 
currently funded directly by the NSU to deliver screening services, that changes to 
funding arrangements may create barriers to participation in the screening programme 
for Māori women. Some of the many issues raised in feedback and during interviews 
with stakeholders were: concerns that women who owe money to primary health care 
providers for other services may be too embarrassed to attend for a free screening; the 
risks of losing ‘outreach’ services currently provided by ISPs; and the need for culturally 
competent providers. 
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The incidence of and mortality rates from cervical cancer in Māori women are twice 
the figures for women of all ethnicities. The age-standardised incidence rate in 2012 
was 6.2 new diagnoses per 100,000 women in the population as a whole and 12.7 
per 100,000 for Māori women. The age-standardised mortality rate in 2010 was 1.7 
per 100,000 women in the population and 3.3 per 100,000 for Māori women. 
 
A 2012 Statistics New Zealand report (Milne et al 2013) states that “socio-economic 
status (SES) is an important determinant of health”. Generally, more affluent groups 
have better health outcomes than less affluent groups. The reasons for this are multi-
factorial and cannot be easily distilled. Lower health literacy, lower education levels and 
lifestyles are just some of the factors that can contribute to higher disease incidence 
among lower socio-economic groups. The NCSP monitoring and annual reports capture 
data by ethnicity, but do not report participation by socio-economic groups. 
Understanding the interplay (if there is any) between ethnicity and socio-economic 
factors may help the NCSP more appropriately identify and develop strategies for 
improving participation for all women. 
 
DHBs and primary health organisations (PHOs) develop and deliver their own 
recruitment strategies to encourage participation in the screening programme at a local 
level. These initiatives are supported by incidental marketing campaigns and funding 
arrangements through the National Screening Unit. However, there is no nationally led, 
strategic recruitment plan that provides leadership, guidance and a coordinated 
approach to improving participation. To address the inequities in cervical cancer 
screening participation to ensure equity in access not only for Māori women but for all 
women, a nationally coordinated and consistent recruitment strategy is essential. 
 
A key factor in achieving improved outcomes for Māori women is the cervical screening 
programme’s ability to regularly access contemporary participation and outcome data. 
One specific need is the ability to match data from the National Cervical Screening 
Programme-Register (NCSP-R) on a regular and continuing basis with PHO databases 
so that unscreened and under-screened women can be identified and strategies 
implemented, where appropriate, to enable access to screening. It is essential that a 
close and collaborative working relationship is forged between the National Kaitiaki 
Group and NCSP, with a shared understanding that access to Māori data is critical to 
reducing cervical cancer incidence and mortality among Māori women. Access to this 
data will assist in developing strategies to improve participation rates and reducing the 
burden of the disease on the Māori population. 
 
Capacity and resource availability are key factors in ensuring all women are able to 
access screening. The Review Committee has not identified a shortage in the workforce 
that may reduce accessibility for women. The one exception relates to the concerns 
expressed by some stakeholders that there is a lack of providers who are culturally 
competent, and that this may be limiting participation, particularly among Māori women. 
Ensuring all providers are aware of their own cultural competency and are trained 
regularly will be important in enabling and supporting access to the programme by 
women from different cultural backgrounds. 
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Early re-screening (more frequently than the three-year screening interval) by women 
who had a previously normal screen and were recommended for the routine re-screen 
interval can place an unnecessary burden on the system, and consequently limit access 
for women who are either unscreened or under-screened. The December 2013 
Monitoring Report (NSU 2014b) calculated a national early re-screen rate of 18.5%, as 
shown in Table 3.3. This rate varied considerably by DHB – from 26.7% to 9.5%. For 
some of these women, early re-screening would be entirely appropriate, if the woman 
became symptomatic subsequent to a ‘normal’ screen. However, given the wide 
variance in early re-screening rates, consideration must be given to whether clinical 
practice has an influence in those areas where there are high re-screen rates. It is 
important for the cervical screening programme to understand and address, where 
necessary, these variations in early re-screening. 
 
Table 3.3: Early re-screening by DHB, 1 July to 31 December 2013 
DHB Women recommended to 
return in 3 years 
Women with ≥ 1 subsequent test 
Number % 
Auckland 4,758 1,216 25.6 
Bay of Plenty 2,186 484 22.1 
Canterbury 3,557 654 18.4 
Capital & Coast 3,584 515 14.4 
Counties Manukau 4,053 751 18.5 
Hawke’s Bay 1,494 232 15.5 
Hutt Valley 1,542 184 11.9 
Lakes 1,035 237 22.9 
Mid Central 1,532 146 9.5 
Nelson Marlborough 1,291 176 13.6 
Northland 1,383 231 16.7 
South Canterbury 546 106 19.4 
Southern 2,830 417 14.7 
Tairawhiti 432 58 13.4 
Taranaki 1,118 132 11.8 
Waikato 3,456 490 14.2 
Wairarapa 432 89 20.6 
Waitemata 5,514 1,471 26.7 
West Coast 270 50 18.5 
Whanganui 522 59 11.3 
Total 41,535 7,698 18.5 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
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Providing timely results and promptly following up women with a cytological abnormality 
are other measures of equity and access for a screening programme. Laboratories have 
targets for turnaround times to ensure women are provided their results within an 
acceptable timeframe. Overall, 95% of cytology samples were reported on within seven 
working days and 99.3% within 15 working days. Both these outcomes surpass the 
national targets. 
 
To ensure women with an abnormality receive timely management and treatment, the 
target is for 90% of women with a high-grade cytology result to have been seen by a 
specialist and have had a histology report within 90 days of their cytology report date. 
Nationally, 82.3% of women had a histology report within 90 days of their cytology 
report, which is below the 90% target. In some instances, women may not have had a 
biopsy performed at colposcopy, and so there would be no histology report. However, 
for the reported period, 2,490 women required follow-up. There were 280 women 
(11.2%) who had no record of any subsequent follow-up within 90 days of their cytology 
report, and 167 women (6.7%) who had no record of any follow-up within 180 days. 
There was significant variation across DHBs (as shown in Figure 3.7) and also by 
ethnicity, with 24.4% of Pacific women and 14.8% of Māori women not having a 
follow-up test reported within 90 days after a high-grade cytological abnormality (see 
Figure 3.8). Asian women were the most likely to have had follow-up tests within 
90 days of an abnormal cytology report. 
 
These variations in outcomes indicate there may be inequities in access or barriers 
particularly for Pacific and Māori women that make it more difficult for them to access, 
or understand the need for, timely follow-up after an abnormal test result. 
Understanding what these barriers and inequities might be will be essential in order for 
the programme and service providers to implement strategies that will remove these 
barriers and inequities in access to timely follow-up. 
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Figure 3.7: Proportion of women without any follow-up test within 90 days and within 
180 days of a high-grade cytology report, by DHB 
 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Figure 3.8: Proportion of women without any follow-up test within 90 days and within 
180 days of a high-grade cytology report, by ethnicity 
 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
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Key issues 
 Socio-economic status is recognised as an important determinant of health (Milne 
et al 2013), with more affluent groups having better health than less affluent groups. 
The NCSP monitoring and annual reports capture data by ethnicity, but do not report 
participation by socio-economic group. Understanding the interplay (if there is any) 
between ethnicity and socio-economic factors may help the NCSP more 
appropriately identify and develop strategies for improving participation for all 
women. 
 The incidence of and rates of mortality from cervical cancer in Māori women are twice 
the figures for women from all ethnicities. The age-standardised incidence rate in 
2012 was 6.2  new diagnoses per 100,000 women in the population as a whole and 
12.7 per 100,000 for Māori women. The age-standardised mortality rate in 2010 was 
1.7 per 100,000 women in the population and 3.3 per 100,000 for Māori women. 
Tailored and well-coordinated national strategies that remove barriers to screening 
and timely follow-up for Māori women are essential so that these inequities in health 
outcomes can be addressed. 
 A nationally coordinated and consistent recruitment strategy is essential to address 
the inequities in cervical cancer screening participation to ensure equity in access not 
only for Māori women but for all women. The NCSP should centrally coordinate at a 
national level a full range of health promotion and recruitment initiatives. 
 A critical part of achieving improved participation rates and reducing the burden of 
the disease on the Māori population will be having a close and collaborative working 
relationship with the Māori Monitoring and Equity Group to work on the development 
of health promotion and recruitment strategies and in partnership with the National 
Kaitiaki Group (NKG) to enable access to data in order to develop and appropriately 
target strategies. 
 It is important to ensure all providers are aware of their own cultural competency and 
are trained regularly to support access to the cervical screening programme by 
women from different cultural backgrounds. 
 Given the wide variation in early re-screening rates among DHBs (see Table 3.3), it is 
important for the cervical screening programme to regularly monitor and review 
performance across DHBs for this indicator. The purpose of this activity is to 
determine whether the variation is due to clinical practice that is not conforming with 
guidelines in those areas where there are high early re-screen rates. 
 The variation in timely follow-up outcomes suggests there may be barriers to 
accessing services, particularly for Pacific and Māori women. Timely follow-up after 
an abnormal test result is important. Overcoming barriers will be essential to reduce 
inequities and ensure timely follow-up. 
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Recommendations 
1. Ongoing strategies are needed to address the disparities among priority groups in 
terms of participation and retention. Improved follow-up is needed after abnormal 
screening results. 
2. The provision of funding for free smears is a commendable initiative, but the 
amount of funding and consequently coverage, is limited. There need to be clear 
strategies to ensure that access to free smears is appropriately targeted to the 
women with the highest need. To improve coverage for high-priority women, the 
cost of smears must not be a barrier. 
3. Cultural competency is vitally important and ongoing education is needed to 
ensure that smear takers are attuned to cultural sensitivities. ISPs play a vital role 
in supporting local communities and providing access to cervical screening. Any 
changes to funding for ISPs for cervical screening should be carefully evaluated in 
terms of their consequences. DHBs and PHOs should be supported to work 
closely with ISPs to facilitate access to screening for unscreened and under-
screened women. 
4. Ongoing HPV education campaigns are important to ensure increased awareness 
and knowledge among the general population and among health care providers. 
This is of particular importance prior to any introduction of primary HPV screening. 
5. It is recommended that NCSP and NKG work closely together to facilitate more 
timely and ongoing access to Māori data.11 
6. The NSU and NCSP must continue to work to meet the priorities of the New 




                                            
11
 See also Chapter 8: NCSP-Register and Chapter 9: Ethnicity data. 
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Chapter 4: Monitoring and evaluation 
Overview 
Historical enquiries and reviews are summarised in Table 1.2 (Chapter 1: Introduction 
and methods). Evaluating the performance of the National Cervical Screening 
Programme (NCSP) currently involves: 
 independent monitoring of a range of performance indicators against agreed targets 
 regular independent audits of specific programme components 
 three-yearly reviews of the programme as a whole, in accordance with the Health 
(National Cervical Screening Programme) Amendment Act 2004. The last review 
took place three years ago (Tan et al 2011) 
 ongoing monitoring of smear takers, laboratories and colposcopy services against 
the programme’s own quality standards 
 investigation of complaints 




The World Health Organization (WHO 2002), in its policy and managerial guidelines for 
cancer control programmes, advises that monitoring and evaluation must be built into a 
programme’s design. The implementation and delivery of a cancer control plan need to 
be evaluated. Evaluation is a means of monitoring the programme design and 
effectiveness so that it can be improved. At the development level, evaluation can help 
answer questions about how well the processes and systems are working and whether 
the goals and objectives are being met. Evaluation can show whether the strategies are 
being implemented, and whether the anticipated outcomes are being realised. 
 
Both outcome and process measures need to be monitored. Process evaluation is 
critical for ensuring the ongoing success of the programme. Gathering feedback from 
key partners on their satisfaction with the programme, then making corrections as 
necessary so that concerns are addressed, is an important part of ensuring trust in, and 
credibility of, the programme within the targeted population. To determine whether a 
screening programme is achieving its designed purpose, it is also necessary to monitor 
process measures. For example, in a cytology cervical screening programme, it is 
important to ensure that women who are at risk of cervical cancer are being screened 
by good-quality Pap smears (process measures) and to monitor trends in incidence and 
mortality from cervical cancer (outcome measures), rather than simply focusing on the 
number of women being screened. 
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For successful programme monitoring and evaluation, it is important to: 
 allocate resources and staff to conduct evaluation activities of all elements of the 
programme 
 identify emerging challenges, develop solutions and conduct ongoing planning for 
improvement (the Plan-Do-Check-Act (PDCA) cycle) 
 appoint the responsible people and set deadlines for remediation or implementation 
of revised processes. 
 
Comprehensive monitoring reports have been produced by the NCSP since 2004. Since 
the last Parliamentary Review Committee Report (Tan et al 2011), external monitoring 
reports have been produced biannually by a team at the Lowy Cancer Research Centre, 
University of New South Wales, Australia, against a suite of eight groups of monitoring 
indicators as follows: 
 Indicator 1: Coverage 
 Indicator 2: First screening events 
 Indicator 3: Withdrawal rates 
 Indicator 4: Early re-screening 
 Indicator 5: Laboratory indicators 
 Indicator 6: Follow-up of women with high-grade cytology and no histology 
 Indicator 7: Colposcopy indicators 
 Indicator 8: Human papillomavirus (HPV) tests. 
 
These reports provide ongoing monitoring against the programme’s process measures 
and indicator targets, where targets are set. Full copies of the reports are available on 
the National Screening Unit (NSU) website at www.nsu.govt.nz including the latest 
report (NSU 2014b). 
 
Indicator 1: Coverage 
The population distribution of women by ethnicity is shown in Table 4.1. Coverage has 
been discussed in detail in Chapter 3: Coverage, participation, equity and access. There 
is, however, an element of population coverage currently not monitored. A New Zealand 
report on Decades of Disparity (Ministry of Health and University of Otago 2006) 
suggests that inequalities in health exist between ethnic groups and social classes in 
New Zealand, as they do anywhere else, and that the inequalities are not accidental in 
that for most countries, “socially disadvantaged and marginalised groups have poorer 
health, greater exposure to health hazards, and lesser access to high quality health 
services than their more privileged counterparts”. The report finds that the extent of 
inequalities in New Zealand is unacceptable. The authors also state that, where health 
is concerned, ethnicity is not confined to ‘socio-economic position’. Hence, both socio-
economic position and ethnicity (as a marker of differential experience and exposure) 
matter in terms of health. These two factors jointly and independently influence mortality 
through multiple pathways and require integrated social and health policy to reduce and 
eliminate inequalities and inequities (Ministry of Health and University of Otago 2006). 
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Regular reporting and monitoring of participation by an additional measure of socio-
economic status would add a valuable dimension to enable greater understanding of the 
barriers to screening, and to inform the development of further, coordinated national 
strategies to ensure equitable access to all elements of the screening pathway by all 
disadvantaged groups. 
 
Table 4.1: Population distribution of women aged 20–69 years 






Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
Indicator 2: First screening events 
This indicator enables the programme to monitor the numbers and proportion of women 
entering the programme, by ethnicity and age. Ideally, and to ensure screening equity, 
the proportion of women undertaking their first screening event should be reflective of 
population demographics and distribution. First screening events should also be 
concordant with screening guidelines, with the majority of New Zealand women 
screening for the first time being in the age group of 20–24 years. Monitoring Report 
Number 40 (NSU 2014b) shows conclusively that the overwhelming majority of women 
entering the programme are, as would be expected, in the age range of 20–35 years. 
Of particular interest is the distribution by ethnicity of first screening events. Although 
the Monitoring Report does not enable absolute conclusions to be drawn, it would 
appear that Māori and Pacific women are significantly under-represented in first 
screening events (based on population distribution data from Indicator 1 – see 
Table 4.2). 
 
The ethnic group with the highest number of women with first screening events, as 
would be expected given the population distribution, was European/Other women 
(13,142). Asian women were the next highest (5,178), then Māori (2,242) and Pacific 
women (1,628). Māori women had the lowest proportion of their eligible population 
being screened for the first time and Asian women had the highest proportion. 
 
Monitoring Indicator 2 has no monitoring target at this time. To support WHO’s doctrine 
of translating ‘knowledge into action’ to enable continuous quality improvement for the 
programme, the NCSP should review whether targets could be implemented for this 
indicator to enable closer monitoring of the distribution of first screening events by 
ethnicity and socio-economic status. 
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Table 4.2: Women (aged 20–69 years) with first screening events as a proportion of 
i) total number of women with screening events, and ii) eligible women, by ethnicity, for 
the period 1 July–31 December 2013 
Ethnicity Women with 
first events 








n % n % 
Māori 2,242 23,093 9.7 177,735 1.3 
Pacific 1,628 10,914 14.9 78,228 2.1 
Asian 5,178 23,644 21.9 174,165 3.0 
European/Other 13,142 155,711 8.4 881,008 1.5 
Total 22,190 213,362 10.4 1,311,136 1.7 
Note: Proportions shown are women with first screening event within a DHB, divided by i) all women with a screening 
event within that DHB (first or subsequent events) and ii) the hysterectomy-adjusted 2006 Census population 
projected to 31 December 2013 for that DHB, as a percentage. 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Indicator 3: Withdrawal rates 
All women who have a cervical screening test have the results of those tests recorded 
on the National Cervical Screening Programme-Register (NCSP-R), unless they elect to 
withdraw from the programme. The NCSP website, under Frequently Asked Questions, 
provides the following information (NCSP 2014a). 
 
Q: Does a woman have to take part in the programme? 
A: No, a woman can decide at any time she does not want to take part in the 
programme and withdraw. When a woman withdraws, she and her smear taker 
are responsible for her own screening. 
This means the programme will not: 
 make sure a complete record of your cervical screening history exists, even if 
you change your doctor or smear taker 
 send reminder letters if you are overdue for a smear 
 make sure you get the right tests and treatment if you have an abnormal result. 
 
To ensure the programme is able to effectively monitor the cervical screening 
programme’s effectiveness and outcomes, it is important that ‘withdrawal rates’ are zero 
or negligible. The NCSP Monitoring Report Number 40 (NSU 2014b) reports the 
number of women who have actively elected to withdraw from the programme has 
increased from 41 women in the previous Monitoring Report to 53 women for the latest 
reporting period. This represents just 0.004% of women on the Register. The data 
completeness to enable appropriate monitoring and evaluation of the programme is 
considered acceptable, and certainly comparable with organised cervical screening 
programmes in other countries. 
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Indicator 4: Early re-screening 
Early re-screening has been discussed in Chapter 3: Coverage, participation, equity and 
access. It is noted that there is no target set for this indicator; however, the objective 
would be to ensure ‘early re-screening’ is maintained at ‘as low as reasonably 
achievable’ levels. 
 
In reviewing ‘early re-screen’ rates by District Health Board (DHB), there is significant 
variance – ranging from the lowest rate of 10% of women (who were recommended to 
return at the routine screening interval (three years) and were re-screened early) to the 
highest rate of 27%. The median early re-screen rate is 16.5% and the mean is 17%. It 
is important for the programme to translate knowledge into action and investigate further 
to understand whether this is a chance anomaly and women are re-screening early for 
symptomatic reasons, or whether quality improvement interventions are necessary and 
work is required to ensure clinical compliance with NCSP screening guidelines. 
 
A watching brief on this indicator will be important to ensure that early re-screening 
does not reduce the cost-effectiveness of the programme and that it does not also limit 
access for women who are not screening regularly. 
 
Indicator 5: Laboratory indicators 
There is a suite of indicators to enable regular monitoring of laboratory performance, the 
quality of samples, positive predictive values and timeliness of reporting. The seven 
pathology laboratories in New Zealand are all meeting performance targets for liquid-
based cytology (LBC) samples reported as unsatisfactory, and the proportion of 
satisfactory samples reported as negative. The number of LBC samples reported as 
unsatisfactory also enables monitoring of the quality of smear-taking technique by 
providers, which is important given that one of the factors contributing to an 
‘unsatisfactory sample’ is inadequate cells being collected due to poor technique. 
 
Performance targets for ‘satisfactory samples reported as abnormalities and as high-
grade squamous intraepithelial lesions (HSIL) by laboratory’ have not been met by all 
laboratories. However, the significant variance for one laboratory may well be explained 
by its case mix, where a significant proportion of samples are from colposcopy clinics, 
and it is to be expected that there would be a higher abnormality rate with these 
samples. 
 
Of particular note is the significant decline in the proportion of samples reported as HSIL 
for women in the age cohorts of < 20 and 20–24 years. Women in these age groups 
were eligible for HPV vaccination (the oldest cohort would have been aged up to 
23 years at the time of the latest Monitoring Report). As the NCSP-R does not capture 
vaccination status, it is not possible to determine whether this decline is consistent with 
an effect of HPV vaccination. It will be essential to monitor whether the decline in high 
grade abnormalities is sustained, as anticipated. Achieving the ability to match data or 
record women’s HPV vaccination status on the NCSP-R is an essential body of work for 
the programme. 
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Indicator 5.3, which monitors the accuracy of negative cytology reports, showed a 
significant variance across some laboratories (NSU 2014b, p 63). Close monitoring of 
this indicator is essential and discussions with pathology experts to determine whether a 
quality intervention is required would be highly appropriate. 
 
Indicator 6: Follow-up of women with high-grade cytology and no histology 
This indicator, which monitors the follow-up of women with high-grade cytology, has 
been discussed in Chapter 3: Coverage, participation, equity and access. It showed 
significant variation across DHBs and also by ethnicity: 24.4% of Pacific women and 
14.5% of Māori women did not have a follow-up test reported within 90 days after a 
high-grade cytological abnormality. Asian women were the most likely to have had 
follow-up tests within 90 days of an abnormal cytology report. 
 
These variations in outcomes indicate there may be inequities in access or barriers 
particularly for Pacific and Māori women that make it more difficult for them to access, 
or understand the need for, timely follow-up after an abnormal test result. 
Understanding what these barriers and inequities might be will be essential in order for 
the programme and service providers to implement strategies that will remove these 
barriers and inequities in access to timely follow-up. 
 
Indicator 7: Colposcopy indicators 
This suite of indicators monitors timeliness of access to colposcopy and treatment and 
the adequacy of documentation of colposcopy assessment. The indicators to monitor 
the minimum colposcopy volumes for providers to maintain competency (against the 
NCSP Policies and Standards) are not yet being reported. 
 
The targets for timely follow-up for women with a high-grade cytology report (both those 
with suspicion of invasive disease and those with no suspicion of invasive disease) to 
accepted referral and colposcopy visit have not been met. As previously identified, the 
proportional over-representation of Māori and Pacific women who are not accessing 
timely follow-up for treatment and management of suspicious high-grade abnormalities 
indicates these women face barriers to accessing services. Strategies to identify and 
address these issues are essential. 
 
Complete data for the timeliness of women accessing colposcopy subsequent to 
persistent low-grade cytology or a low-grade cytology and positive HPV test was not 
available from the NCSP-R for the latest Monitoring Report. Because the e-colposcopy 
project has experienced interoperability challenges, the majority of providers have been 
unable to upload colposcopy reports. A comprehensive national intervention to resolve 
these information technology (IT) issues is essential. For more information on 
colposcopy, refer to Chapter 10: Colposcopy. 
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Indicator 8: HPV tests 
This indicator monitors the use of HPV testing. Currently two indicators are reported (no 
targets have been set), while further work is to be undertaken to identify other measures 
that will enable monitoring of the use of HPV testing. For more information on HPV and 




Determining the priorities for a health system draws on a variety of technical, political 
and ethical criteria. Cost-effectiveness is never the only criterion to be considered, but it 
is the one that must be met most often when deciding which interventions to choose 
(WHO 2006a). 
 
All countries have to make difficult choices on how best to allocate resources for health 
and health care. Cost-effectiveness summarises the efficiency with which an 
intervention produces health outcomes. A ‘highly cost-effective’ intervention is defined 
as one that generates an extra year of healthy life (equivalent to averting one disability-
adjusted life year – DALY) for a cost that falls below the average annual income or 
gross domestic product per person. In 2011, the First Ministerial Conference on Healthy 
Lifestyles and Noncommunicable Disease Control (WHO 2011) found that cervical 
cancer screening and treatment of pre-cancerous lesions to prevent cervical cancer are 
very cost-effective and very low cost, averting a current global disease burden of five 
million DALYs. 
 
What is a disability-adjusted life year? 
The World Health Organization (WHO 2015a) explains that one disability-adjusted life 
year (DALY) can be thought of as one lost year of ‘healthy’ life. The sum of these 
DALYs across the population, or the burden of disease, can be thought of as a 
measurement of the gap between current health status and an ideal health situation, 
where the entire population lives to an advanced age, free of disease and disability. 
DALYs for a disease or health condition are calculated as follows. 
 
The sum of the years of life lost (YLL) due to premature mortality in the population 
and the years lost due to disability (YLD) for people living with the health condition 
or its consequences (DALY = YLL + YLD). 
 
A QALY, the ‘quality-adjusted life year’, is a measure of disease burden, including both 
the quality and the quantity of life lived. It is used in assessing the value for money of a 
medical intervention. 
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Key issues 
 Including an additional measure of socio-economic status in the regular reporting and 
monitoring of participation would enable a greater understanding of the barriers to 
screening, and would inform the development of further national strategies to ensure 
equitable access to the screening pathway by all disadvantaged groups. 
 Monitoring Indicator 2 (first screening events) has no monitoring target at this time. 
The NCSP should review whether targets could be implemented for this indicator to 
enable closer monitoring of the distribution of first screening events by ethnicity and 
socio-economic status. 
 Review of ‘early re-screen’ rates shows significant variance among DHBs. It is 
important for the programme to understand whether these are chance anomalies and 
women are re-screening early for symptomatic reasons, or whether quality 
improvement interventions are necessary to ensure clinical compliance with NCSP 
screening guidelines. A watching brief on this indicator will be important to ensure 
that early re-screening does not reduce the cost-effectiveness of the programme and 
that it does not also limit access for women who are not screening regularly. 
 The number of smears reported as HSIL for women in the age cohorts of < 20 and 
20–24 years has declined significantly. Women in these age groups were eligible for 
HPV vaccination. However, as the NCSP-R does not capture vaccination status, it is 
not possible to determine whether this decline is consistent with an effect of HPV 
vaccination. It will be essential to monitor whether the decline in high-grade 
abnormalities is sustained, as anticipated. Achieving the ability to match data or 
record women’s HPV vaccination status on the NCSP-R is an essential body of work 
for the programme. 
 There is significant variance across laboratories for Indicator 5.3, which monitors the 
accuracy of negative cytology. Close monitoring of this indicator is essential. It would 
be highly appropriate to review and discuss these findings with pathology experts to 
determine whether a quality intervention is required. 
 The targets for timely accepted referral and colposcopy visit for women with a high-
grade cytology report have not been met. As previously identified, the proportional 
over-representation of Māori and Pacific women who are not accessing timely follow-
up for treatment and management of suspicious high-grade abnormalities indicates 
these women face barriers to accessing services. Strategies to identify and address 
these issues are essential. 
 Complete data for the timeliness of women accessing colposcopy subsequent to 
persistent low-grade cytology or a low-grade cytology and positive HPV test was not 
available from the NCSP-R for the latest Monitoring Report. Because the 
e-colposcopy project has experienced interoperability challenges, the majority of 
providers have been unable to upload colposcopy reports. A comprehensive national 
intervention to resolve these information technology issues is essential. 
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Recommendations 
7. There should be more stringent monitoring of the quality of colposcopy. 
8. Regular reporting and monitoring of participation by a measure of socio-economic 
status should be considered as an additional monitoring indicator to ensure 
equitable access by all disadvantaged groups. 
9. Monitoring Indicator 2 (First screening events) has no monitoring target at this 
time. The NCSP should review whether targets could be implemented for this 
indicator to enable closer monitoring of the distribution of first screening events by 
ethnicity and socio-economic status. 
10. Early re-screen rates vary significantly by DHB. The NCSP should investigate to 
understand whether these are chance anomalies or whether training or 
interventions are required to ensure clinical compliance with NCSP screening 
guidelines. 
11. It will be important for the NCSP to determine if the decline in the proportion of 
samples reported as HSIL for women in the age cohorts of < 20 and 20–24 years 
is consistent with an effect of HPV vaccination. The ability to match data or record 
women’s HPV vaccination status on the NCSP-R is an essential body of work for 
the programme. 
12. There is significant variance across laboratories for Indicator 5.3, which monitors 
the accuracy of negative cytology. Close monitoring of this indicator is essential. It 
would be highly appropriate to review and discussions these findings with 
pathology experts to determine whether a quality intervention is required. 
13. The proportion of women who did not have a follow-up test reported within 90 days 
after a high-grade cytological abnormality varied significantly across DHBs. It also 
varied by ethnicity, with 24.4% of Pacific women and 14.8% of Māori women, not 
having a follow-up test within an appropriate timeframe. The NCSP should 
investigate the barriers to attendance that are preventing timely investigations and 
treatment, and develop strategies to improve outcomes for these women. 
14. A comprehensive national intervention to resolve the barriers to the successful 
implementation of the e-colposcopy project is essential to ensure complete data 
for women referred for colposcopy is captured on the Register. 
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Chapter 5: Quality assurance 
Overview 
‘Quality assurance’ has been an approach applied in health service delivery for many 
years. Duke University Medical Centre (2014), in a document considering the terms 
‘quality assurance’ and ‘quality improvement’, states that some perceive ‘quality 
assurance’ as having negative connotations and associate it with a reactive, 
retrospective and sometimes punitive approach. For the purposes of this report, the 
chapter title of ‘Quality assurance’ is referring to the strategies and practices employed 
within the National Cervical Screening Programme (NCSP) to assure the quality of 
services provided to women accessing the programme. This is otherwise known as a 
philosophy of continuous quality improvement. 
 
The World Health Organization (WHO), in its document Quality of Care. A process for 
making strategic choices in health systems (WHO 2006b), notes that medical science 
and technology have advanced at a rapid pace, and that health care systems have 
floundered in their ability to provide consistently high-quality care to all. The document 
notes that the scientific and technological advances will not, in and of themselves, lead 
to the high-quality health care that populations and individuals rightly have come to 
expect. Taking a systems perspective and orienting systems to the delivery and 
improvement of quality services are fundamental to meeting the expectations of the 
population. 
 
WHO’s report Comprehensive Cervical Cancer Control: A guide to essential practice 
(WHO 2014) states that quality assurance and a quality control approach are essential 
for cervical cancer prevention and control programmes. One risk of screening, which 
applies to all screening tests described, is a variable rate of over-detection of pre-cancer 
(i.e. false-positive results), which leads to overtreatment of women who are in fact not at 
increased risk of invasive cancer at that time. Another, more significant risk of screening 
is the risk of obtaining a false-negative result, which may result in missing signs of 
disease and thus a missed opportunity for treatment of pre-cancer or early cancer. 
Another risk to the success of the screening programme is represented by women who 
do not screen, or do not screen regularly. 
 
Current status 
The National Screening Unit (NSU) has produced a draft document, released for 
consultation in December 2014, titled National Screening Unit Quality Framework 2014: 
Delivering screening programmes (NSU 2014c).The core set of six principles is 
intended to provide a foundation for achieving the NSU’s strategic vision for achieving 
high-quality, equitable and accessible screening programmes. 
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NCSP Policies and Standards documents provide agreed policies, guidelines and 
standards of practice for health professionals who provide cervical screening services 
(Ministry of Health 2014a). Their purpose is to support all those involved in the NCSP to 
achieve the programme’s aims and objectives, by ensuring a high standard and national 
consistency of service at each step of the screening pathway. These Policies and 
Standards establish the baseline for the programme’s delivery. Regular monitoring and 
evaluation of the programme’s performance against key indicators should inform and 
facilitate continuous quality improvement by identifying areas where performance is not 
to the expected standard, or where gaps in programme design or service delivery are 
identified. 
 
The NCSP also has well-established advisory group structures, including the NCSP 
Advisory Group and the Māori Monitoring and Equity Group, which can both support 
and inform the identification of issues and development of strategies that will assist in 
the achievement of its quality strategic vision. In addition to these groups will be the 
reformed National Screening Advisory Committee, which will provide overall 
governance to the roll-out of human papillomavirus (HPV) screening as the primary 
screening test. Engaging these groups in the quality improvement initiatives for the 
programme will be critical to the success of the initiatives. 
 
The United Kingdom’s Health Foundation has instituted a broad research agenda into 
quality services and quality improvement initiatives (Health Foundation 2009). The so-
called ‘quality enhancing interventions’ offer a resource to inform health services on 
similar quality issues and improvements implemented. When monitoring and evaluation 
data shows areas for improvement, the next step is to identify the most effective actions. 
 
In Comprehensive Cervical Cancer Control, the WHO (2014) advises that all screening 
programmes require a well-functioning quality control and quality assurance 
programme. According to its Health Systems Strengthening Glossary (WHO 2015b), 
‘monitoring’ is the continuous oversight of an activity to assist in the programme’s 
supervision and to see that it proceeds according to plan. It involves the specification of 
methods to measure activity, the use of resources, and the performance by services 
against agreed criteria. 
 
Programme performance monitoring and continuous quality improvement initiatives 
developed as a result of monitoring are critical to the ongoing success of screening. The 
Plan-Do-Study-Act (PDSA) cycle or Plan-Do-Check-Act (PDCA) cycle, otherwise known 
as the ‘Deming cycle’, is a model for continuous quality improvement that is particularly 
pertinent for screening programmes (see Figure 5.1). The cycle begins with a ‘Planning’ 
phase in which the issue to be addressed is clearly identified and understood. A critical 
element in identifying the issue is to ask – over and over again – ‘Why is this occurring?’ 
Potential solutions can then be generated and tested in the ‘Do’ phase, and the 
outcome of this testing is evaluated during the ‘Check’ phase. ‘Do’ and ‘Check’ phases 
can be iterated as many times as is necessary before the full, polished solution is 
implemented in the ‘Act’ phase. The cycle is perpetual and based on continual 
monitoring and evaluation of performance. 
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Figure 5.1: The Plan-Do-Check-Act cycle 
 
 
The National Screening Unit is taking a proactive approach by developing a draft 
Quality Framework for delivering screening programmes. Once endorsed, the next 
stage will be to identify areas where there is a need to develop actions or interventions. 
The biannual monitoring reports have been developed to monitor the effectiveness of 
the screening programme. It is essential that the knowledge gained through these 
reports is used for the ongoing quality improvement of the programme through the 
development of a Quality Improvement Plan – based on the PDCA cycle. Where 
monitoring targets have not been met, or when performance across any of the 
measures falls outside of the expected norms, the proactive development of strategies 
to improve performance is an essential element of a successful screening programme. 
 
For example, this approach could be applied to address the variations in Indicator 4 
(Early re-screening) identified in Chapter 4: Monitoring and evaluation. The first phase 
of the planning cycle for quality improvement in outcomes for Indicator 4 would be to 
recruit experienced clinicians and engage them in reviewing variations across District 
Health Boards (DHBs). This could include case study reviews or audits. 
 
If unexplained deviations from clinical guidelines were identified, the ‘Planning’ phase 
would see the development of strategies such as training or education interventions for 
clinicians to encourage compliance with guidelines. The ‘Do’ phase of the cycle would 
be implementing these strategies and the ‘Check’ phase would be ensuring clinicians 
understand and feel confident with the screening guidelines. Finally, the ‘Act’ phase 
would involve the ongoing monitoring of ‘early re-screening’ rates, ensuring that 
clinicians are complying with the guidelines and that early re-screening rates fall within 
expected margins. Ongoing monitoring will identify if or when further interventions may 
be needed. 
 
Monitoring and evaluation are neither static nor stand-alone elements of the screening 
system and processes. Performance monitoring must inform the development and 
implementation of strategies that become part of the continuous quality improvement 
cycle. 
 
 52 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Quality improvement of service provision by providers should be carried out continually, 
with any quality improvement strategies instituted in a timely manner. Improving quality 
is a responsibility of all stakeholders, and may include: 
 self-assessment and local problem-solving, as participatory methods that should 
involve all providers as well as representative members of the community 
 supportive supervision, which is particularly pertinent to service providers at the 
primary health organisation (PHO) level who are performing cervical screening tests, 
and also staff in laboratories. This process should be facilitated by trained 
supervisors, and may include mentoring and updating the skills of health workers and 
working with them to solve any issues noted 
 seeking feedback from consumers of the service to identify shortfalls or gaps in 
service delivery. 
 
Process evaluation is critical for ensuring the ongoing success of the programme. 
Gathering feedback from key partners (including providers and consumers of the 
services) on their satisfaction with the programme, then making corrections as 
necessary so that concerns are addressed, is an important part of ensuring trust in, and 
credibility of, the programme within the targeted population. 
 
The Parliamentary Review Committee has reviewed a report on complaints relating to 
cervical screening submitted to the Health and Disability Commissioner (HDC) for the 
period 23 June 2011 to 26 March 2015. In all, 15 complaints were received by the HDC 
during this period. Most (eight) complaints were from women who had experienced 
delays in communication of results or in diagnosis of abnormalities, or failure to refer 
appropriately or in a timely manner. Six complaints were about inappropriate conduct, 
inadequate communication or incorrect information being provided by the health care 
provider/s. One complaint was regarding a perception of inappropriate cervical 
screening posters in general practices and coercion by doctors of women to be 
screened. Two complaints (one from July 2013 and the other from July 2014) are still 
under investigation by the HDC. 
 
It is important to note that the 15 complaints are only those that have reached the level 
of submission by consumers to the Health and Disability Commissioner. It is not known 
what complaint management processes are in place within DHBs and general practices, 
nor what the quantum or scope of those complaints might be. Around 270 complaints 
have been received over the last four years by the NSU regarding a range of issues 
relating to cervical screening services. 
 
Core principles of a successful screening programme are that the test/s are acceptable 
to the population being screened, and that the screening programme is safe for 
participants, both physically and psychosocially. Monitoring and acting on (where 
appropriate) feedback on the delivery and acceptability of screening services is a critical 
element of programme continuous quality improvement. It is important that the NCSP 
continually seeks and monitors feedback on the acceptability of the programme to 
participants, and implements remedial strategies where required. 
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For successful programme monitoring, evaluation and continuous quality improvement, 
it is important to: 
 allocate resources and staff to conduct evaluation activities of all elements of the 
programme 
 identify emerging challenges, develop solutions and conduct ongoing planning for 
improvement as shown in the PDCA (see Figure 5.1) 
 appoint the responsible people and set deadlines for remediation or implementation 
of revised processes 
 have ready access to timely data. 
 
Monitoring and evaluation and the implementation of quality improvement strategies 
must be a collaborative process between the NCSP, DHBs, laboratories and the 
National Cervical Screening Programme-Register (NCSP-R) so that lessons can be 
shared and strategies implemented consistently across the country. Regular, ongoing 
monitoring and quality improvement meetings should be scheduled shortly after the 
release of the biannual monitoring reports, and the agenda for these meetings should 
be informed by the monitoring report indicators. The actions and outcomes from these 
meetings would inform the development of, on an ongoing basis, a Quality Improvement 
Plan for the NCSP. 
 
Canada’s cervical screening programme has also led to significant reductions in cervical 
cancer incidence and mortality (Canadian Partnership Against Cancer 2013). Despite 
this success, over 1,400 Canadian women are diagnosed with invasive cervical cancer 
each year. Canadian studies have found that women diagnosed with invasive cervical 
cancer were not screened in the five years before diagnosis, were not followed 
appropriately after an abnormal Pap test result, or had a Pap test that failed to detect 
their cancer. The Canadian Cervical Screening Program states that the continuous 
monitoring and evaluation of cervical cancer screening is critical to ensure that 
Canadian women have access to and receive high-quality cancer prevention services. 
 
The 2011 NCSP Parliamentary Review Committee (Tan et al 2011) recommended 
ongoing audit of the screening histories of women who develop cervical cancer. The 
underpinning rationale is that there are likely to be valuable lessons from these audits 
that would inform the implementation of quality improvement initiatives. It is essential 
that these audits occur regularly and involve expert clinicians involved in the 
programme. Any identified system or process gaps or failures should be used to inform 
quality improvement strategies, and be incorporated into a quality improvement plan. 
 
Other opportunities for quality improvement have been identified under other sections in 
this report – including Chapter 3: Coverage, participation, equity and access, and 
Chapter 4: Monitoring and Evaluation. The NCSP would be enhanced with the 
introduction of the PDCA cycle, particularly during the NCSP’s consideration of the 
biannual monitoring reports, and the institution of a Quality Improvement Plan that 
informs the ongoing work plan for the programme. 
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Key issues 
 Monitoring and evaluation are neither static nor stand-alone elements of the 
screening system and processes. Performance monitoring must inform the 
development and implementation of strategies that become part of the continuous 
quality improvement cycle. 
 Monitoring and evaluation and the implementation of quality improvement strategies 
must be a collaborative process between the NCSP, DHBs, laboratories and the 
Register so that learnings can be shared and strategies implemented consistently 
across the country. 
 Regular, ongoing meetings for monitoring and quality improvement should be 
scheduled shortly after the release of the biannual monitoring reports, and the 
agenda for these meetings should be informed by the monitoring report indicators. 
The actions and outcomes from these meetings would inform a Quality Improvement 
Plan for the NCSP both during its development and on an ongoing basis. 
 Ongoing audit of the screening histories of women who develop cervical cancer is 
recommended. The underpinning rationale is that there are likely to be valuable 
lessons from these audits that would inform the implementation of quality 
improvement initiatives. It is essential that these audits occur regularly and involve 
expert clinicians involved in the programme. Any identified system or process gaps or 
failures should be used to inform quality improvement strategies, and be incorporated 
into a quality improvement plan. 
 The NCSP would be enhanced with the introduction of the PDCA cycle, particularly 
during the NCSP’s consideration of the biannual monitoring reports, and the 
institution of a Quality Improvement Plan that informs the ongoing work plan for the 
programme. 
 Other opportunities for quality improvement have been identified under other sections 
in this report – including Chapter 3: Coverage, participation, equity and access; 
Chapter 4: Monitoring and evaluation; and Chapter 8: NCSP-Register. 
Recommendations 
15. Regular, ongoing meetings for monitoring and quality improvement should be 
scheduled shortly after the release of the biannual monitoring reports. The 
agendas for these meetings should be informed by the monitoring report indicators 
in particular areas where targets have not been achieved. The actions and 
outcomes from the meetings would inform the development of a Quality 
Improvement Plan for the NCSP. 
16. The development of specific Quality Improvement Plans must be a collaborative 
process between the NCSP and the relevant partners in the screening programme 
– DHBs, primary health care providers, laboratories, the Register – so that 
strategies are implemented consistently across the country. 
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17. Regular, ongoing audit of the screening histories of all women who develop 
cervical cancer is essential. The knowledge gained from these audits must be 
used to inform quality improvement of the programme. 
18. Complaints and feedback from consumers of the screening programme received 
by the Health and Disability Commissioner, the Register and the NSU must be 
reviewed regularly and also be used to inform quality improvement strategies. A 
process for the NCSP to review complaints received at the provider level should 
be developed so the NCSP has an understanding of issues for the programme at 
the point of service delivery. 
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Chapter 6: Organisational and structural issues 
Overview 
Each year in New Zealand around 170 women are diagnosed with cervical cancer (in 
2010 the figure was 180) and around 60 women die from the disease. In 2010 cervical 
cancer accounted for 1.8% of all female cancer registrations and 1.3% of all deaths 
from cancer in women (National Health Committee 2015). 
 
In the three years ending December 2013, 879,862 women were screened in New 
Zealand, with an overall coverage rate of 77% of eligible women aged 25–69 years. The 
National Cervical Screening Programme (NCSP) 2013/14 budget was $40.4 million. 
This amount comprised: 
 laboratory costs: $16.2 million 
 colposcopy costs: $9.3 million 
 regional services: $7.0 million 
 other funding: $7.9 million. 
 
Regional services include promotion and coordination, some smear taking and 
supporting women through screening. Other funding includes monitoring, audits, the 
National Cervical Screening Programme-Register (NCSP-R) (including invitation and 
recall and social marketing) and programme resources (National Health Committee 
2015). 
 
Figure 6.1 shows coverage rates for a number of international programmes. Although 
the ethnic mix, and focus on achieving equity across all ethnic groups in New Zealand, 
mean figures across different countries are not directly comparable, it does provide a 
general idea of New Zealand’s position in relation to other countries. 
 
New Zealand continues to have one of the highest coverage rates in the Organisation 
for Economic Co-operation and Development (OECD) with resources distributed to 
ensure a high-quality and well-organised screening system for the early detection of 
cervical cancer. 
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Figure 6.1: Cervical cancer screening in women aged 20–69 years in OECD countries 
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Current status 
A high-quality, organised screening system 
Five essential components of a high-quality, organised screening system are identified 
in the Quality Framework of the National Screening Unit (NSU 2014c) as critical to the 
safe and effective practice of organised screening (adapted from Hale 2012). These 
are: 
1. a central agency to lead and coordinate the screening pathway 
2. clinical governance 
3. infrastructure and systems to manage a screening programme 
4. monitoring and evaluation 
5. quality cycle. 
 
The National Health Committee (NHC) affirms that a screening programme displaying 
these characteristics “lifts the screening game” for the programme concerned. Therefore 
the challenge to national screening programmes is to maintain this quality by working 
more closely with the wider health sector especially in times of fiscal constraint (National 
Health Committee 2015). 
 
The NHC also notes that many screening programmes are underperforming for Māori, 
Pacific, Asian and economically deprived populations.12 
 
Therefore, unless carefully planned, health interventions tend to increase inequalities. In 
undertaking assessments, the NHC is required to consider both existing and potential 
disparities in health in relation to a proposal.13 Another critical role of the NHC is to 
maintain a continuing interest in emerging screening technologies and significant 
extensions and/or modifications to existing screening programmes, such as in the 
NCSP’s human papillomavirus (HPV) primary screening (NSU 2014d). 
 
This Parliamentary Review Committee (PRC) 2015 acknowledges that challenges have 
consistently arisen from many of the interviewees and key informants whose collective 
commentary spanned the five essential components that are critical to the effectiveness 
of the programme (NSU 2014c). For the purpose of this report, an interviewee is defined 
as a participant interviewed by the PRC who is external to the Ministry of Health, 
including the advisory groups of the National Screening Unit and the National Cervical 
Screening Programme. A key informant is a key staff member from the Ministry of 
Health. More information about the interview process is available in Chapter 1: 
Introduction and methods. More of the detail provided in the interviews is given in 
Appendix F. 
 
In addressing the organisational and structural issues of the NCSP, the first three 
components in the NSU Quality Framework as listed above are most pertinent. 
 




 Ibid 12. 
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Each of the components of the NCSP screening pathway must operate to a high 
standard for the programme to meet its objectives for providing the screening pathway 
for women in New Zealand (Ministry of Health 2014b). This pathway includes invitation 
and recall of women through smear taking, laboratory testing, colposcopy and 
information systems that support these processes. The screening pathway is further 
supported through the scope of the NCSP’s service provision, which includes: 
 national services for management, coordination, monitoring and information 
management through the NCSP-R 
 regional/local services for rollout and effective programme coordination. Many of the 
components of the screening pathway are at this level, contracted and subcontracted 
to major sector providers such as: District Health Boards (DHBs), Primary Health 
Organisations and Independent Service Providers. 
 
Clinical governance 
Clinical governance as a system of accountability for continuous improvement in the 
quality of the (screening) services and guarding high standards of care is essential for 
creating an environment in which excellence in clinical care will flourish (Scally and 
Donaldson 1998). This definition embodies three attributes: recognisable high standards 
of care; transparent responsibility and accountability for those standards; and a constant 
dynamic of improvement (NSU 2014c). 
 
Advisory groups 
The National Screening Unit seeks external advice from a range of sources to support 
its work. The groups that have particular relevance and importance to the NSU and 
NCSP at governance level are the: 
 Māori Monitoring and Equity Group (MMEG) 
 National Screening Advisory Group 
 National Cervical Screening Programme Advisory Group. 
 
Māori Monitoring and Equity Group 
Up to 12 members are appointed to the MMEG for their particular expertise in matters 
relating to Māori health and screening programmes. The group provides Māori 
leadership on strategic issues for planned screening programmes that are clinically and 
technically sound, and is using an equity assessment framework for monitoring 
reductions in inequalities in health for Māori. 
 
National Screening Advisory Committee 
Up to 12 members are appointed for their particular expertise in matters relating to a 
wide range of screening policies, practices and research. This group provides advice on 
the Ministry of Health’s screening policy work programme, which covers screening in 
health and disability practice and research, including cancer and genetic screening. 
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National Cervical Screening Programme Advisory Group 
The group is composed of members who collectively have wide knowledge and 
experience of the NCSP screening pathway. It includes: obstetricians and 
gynaecologists, pathologists, cytologists and laboratory scientists, primary care plus 
medical and nursing experts in screening. Māori, Pacific and consumer representatives 
are also members of the group. 
 
Clinical leadership 
The NSU and NCSP were challenged in the 2011 Parliamentary Review on the variable 
balance of clinical leadership skills and capacity demonstrated over time within these 
units of the Ministry of Health. In response, the NSU appointed a new Clinical Director in 
January 2013; the position of NCSP Clinical Leader was retained. Both post-holders are 
public health physicians with population health, public health and screening expertise. 
A public health physician with applied epidemiology skills was appointed to lead the 
monitoring and evaluation analysis within the NSU’s Information, Quality and Equity 
team and an additional public health physician with a lead role in promoting 
achievement of equity for all NSU screening programmes was appointed. A Clinical 
Governance Group was established in 2010 to provide clinical, public health and 
strategic advice on screening practice, including monitoring and resourcing. 
 
The National Cervical Screening Programme is essentially a clinical programme; 
therefore, having high-quality clinical competence across the screening pathway 
remains the central focus of its success. Clinical competence must also embrace the 
future developments for the programme as it moves towards a screening route of HPV 
primary testing. 
 
Sustaining the clinical competency of the programme requires a fine balance between 
consumer and stakeholder opinions of clinical competence at governance and 
programme leadership levels, and the reality for the programme to be continually 
striving to meet these demands through appointments of key skilled personnel. 
Achieving this balance is important to maintain the programme’s clinical integrity. 
 
The National Screening Advisory Group reported that the NSU and the NCSP are 
engaging with it more and are providing improved insights into programme planning at 
this governance level in a timelier manner. 
 
There have not been in-depth discussions within the group regarding the National 
Kaitiaki Group, apart from receiving informal expressions of frustration about not getting 
timely access or timely permission to commission for data. However, the last Monitoring 
Report (NSU 2014b) raised no further issues relating to data access. 
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The National Health Committee 
The National Health Committee (NHC)14 is an independent statutory body charged with 
prioritising new and existing health technologies and making recommendations to the 
Minister of Health. It was reformed in 2011 to establish evaluation systems that would 
provide the New Zealand people and the health sector with greater value for money 
invested in health. 
 
Section 13 of the New Zealand Public Health and Disability Act 2000 specifies the 
NHC’s purpose is to provide advice to the Minister of Health on: 
a) the kinds, and relative priorities, of public health services, personal health 
services, and disability support services that should, in the NHC’s opinion, be 
publicly funded 
b) other matters relating to public health, including – 
i) personal health matters relating to public health; and 
ii) regulatory matters relating to public health 
c) any other matters that the Minister specifies by notice to the NHC. 
 
The NSU and NCSP will have a future role and referral process with the NHC regarding 
the development and rollout of primary HPV screening, a major project advancement 
that is in the early stages of investigation and policy framework expansion in cervical 
screening. For more information on HPV screening, see Chapter 11: Human 
papillomavirus and cervical cancer. 
 
Equity 
Currently the single most important issue facing the national screening programme in 
New Zealand is addressing the disparities and inequities that continue to challenge all 
levels and component parts of the programme. 
 
There is a need to continue to make improvements for Māori, Asian and Pacific women 
and consider what the opportunities are from an equity perspective. The NSU and 
NCSP need to make sure there are strong relationships with the sector, there is good 
dialogue, and the sector is much more involved with decision making. 
 
Two key examples of what did work and what should be considered as necessary to 
improve performance for reaching priority women – especially Māori women – are the 
television advertisements promoting cervical screening and the education of women 
about the importance of having smears: 
                                            
14
 http://www.nhc.health.govt.nz 
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 “The TV adverts were a great way of addressing (this) – promoting cervical 
screening – as they highlighted that it isn’t just the woman herself who matters 
but the whole whānau … whānau ora strategies are needed. 
 Very disappointing that the TV adverts are no longer being broadcast, these 
were impressive and had a great deal of impact. 
 The other issue is that the priority women do not consider cervical screening a 
priority in their lives. Education is important.” 
Interviewee 
 
Social marketing programmes were also viewed as important by those interviewed by 
the Parliamentary Review Committee: 
“Having social marketing programmes that make women visible is highly 
beneficial. Social media and web-based culture should be considered as a means 
to disseminate information. Health promotion and literacy is essential for quality 
assurance and data access. It is important that the results from programmes are 
easily accessible to consumers and understandable in layman terms. This is seen 




These issues have not gone unnoticed by the National Screening Unit, which has made 
it clear in its Quality Framework document (NSU 2014c) that: 
“Achieving equitable coverage is the emphasis and the NSU must lead the 
screening sector to achieve equity; this is the absolute focus for the future.” 
Key informant 
 
The intent must now be followed through by improvements in engagement with the 
priority women’s groups and innovative ways to execute this. The foundations are now 
in place to increase coverage according to another key informant: 
“An internal operational group (Equity Forum) is in place, as well as the Māori 
Monitoring and Equity Group (MMEG). There is now a need to get to the target 
rate of 80% for Māori. While there are many initiatives, there is still a need for a 
‘real plan’ to have improved progress.” 
Key informant 
 
Another current concern was the lack of plans in place to promote screening to Asian 
women, who are another priority group in the NCSP, but the Parliamentary Review 
Committee was informed that Asian advisors are to be engaged in the future. 
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Regional coordination issues 
Following the previous Parliamentary Review (Tan et al 2011), the NSU and NCSP 
have responded to the recommendations made and have provided a system of 
consultation and reporting to progress these. 
 
The responses from the NSU and NCSP were as follows: 
 A newsletter Screening Matters is produced and provides quarterly updates to the 
sector with highlights and monitoring information. 
 Policy and quality standards have been reviewed and relationships with the Cancer 
team and cancer networks about the Cancer Control Strategy are ongoing. 
 Work plans are developed with initiatives and programmes aligned to the Cancer 
Control Strategy and the associated work plans. 
 The NCSP and the Immunisation team within the Ministry of Health are building a 
strong relationship around HPV immunisation and cervical screening, especially to 
ensure messaging is consistent and supportive of both programmes. 
 Close collaboration occurs across the Ministry integration programme, with a 
particular focus on primary care. There is consultation with the Māori Health Business 
Unit to monitor progress against the Māori Health Plans, and the whānau ora 
collectives’ reports, and to discuss initiatives or policy developments. 
 
It was also reported to the Parliamentary Review Committee that over the last three 
years there has been limited regional coordination and consultation. However, since 
2013, two senior portfolio managers have undertaken a programme of visiting providers. 
 
A quarterly teleconference with regional coordination services and non-government 
organisations takes place to share successes and discuss current issues and 
developments concerning providers. Interviewees stated that these meeting points are 
for the “higher level managers” only and they would prefer to see a different approach: 
“A national meeting and regular regional face-to-face meetings would be 
useful to help fit together the pieces of the jigsaw.” 
Interviewee 
 
Infrastructure and systems issues 
High-quality screening programmes need to be supported by high-quality infrastructure. 
A common element of all programmes is the necessity for information systems that 
meet the specific requirements of screening. Within the confines of available resources, 
systems should be thoughtfully developed to be as user-friendly as possible. This helps 
to make doing the right thing easy to do (NSU 2014c). 
 
Continuing change processes have had major impacts on the organisational systems in 
the NSU and NCSP in the past three years, with staff turnovers making change 
necessary for the continuation of the NCSP. Many of the stakeholders interviewed 
brought this issue to the forefront throughout the review. 
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In 2012, following the past reviews of both the NCSP and the BreastScreen Aotearoa 
(BSA) programme, the NSU undertook a change management process affecting the 
configuration of positions across these two programmes at a national level, and within 
the Ministry of Health itself (NSU 2012b). The changes made by NSU were: 
 dually arranging reporting lines of senior clinical leaders in the programme for 
operational and clinical accountabilities 
 changing the Clinical Advisor title to Clinical Leader, NCSP and retaining the role 
 disestablishing roles for the two management and leadership positions of the NSU 
and the NCSP 
 establishing a dedicated reporting line for two analysts; one administration role, and 
one management role for the NCSP. 
 
While it was acknowledged that in the previous two years the team had been relatively 
stable, there had been recent staff losses prior to this review in 2015. These vacancies 
comprised senior staff within the NSU and NCSP. The NSU Group Manager, NCSP 
Programme Manager and NCSP Clinical Leader all resigned in the two months prior to 
or at the commencement of this review. 
 
These sudden changes have implications for the institutional knowledge and ongoing 
functioning of the programme. It is imperative that clinical leadership positions are at the 
forefront of the National Cervical Screening Programme and that these are sustained as 
its driving force. 
 
The remaining position to be filled is Clinical Leader for the NCSP. There is a need to 
seek strong leadership skills in areas of clinical knowledge and experience such as 
colposcopy, pathology and cervical screening nationally, and substantial capability in 
quality management and research. 
 
This role will require an ability to work as a team leader with colleagues of 
complementary ability – operationally such as with the NCSP Programme Manager; 
regionally with the portfolio managers working directly with DHBs; and nationally with 
the Clinical Director and Group Manager across the NSU. 
 
The Clinical Leader must also demonstrate energy and passion for their area of 
expertise. The Clinical Leader will have a critical role in future HPV developments and 
changes within the NCSP. 
 
It is crucial that the new incumbents, including the new Clinical Leader, are promptly 
oriented in their positions and that the new leadership team establishes strong regional 
coordination and communication across the national screening sector. 
 
Much effort for the programmes has been focused on business as usual, the NCSP-R 
and the Quality Framework (for the NSU). 
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The following organisation charts show the National Health Board structure (Figure 6.2) 
and the structure of National Services Purchasing (Figure 6.3). The NSU senior 
management team is shown in Figure 6.4 and the NCSP organisational structure is 
shown in Figure 6.5. 
 

















Figure 6.3: National Services Purchasing structure 2015 
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Despite the impact of high staff turnovers being felt at all levels internally and externally 
in work related to regional coordination, the infrastructure support systems for both the 
NSU and NCSP, including for senior management, have provided sound decision 
making and well-considered resolution for human resource management issues 
internally. 
 
The management position for the Information Quality and Equity Unit has recently been 
filled after being in abeyance as an ‘acting’ position for the last 18 months. 
 
The Clinical Director position is in the NSU and is spread over five organised national 
screening programmes that the NSU manages.15 As described to the PRC, an 
estimated 20% of the workload for this role is dedicated to the NCSP Strategic and 
operational work is ongoing and engaging with staff is seen as very important. HPV 
planning takes up to 50% of the role at the time of this review (2015). The broad 
responsibilities of the Clinical Director are ensuring the safety and high quality of 
national screening programmes; providing professional leadership and guidance to 
Clinical Leaders in the national screening programmes; and providing risk 
                                            
15
 JD NSU Clinical Director revised 03.05.12, Ministry of Health. 
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management advice and direction on issues relating to the screening programmes. In 
regard to the NCSP specifically, some of the Clinical Director leadership functions 
involve the oversight of: 
 improvements to systems and links to primary care and with women 
 increased and improved relationship building by the NCSP with providers regionally, 
through the portfolio management roles that are dedicated to this area and with 
planning and funding activities of the DHBs for distribution modelling on investment in 
the screening programme. 
 
This strategic and clinical leadership from the NSU strengthens opportunities for 
provision of a good programme overall for the future. 
 
The improvements in the programme also extend to the information needs of the priority 
groups of the NCSP. Attention must be appropriately given to Māori, Pacific and Asian 
people in regard to HPV vaccination and primary screening, just as these groups have 
been considered in the past in regard to cervical screening and treatment. 
 
Past studies have reported key areas that have to be taken into consideration when 
promoting and raising awareness of important health programmes and treatments that 
require involvement and participation, especially by priority population groups such as 
those for the cervical screening programme.16 This has covered areas including the use 
of the person’s (or group’s) first language (Cartwright 1988); addressing the personal 
barriers of the women – then encouraging their participation and implementing a multi-
faceted advertising strategy.17 
 
Other areas covered are the use of easy-to-understand language18 and finding the best 
messenger.19 
 
Important to this issue are NCSP efforts in working collaboratively with the HPV 
Immunisation team within the Ministry of Health. A critical focus of this relationship is to 
ensure messaging is consistent and supportive for both the HPV vaccination and 
primary screening programmes. Screening services and health information are both 
activities used to improve individual and population health (Ministry of Health 2003). 
                                            
16
 http://www.moh.govt.nz/notebook/nbbooks.nsf/$FILE/kiawhaitemaramatanga. Cited in Ministry of Health (1994), 
p 58. From Lynch (1989), quoting Cartwright Report (1988). 
17
 Ibid 16, p 63. 
18
 Ibid 16, p 64. 
19
 Ibid 16, pp 64–65. 
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“The health promotion messages are important; we need to ensure that we talk 
about the importance of family, we need to help people feel they are strong and 
we need to help encourage people to feel good about themselves and to be happy 
and confident to seek medical help. These strategies will help to overcome fears 




 Addressing equity is important. In particular, the variable achievement of the 80% 
target for Māori, Pacific and Asian women must be eliminated as an outstanding 
disparity of this programme. 
 While steps have been taken to improve regional coordination with providers, further 
strategies must be identified to rectify remaining issues of coordination and 
communication with them. 
 It is essential to sustain the infrastructure and systems within the programme. 
Therefore the orientation of the new incumbents to their positions in the NCSP needs 
to be prompt and thorough. 
 Information and appropriate messaging about HPV and changes to the NCSP are 




19. The NCSP must address the variable achievement of the target rate of 80% for 
Māori, Pacific and Asian women by producing Action Plans for each of the priority 
groups that can demonstrate progressive reduction in disparities for each of these 
groups. 
20. NCSP regional portfolio managers must continue to demonstrate improvements in 
coordination with providers through at least one planned national meeting each 
year and ongoing regional face-to-face meetings with local service leaders for the 
cervical screening programme in the regions. 
21. High-quality screening programmes need to be supported by high-quality 
organisational structures, systems and processes. The NCSP has been stable for 
a good part of the past three years but experienced significant change previously, 
and over recent months has again seen major senior management change with 
the resignation of personnel from the three most senior positions impacting the 
NCSP. 
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22. Particularly important within the NSU and the NCSP is the robustness of the 
clinical leadership structures. It is imperative that clinical leadership positions are 
at the forefront of the National Cervical Screening Programme and that these are 
sustained as its driving force. 
23. Information about HPV must be appropriately provided to the NCSP priority 
groups: Māori, Pacific and Asian people. The NCSP must also work collaboratively 
with the HPV Immunisation team within the Ministry of Health to ensure consistent 
and supportive messaging for both HPV vaccination and primary screening/testing 
programmes is achieved for these groups. 
 
  
  Report of the Parliamentary Review Committee 71 
 regarding the New Zealand Cervical Screening Programme 
Chapter 7: Workforce issues 
Overview 
The outstanding area of concern in the near future for the laboratory science workforce 
is the impact that human papillomavirus (HPV) screening will have across this sector, 




The National Screening Unit (NSU) and National Cervical Screening Programme 
(NCSP) responded to the 2011 Parliamentary Review workforce development 
recommendations by suggesting that professional colleges and associations are best 
positioned to administer the Individual External Quality Assurance Programme and 
training (as opposed to quality standards more generally). 
 
Contract for the national cervical pathology training service 
The Ministry of Health has contracted for a national cervical pathology training service 
since October 2011. The service is currently provided through a contract with Southern 
Community Laboratories Ltd20 (see Appendix G). 
 
There is an allowance in this contract for continuing professional development for the 
laboratory workforce. The NCSP encourages the workforce to keep updated, and attend 
conferences and meetings for continuing professional development. 
 
Contract outputs (NCPTS 2014) included: 
 providing comprehensive training in up to eight regions to all laboratory sector groups 
 establishing an independent training committee 
 completing a national laboratory workforce training needs assessment 
 circulating an informative annual newsletter 
 establishing a scholarship fund 
 developing eight specific training plans for each of the laboratory sector groups 
 providing a plan for the HPV screening programme. 
 
New training initiatives to December 2014 have been reported to the NCSP and are 
comprehensive (see Appendix G). 
 
                                            
20
 Agreement: NZ Govt. and Southern Community Laboratories Ltd. Laboratory Training Services Provider No: 
420619 / Contract No: 347182/00. 28.06.2013 – see Appendix G. 
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Contract for NCSP Individual External Quality Assurance Programme Training:21 
Royal College of Pathologist Associates Proprietary Limited, RCPA QAP Pty Ltd 
This contract ensures the training for cytoscientists provides evidence and further 
development of competence at an individual level – a key requirement of the Cervical 
Screening Inquiry. 
 
The NSU and NCSP have committed to consult with the provider on the strategy to 
transition from the current contract to new arrangements, should the current contract be 
affected by developments as the programme moves towards primary HPV screening. 
Progress is being made in providing guidelines for managing underperformance of 
programme participants, and there is intent to continue with (liquid-based) cytology as 
part of the screening pathway as the programme is developed to move to primary HPV 
screening. 
 
The National Health Board, NSU and NCSP agreed in November 2014 to also renew 
the existing contracts to roll forward to 2017 for cytology pathology training and for 
Individual External Quality Assurance for Pathologists and Scientists competencies. 
This ameliorates the concerns in 2011 that indicated future impact on the workforce. 
 
Smear takers 
A smear taker must be a registered health professional, such as a medical practitioner, 
a registered nurse, an enrolled nurse or a registered midwife. All smear takers are 
required to complete cervical screening training through one of the following training 
programmes: 
 training as part of a medical degree 
 New Zealand Qualifications Authority (NZQA) midwifery training programmes 
 NZQA accredited courses for non-medical smear takers. 
 
The main regulations that surround the practice and competency of smear takers are: 
 the Health Practitioners Competency Assurance Act 200322 (HPCA Act) 
 section 112L of the Health Act 1956, Part 4A23 
 section 4 of the NCSP Policies and Standards.24 
 
                                            
21
 Procurement Plan for NCSP Cytology Individual External Quality Assurance Programme 1 July 2012. 
22
 HPCA Act http://www.legislation.govt.nz/act/public/2003/0048/latest/DLM203312.html 
23
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Professional development for smear takers 
The NCSP expects smear takers to have an up-to-date knowledge of smear-taking 
techniques, screening issues and the NCSP, including its benefits and limitations. 
Smear takers are expected to maintain their competence and those who have 
persistently high rates of unsatisfactory smears are required to seek further training in 
smear-taking techniques. 
 
Smear Taking Training Grant 
Smear takers are supported by the Smear Taking Training Grant, which is a 
reimbursement of course fees and is paid on successful completion of smear taker 
training at a recognised course. 
 
The NSU provides the following resources for cervical screening and smear taker 
training: 
 education and professional updates for smear takers25 
 NCSP Guidelines for Cervical Screening (NSU 2008) 
 Responsibilities of Smear Takers26 
 Competencies for Smear Taker Training.27 
 
HPV testing: smear-taker responsibilities 
Smear takers also have responsibilities for the provision of HPV screening/testing, as 
shown in Table 7.1. 
 
Table 7.1: The role of the smear taker in the screening pathway 
Role of the smear taker 
 Informs women about the role of high-risk HPV testing in the pathogenesis of cervical cancer and the use of 
HPV testing as an adjunctive test. 




 Every woman aged 30 years or over without a recent abnormal smear is informed that on the slight chance her 
smear result is mildly abnormal (ASC-US or LSIL), the laboratory will do an HPV test using some liquid taken 
from the same liquid-based cytology sample (this is called ‘reflex testing’). 
 Informs women that all HPV testing results will be sent to the NCSP-Register (unless the woman has 
withdrawn from the NCSP). 
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HPV testing for women following treatment of high-grade lesions 
The smear taker has a responsibility to identify if a woman has previously been treated 
for CIN 2/3 and is on annual smears, and to offer her an HPV test with her smear. HPV 
testing will mean it may be possible for her to return to a normal three-yearly screening 
interval, if her test results are negative for both cytology and high-risk HPV on two 
consecutive occasions, 12 months apart.29 The same regime applies to historical testing 
where prior high-grade squamous abnormalities more than three years ago (treated or 
not treated) are identified. 
 
HPV online learning tool 
Following the 2011 review, the NSU was advised to ensure equitable access in outlying, 
rural and under-serviced areas, and to consider options such as: 
 train-the-trainer approaches 
 training local health professionals to coach such populations in the use of self-
collected specimens. 
 
In response, the NSU and NCSP have placed an HPV online learning tool on their 
website for health professionals. This has been available since February 201530 for 
smear takers to maintain their competencies. Cervical screening information on the 
website is regularly reviewed and updated. LearnOnline.Health.nz is a vocational 
training resource hub for New Zealand’s community of health practitioners, providing a 
collaborative approach to educational resources for the health sector. There is a 
growing number of courses available, provided by different organisations for health 
workers either studying or working in different fields of practice. 
 
HPV training course for health professionals31 
The training is aimed at cervical smear takers in primary care, and focuses on the use 
of HPV testing in the NCSP. The training also includes information on HPV 
immunisation for girls. The module is designed to support existing knowledge of HPV 
and the HPV vaccine. It will assist with knowing when to order an HPV test as part of 
regular cervical screening, and discussing the results of those tests with women. The 
NCSP has advised that the introduction of self-collected specimens will be considered 
as part of any future policy development on HPV primary screening. 
 
                                            
29
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Commentary from regional providers revealed that the HPV online course has its 
limitations; it is “very slow” and not designed for the primary care setting. Providers 
stated they needed updated information in primary care and that this should be 
available online. The Clinical Leader role was seen as addressing the education and 
facilities that are needed for staff. Having to pay for their training courses and then 
being reimbursed was also a limitation. According to one interviewee (external to the 
Ministry of Health), “if the practice nurse has to pay and do it in her own time, they won’t 
do it”. 
 
Family Planning Association training courses 
The Family Planning Association of New Zealand provides an average of up to 20,000 
smears annually and is not funded to provide free smears. The organisation provides 
cervical smear training and other related courses can be found on its website.32 
 
Health Workforce New Zealand 
Health Workforce New Zealand (HWNZ) is part of the Ministry of Health, has its own 
governance board and advises the Minister and Director General of Health. It has a 
budget of $76 million, all of which is directed towards training the New Zealand health 
workforce. The focus groups of HWNZ are the regulated and non-regulated workforces. 
 
The national screening workforce (including cervical screening), while making up both 
focus groups for HWNZ, is considered in the broader context of workforce groups. 
HWNZ invests very heavily NZ in medical training, allocating far less to the allied health 
categories. 
 
Health workforce planning is executed through a set of service reviews in principal 
areas (eg, aged care and mental health) and completed by experts. A recent report, 
Health of the Health Workforce, gives a direction about available workforce data (Health 
Workforce New Zealand 2014). 
 
HWNZ advised that professions should be mindful of changing technology and 
changing needs. “Retraining workforces should be done in a way where they aren’t 
starting from the bottom.” There is commitment from HWNZ to work with professions to 
find a balance in this respect. 
 
Within the professions that the NCSP relies on, there is a large number of nurse (Pap) 
smear takers and colposcopists (providers). A focus has been to move services closer 
to the women and HWNZ has reported that some of its funds are used on the 
employment and training for first-year trainee general practitioners (GPs) (Health 
Workforce New Zealand 2014, p 6), and for Nurse Entry to Practice (NETP) training 
programmes for nursing graduates in their first year of employment (p 9). 
 
                                            
32
 http://www.familyplanning.org.nz/courses 
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Advancing primary HPV screening 
The NSU reported that policy work has commenced. HPV primary screening could be 
achieved in the New Zealand NCSP. The NSU will lead the project through the NSU 
Clinical Director, and technical experts from across areas relevant to cervical screening 
have been solicited for membership of a Technical Reference Group to provide advice 
and expert guidance. Various other aspects of implementation will be considered with 
appropriate experts as part of constituted working groups to collaborate on designing 
the future model for the NCSP. Strong linkages with the Australian NCSP are enabling 
NSU to build on its work but contextualise it for the New Zealand environment. 
 
Part 1 of this policy work includes modelling the testing methodologies and developing 
high-level implementation ideas for consultation. Two pieces of work are nearing 
completion: 
1. Finalising the policy question to guide the assessment of HPV primary screening 
in the New Zealand NCSP 
2. Modelling the testing methodologies (being undertaken by the University of New 
South Wales, which undertook the modelling for the Australian NCSP renewal 
project). 
 
The technical reference group will consider the testing methodologies and associated 
high-level implementation options. This will lead to the development of a paper for 
sector consultation, which will include the public. The high-level implementation 
considerations will include: 
 impact on the workforce 
 service delivery options, including the feasibility of self-testing 
 impact of HPV vaccination 
 achieving equity. 
 
Anticipated impacts on the workforce of introducing primary HPV screening 
In 2011 the Parliamentary Review Committee advised that, as cervical screening 
technology evolves, professional requirements will also change. It recommended that 
the health system must first decide on the best approach for its population and existing 
infrastructure. Since 2011 the NSU, Health Workforce New Zealand and provider 
representatives have continued to meet to consider future planning, and the impact that 
systems and technology will have on the screening workforce. Working groups are 
established as required to inform new standards or processes. The NSU recognises 
that there may be workforce impacts, particularly for the laboratory sector, should HPV 
primary screening be introduced. The NSU will work with the sector to ensure clear 
communication of any changes and will support a planned transition for providers and 
their workforce. 
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Impacts of primary HPV screening on the laboratory workforce 
During this 2015 review, stakeholders expressed opinions in regard to HPV screening 
impacts. Impending developments towards introducing primary HPV screening will 
dramatically reduce cytology and this will impact on the laboratory workforce. 
 
Concerns were expressed for senior scientists, who are a small number, working at a 
national level. Loss of the workforce will be felt dramatically as the level of expertise 
drops. The NCSP has indicated it is in the early stages of having plans in place to 
develop workforce standards and guidelines to provide greater certainty around 
workforce impacts. This will include working with the sector and the health workforce in 
New Zealand generally to ensure implementation of the standards is feasible. 
 
However, there should also be a planned approach that supports cytologists, 
pathologists and laboratory scientists to move or relocate to appropriate areas where 
their expertise is not lost to the sector. This can include working with employees to set 
up structured career pathways and professional development programmes, supporting 
staff through transition into other areas of work or other career pathways, and exploring 
ways in which career pathways could be established to further develop this workforce. 
 
Well-designed and integrated education and training, together with ongoing competency 
assurance, will be vital to support change. It will also be important to ensure that service 
specifications, purchase agreements, funding arrangements and industrial 
arrangements do not unnecessarily impede this kind of development and work redesign 
(Ministry of Health 2006). 
 
Addressing disparities for NCSP priority groups 
Three-yearly coverage overall varied by ethnicity and the target of 80% was not met for 
Māori, Pacific, or Asian women across all District Health Boards (DHBs). Coverage in 
these groups for women aged 25–69 years was 62.6%, 68.6% and 64.8% respectively 
(NSU 2014b). 
 
One of four DHBs that demonstrated some success in getting closer to Māori women’s 
participation targets for the NCSP cited the following as key factors for success: 
 working in a more integrated way with stakeholders and utilising targeted funding 
schemes (support to screening services and the Very Low Cost Access funds) to 
facilitate community workers’ activities in accessing women and overcoming barriers 
for them, such as outstanding bills at general practices 
 setting an example – three senior Māori women in health leadership positions have 
made it their business to make the systems work for them 
 standardising the systems in the Ministry of Health, with a focused prioritisation for 
Māori, Pacific and Asian populations 
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 having key people in strategic places who possess certain attributes such as: 
– cultural competency 
– knowing how to talk to Māori communities 
– achieving health literacy by breaking down complicated issues 
– demonstrating cultural understanding. 
 
Factors influencing demand for health and disability support services 
Demographic change and consumer demand across the health sector are also 
influenced by factors beyond the control of the health care sector. It is well established 
that policy and the social, cultural, economic and physical environments in which people 
live their lives affect health outcomes (Public Health Advisory Committee 2004). This is 
depicted graphically in Figure 7.1. 
 
Figure 7.1: Environmental factors that influence health outcomes 
 
 
Source: Ministry of Health (2002) 
 
In most Organisation of Economic Co-operation and Development (OECD) countries, 
education and health policy, legislative and economic developments and growth, 
coupled with technological and medical advances, have led to an overall improvement 
in health treatment, longer life expectancy and greater expectations about health care. 
 
Since 2000, one of two major Government responses to trends influencing requirements 
placed on health and disability support services in New Zealand is an overarching 
strategy aimed at improving population health outcomes and reducing disparities 
(Ministry of Health 2002). 
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Customer-centred service models 
Service delivery models should be consumer-centred and focused on primary care 
public health (population health) rather than secondary and tertiary health care. These 
models of care are based on higher cognitive and higher generalist skills rather than 
specialist skills, and emphasise collaboration and teamwork over individual work, as 
well as integration across health, disability and social services. 
 
These service models require changes in service practice. For example, there is a need 
to expand the roles of primary care nurses, practice nurses, GPs and community 
providers (urban and rural) to increase the range of services they can provide and to 
encourage early intervention. 
 
Focus on the non-regulated workforce 
Specific workforce strategies focused on service changes have been developed in 
some priority areas, including Māori health, Pacific health and mental health. Others are 
under development. 
 
It has long been recognised that, as the general Māori population increases, it is likely 
that the demand for the Māori non-regulated workforce will also increase (Robson and 
Harris 2007). According to a report by Lehmann and Sanders (WHO 2007), the 
credibility of Māori community health workers, (kaimahi/community health workers), 
kaiarahi/coordinators and team leaders depends primarily on: 
 their community credentials 
 being members of the communities with which they work 
 an understanding of Māori cultural norms 
 utilisation of kaupapa Māori approaches to their work 
 unwavering commitment to supporting those communities in need. 
 
This workforce provides added value to their services because they improve the Māori 
community’s access to, delivery of, compliance with and self-management of health 
care, disability support and social services. Interviews with key contacts in the regions 
gave the following examples of how these success factors look in practice: 
 working with a local Māori independent service provider 
 building a good reputation 
 prompting many first-time smear event through word of mouth or health promoters 
(community health workers) 
 providing good health promotion. 
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Successful strategies 
Further success factors in working with Pacific and Māori women, identified since the 
2011 Parliamentary Review, include training Pacific providers to take smears and telling 
Pacific communities what providers do. A workforce that has the ability to engage with 
the people/ communities is what makes a difference, as does having essential 
workforce positions, particularly at the front line and in colposcopy. 
 
The Ministry of Health is aware that the priority groups for the NCSP, in particular 
Pacific and Māori women, need things done differently (equity focus). For example, 
there is a need to ensure interaction with key Pacific people and to use media 
campaigns to increase awareness. 
 
Health literacy 
Health literacy is defined as the ability to obtain, process and understand basic health 
information and services in order to make informed and appropriate health decisions 
(Ministry of Health 2010). In May 2014 the Ministry of Health held a roundtable 
discussion33 with Pacific and Māori health sector participants who provided broad views 
and opinions on the importance of both health literacy and cultural competency in 
addressing participation in health services and developments for priority groups. 
 
The views highlighted: 
 strong support for both health literacy and cultural competency, and how these two 
concepts cannot be addressed in isolation and instead should be recognised as 
complementary to each other 
 the consistent view that both health literacy and cultural competency require a whole-
of-system response. This includes making sure there is organisational and systemic 
cultural competency along with sound health literacy practices 
 a theme emerged that health professionals need to “know the person well” before 
they focus on conditions and treatment. This was a call to understand a person’s 
background, avoid making assumptions, take time to get to know the person (and, 
where appropriate, their whānau) and change practice if necessary 
 the need to think about how to build the competence of families and communities 
around health literacy and engender cultural competency and cultural confidence 
 Pacific interviewees reported that health literacy should be considered within a 
systems approach where the key message is about family and not just the women. 
Once women are aware about how they can access services, they respond well. All 
DHBs should be required to produce a Pacific Action Plan. 
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 Health Literacy & Cultural Competency Roundtable Discussion, Ministry of Health, Wellington, 16 May 2014. 
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Workforce cultural competencies 
A number of professional groups, such as the Health Promotion Forum, have developed 
competencies to provide advice on workforce development (Auckland Regional Public 
Health Service 2014). These competencies have also been used in the employment of 
staff and in salary negotiations. 
 
Interviews from across the screening sector in this review regularly identified the need 
for cultural competency in the screening workforce. 
 
Why is it important for health professionals to be culturally competent?34 
All health professionals should have the ability and knowledge to communicate and 
understand health behaviours influenced by culture. Health professionals who have this 
level of cultural competency will find ways to better communicate with people from 
different cultures who use health services. A culturally competent health workforce can 
make a positive difference to patient experiences and their health outcomes. 
 
Cultural competency training tool 
New Zealand’s first online Foundation Course in Cultural Competency,35 designed 
specifically for health workforce professionals, was released on 3 July 2012. 
 
The Foundation Course in Cultural Competency provides support to practitioners to 
build their understanding of cultural competency and health literacy in New Zealand, 
with a focus on improving Māori health outcomes. The multimedia interactive course is 
a voluntary programme spread across four modules and is available for all people 
working in the health sector. Each training module is supported by videos, video 
transcripts, additional reading resources and library references. 
 
Cultural competency training has been found effective in updating health workers’ 
knowledge, skills and attitudes, allowing them to be more ‘in tune’ with their patients or 
clients. The training tool also addresses the need for a nationally consistent online 
Foundation Course in Cultural Competency and health literacy for the regulated and 
non-regulated health workforces. 
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Key issues 
 The introduction of primary HPV screening is likely to have a significant impact on the 
laboratory workforce. This will precipitate the need to have a planned approach to 
support cytologists, pathologists and laboratory scientists to move or relocate to 
areas where their expertise is not lost to the sector. 
 Well-designed and well-integrated education and training, together with ongoing 
competency assurance, will be vital to support change. It will also be important to 
ensure that service specifications, purchase agreements, funding arrangements and 
industrial arrangements do not unnecessarily impede this. 
 The NCSP expects smear takers to have an up-to-date knowledge of smear-taking 
techniques, screening issues and NCSP standards and guidelines. They are 
expected to maintain their competence and those who persistently have high rates of 
unsatisfactory smears are required to seek further training in smear-taking 
techniques. 
 Cultural competency is important. The coverage target was not met for Māori, Pacific 
or Asian women (with a coverage rate of 62.6%, 68.6% and 64.8% respectively) 
screened within the previous three years. New Zealand’s first online Foundation 
Course in Cultural Competency, designed specifically for health workforce 
professionals, was released on 3 July 2012. The Foundation Course provides 
support to practitioners to build their understanding of cultural competency and health 
literacy in New Zealand, with a focus on improving Māori health outcomes. 
 Specific workforce strategies focused on service changes have been developed in 
some priority areas, including Māori health, Pacific health and mental health, and 
others are under development. As the general Māori population increases, it is likely 
that the demand for the Māori non-regulated workforce will increase as well. This 
workforce has a critical role in the promotion and provision of health messages to all 
the priority groups of the NCSP. 
 It is important to address disparities in the NCSP for all of its priority groups. For 
more information, see Chapter 3: Coverage, participation, equity and access. 
 
Recommendations 
24. In light of momentous changes in cervical screening in other countries, it is likely 
that New Zealand’s NCSP will also move towards primary HPV screening. It is 
therefore advised that a planned process be developed over the next two years 
(2015 to 2017) to support the laboratory workforce to identify pathways and/or 
professional development programmes that assist staff to transition into other 
areas of work and future career pathways. This process will need to be supported 
by a specific communication and consultation plan that is appropriately developed 
with the laboratory workforce. 
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25. The NCSP must ensure online courses are regularly updated and access is 
improved access to online training for primary care workers, including practice 
nurses, midwives, registered nurses, enrolled nurses and general practitioners. It 
is noted that District Health Board contracts also require DHBs to provide annual 
smear-taker updates. 
26. The NCSP can learn much from the many successful examples of reducing 
disparities across the health sector. This learning must be continually 
demonstrated and supported by actions the NCSP takes to ensure the flexible but 
targeted use of funds in future contracts, such as those for services to support 
screening, and the Very Low Cost Access funds. 
27. The NCSP must ensure that, for District Health Boards that are not achieving the 
target rate of 80% for each of the NCSP’s priority groups, the DHBs have well-
planned programmes to avoid increasing their inequalities.36 
 
                                            
36
 See also Chapter 6: Organisational and structural issues. 
 84 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Chapter 8: The NCSP-Register 
Overview 
The National Cervical Screening Programme-Register (NCSP-R) is the national 
database that stores screening and diagnostic test results for women who are enrolled 
in the National Cervical Screening Programme (NCSP). The Health Act 1956, 
section 112F(2), requires that every cervical screening and diagnostic follow-up test 
must be recorded on the NCSP-R. 
 
The role and functions of the NCSP-R also include the following (NCSP 2014b): 
 providing screening histories to inform smear takers, laboratories and colposcopists 
in their management of women 
 providing smear-taker recall and overdue reports to women’s health care providers 
 sending letters to women with an overdue reminder and/or to provide their screening 
history 
 sending women letters confirming their enrolment on the NCSP-R or advising of their 
withdrawal if they have elected to do so 
 collecting and providing statistical data for the purpose of monitoring and evaluating 
the NCSP. 
 
Monitoring quality and outcomes in any health programme ensures that the programme 
maximises the benefits to the target population. Quality assurance refers to an overall 
management plan (the ‘system’) that guarantees the provision of good-quality service. 
Quality control refers to the application of a series of measurements (the ‘tools’) used to 
assess the quality of the services and facilities. 
 
Quality assurance of a cervical screening programme involves the systematic 
monitoring and evaluation of the various aspects of screening to maximise the 
probability that the programme is achieving its goals. The expected benefits of a 
screening programme, in terms of significant reductions in morbidity and mortality from 
cervical cancer, can only be achieved if quality is optimal at every step in the screening 
process, from identifying the target population to ensuring appropriate follow-up and 
treatment of women with screen-detected abnormalities. 
 
Quality control activities of a cervical screening programme include the use of 
standardised procedures for collecting data from different levels of service delivery, and 
the preparation of reports in an approved format at regular intervals. 
 
Critical information required to assess the above-mentioned indicators should be 
collected on a regular basis, generated in a timely manner and analysed to inform 
ongoing programme implementation. It is crucial that the denominators and numerators 
used are as accurate as possible. 
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A fully computerised register is the most effective way to monitor and evaluate a 
screening programme. The ideal register links with health facilities, laboratories and 
population-based cancer registries (WHO and PAHO 2013). 
 
History 
In 1991 the NCSP-R was introduced in 14 Area Health Boards (AHBs) as a stand-alone 
system. In 1994 the NCSP-R became a national database operating out of the 
14 AHBs. Data input was maintained at the AHB level, and in 1996 the NCSP-R was 
centralised in Wellington, with the operational teams remaining in AHBs. After the 
formation of District Health Boards (DHBs) in 2001, data input to the NCSP-R was 
reduced in 2002 from 14 to 6 DHBs. 
 
After consultation with stakeholders in 2006, the Ministry of Health assumed 
responsibility for NCSP-R operations and the upgraded national NCSP-R was 
implemented in September 2008. From July 2010, the administrative and technical 
support functions of the NCSP-R were transferred to New Zealand Post. The day-to-day 
management of the NCSP-R is currently provided by New Zealand Post Health 
Services (NZPHS). Overall management of and accountability for the NCSP-R remain 
with the Ministry of Health (Tan et al 2011). 
 
Current status 
The Ministry of Health retains ownership of the hardware on which the Register 
operates and is responsible for ensuring the NCSP-R software licences are current. The 
day-to-day management of the NCSP-R is the responsibility of NZPHS. The current 
contract is due to expire in 2017. 
 
In April 2014 the NCSP submitted the Stack Upgrade Project Business Case for the 
upgrade of expired versions of the operating system for the NCSP-R to ensure the 
system is fully supported by vendors and that ‘bug fixes’ and security upgrades occur 
when necessary (NCSP 2014b). The Project Plan agreed between the National 
Screening Unit (NSU) and NZPHS was signed in November 2014, and the upgrade 
project is expected to take 17 months. 
 
In October 2014 the NSU undertook the first audit of the NCSP-R’s operations to 
assess whether the Register is being managed efficiently, effectively and in accordance 
with best practice and the requirements of the NCSP. 
 
Overall, the audit made 22 recommendations for improvement and found that the 
NZPHS has good governance and a strong focus on continuous quality improvement. 
The audit identified the need for strong strategic governance and also information 
technology (IT) expertise within the Ministry as decisions are made regarding changes 
to the clinical service delivery of the NCSP and the redesign of the NCSP-R and its 
functions. 
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Management and accountability 
The contract for the formal governance and reporting structure for the NCSP-R 
includes: 
 weekly operational meetings 
 monthly service delivery meetings 
 quarterly quality and audit meetings 
 change control meetings 
 quarterly governance meetings 
 annual strategic review. 
 
The October 2014 audit found that the meetings are run formally and professionally, 
and that NZPHS completes action items in a timely manner. Monthly and quarterly 
reports by NZPHS were also found to be delivered on time and to a high standard. The 
audit recommended streamlining reports to eliminate duplication between monthly and 
quarterly reports. 
 
The audit found the NZPHS team has a sound knowledge of the NCSP pathway and 
their roles and responsibilities in the delivery of the programme. The team’s knowledge 
has been developed over a number of years, and is not easily replaceable. There is a 
team of 20 people who undertake day-to-day tasks of the NCSP-R. Complex business 
rules align to the screening guidelines. 
 
The NZPHS operational team has a schedule for providing the services of the NCSP-R. 
The services provided include: 
 business services 
 printing services and letter mail-outs 
 hosting and infrastructure – looking after the NCSP-R platform 
 development and support from an IT perspective 
 reporting to NSU as per contractual arrangements. 
 
Operationally, when results are received by the NCSP-R, demographics information is 
analysed to match date of birth, address, first name and last name in the Register, and 
checked against the equivalent information in the National Health Index, and any 
duplicates on the Register are merged. The NCSP-R advises challenges with ethnicity 
data in determining which source is correct in cases where the sources differ. The 
NCSP Monitoring Report Number 40 reports that ethnicity coding follows the 
classification used by the Ministry of Health, and the current data analysis contained 
ethnicity codes for 98.4% of women on the NCSP-R (NSU 2014b). 
 
Robust systems are in place for managing the security and confidentiality of the data on 
the NCSP-R, as well as operational processes to ensure back-up of data, business 
continuity systems and disaster recovery. 
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Accessibility of the NCSP-Register 
The NCSP-R is available online for laboratories and at DHBs to access women’s 
screening histories. Screening histories must be available at each stage of the 
screening process to inform recommendations for recall, referral or treatment in 
accordance with the NCSP guidelines. The contract between the NCSP and NZPHS 
sets a 100% availability target for the NCSP-R during working hours (8 am to 6 pm 
Monday to Friday), with a minimum acceptable performance of 99%. During the 
12-month period from February 2014 to January 2015, there were five outages totalling 
4.5 hours. This is a ‘downtime’ of 0.18% for the 12 months, as shown in Figure 8.1. 
 
Figure 8.1: Information system hosting and infrastructure service levels from 2014 to 
2015 
 
Source: Data provided by NZPHS 2015 
 
Direct online access to the NCSP-R is not available to smear takers and direct access 
for colposcopists is, at times, limited. To ensure a woman’s complete screening history 
is available to the clinician at the time of appointment, health care providers rely on DHB 
staff employed to download the screening histories of women due to attend for 
screening or to receive their results. Ongoing issues – identified by Tan et al (2011) in 
the previous Parliamentary Review Committee Report – exist with the completeness of 
colposcopy data on the NCSP-R. 
 
Colposcopy data 
The 2015 Parliamentary Review Committee’s interviews with key personnel across all 
services and IT areas revealed that the majority of issues with electronic transfer of 
colposcopy reports are due to operating system interoperability challenges. However, 
other reasons contributing to the incompleteness of the required data fields may be 
difficulties in completing the e-colposcopy form, and the competing priorities for 
clinicians’ time. The NCSP Monitoring Report Number 40, Indicator 7.3, requires 100% 
of medical notes to accurately record colposcopic findings, the colposcopic opinion 
regarding the nature of the abnormality, and the type of and timeframe for 
recommended follow-up (NSU 2014b). No DHB, nor the aggregate of colposcopy visits 
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to private practice, meets the target of 100%. Completion of most recommended fields 
has decreased since Monitoring Report Number 39, and overall completion (89.8%) is 
also lower than the previous report (91.8%). 
 
Timely access to and reporting of colposcopy findings is critical to the outcomes of the 
NCSP. Issues impeding the successful completion of the e-colposcopy project to enable 
electronic uploading of colposcopy data must be resolved as a priority. This must 
include working with providers who are responsible for uploading colposcopy reports to 
ensure the colposcopy forms are user-friendly and able to be transmitted in a timely 
manner. A comprehensive national intervention to resolve the barriers to the successful 
completion of the e-colposcopy project is essential to ensure complete data for women 
referred for colposcopy is captured on the Register. It is recommended that an audit 
across all DHBs should be undertaken by December 2015 to ensure colposcopy data is 
successfully being uploaded to the Register. 
 
Invitation and recall for screening 
Consistent feedback from screening providers was that the system could not match 
local health databases with the NCSP-R data to identify unscreened or under-screened 
women. This gap was identified as a primary concern for identifying women from ethnic 
groups who are at greatest risk of developing cervical cancer. Having the ability to 
populate the NCSP-R with population level data and issue invitations to all eligible 
women to screen would enable proactive approaches to unscreened and under-
screened women, and should be a strategic priority for the NCSP to investigate. 
 
Currently, invitations to screen are only generated by primary health organisations 
(PHOs). Sending an invitation is obviously contingent on a woman actually being 
registered with a PHO. Data shows that a significant proportion of women in the target 
age group, particularly those who are at greatest risk, are not screening. Cervical 
cancer is almost entirely preventable, and the inequities in the screening programme 




The previous Parliamentary Review Committee Report (Tan et al 2011) identified 
inconsistencies in colposcopy and test results in comparison with results on the 
NCSP-R. The Parliamentary Review Committee Report identified the lack of any fail-
safe mechanism to ensure that laboratories and the NCSP-R are coding correctly. It is 
noted the NCSP-R audit in 2014 did not include a random audit of coding on the 
NCSP-R and correlation with laboratory and colposcopy records. This quality assurance 
intervention should be considered for future audits. 
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Complaints and incidents 
The NCSP-R management advises there is a 0800 telephone number for any 
complaints regarding the NCSP-R, and that most of the complaints relate to 
administrative issues. Issues that have arisen include the use of a Māori salutation, or a 
letter going to the wrong address, or addressed to the wrong person. The NCSP-R 
management advises that around 80% of complaints are administrative. The remaining 
20% relate to clinical issues and these are sent to the Ministry of Health. 
 
A review of the approximately 270 records of feedback to the NCSP from consumers 
from 2011 to 2015 (mostly complaints, and many issues not relating to the NCSP-R) 
showed that most were from women requesting removal of their data from the NCSP-R, 
or complaining about letters sent to the wrong address, incompleteness of data on the 
NCSP-R and delays in follow-up. The issue, action and outcome of complaints, 
regarding either the NCSP-R or the programme as a whole, need to be regularly 
reviewed and monitored. A summary report should also be provided to the NCSP 
Advisory Group and, where relevant, to the NCSP-R, so that any trends can be 
identified and addressed. 
 
NCSP-Register reports to providers 
The NCSP-R provides regular standard reports for: 
 smear taker recall reports – women due for a smear 
 overdue reports – Pap smear providers of women overdue by up to 90 days 
 quality of smear reports – adequacy of specimen 
 cytology/histology correlation – for laboratories to identify slides for review where 
there is discordance (part of laboratory quality assurance processes). 
 
DHB regional staff advise that the routine reports to providers are well received, and 
they are a valuable quality improvement opportunity for providers to enable personal 
performance benchmarking and monitoring. 
 
The NCSP-R advised that it has little interaction on a daily basis with the end user (Pap 
smear provider), but regional services at a DHB level are in regular contact. Smear 
takers may get in touch in regard to screening history. The NCSP-R identified that 
providing data for monitoring to the monitoring report authors is a priority for the NCSP. 
A focus for the NCSP into the future should be reporting back to providers and 
reviewing, in collaboration with providers, the data and outcomes as part of the 
continuous feedback cycle for quality improvement. 
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National Kaitiaki Group 
The inequities in coverage, particularly for Māori women, have been identified in 
previous chapters. Māori women are over-represented in cervical cancer statistics, and 
under-represented in cervical screening participation. The NCSP, through the NSU, 
must apply to the National Kaitiaki Group (NKG) every time Māori women’s data is 
required to monitor the programme. The mechanisms currently in place appear to be an 
impediment to improving the health outcomes and reducing cervical cancer incidence 
and mortality for Māori women. It is strongly recommended the NCSP and NKG work in 
partnership to identify more streamlined processes that minimise the burdens the 
current processes for accessing data place on both parties. 
 
Future directions 
Decisions regarding the future directions of cervical screening must be strategically 
planned, with realistic and achievable timeframes and resourcing so that robust registry 
systems can be developed to support any revised screening pathway. The NCSP-R 
understands human papillomavirus (HPV) screening is on the horizon. It needs timely 
advance notice and clearly defined timeframes to manage its business and to ensure 
that business continuity for any transition is achievable. The Register currently has no 
links with the HPV immunisation data and there has been no discussion with the 
NCSP-R regarding this. 
 
NCSP staffing 
The NCSP-R identified concerns regarding the high staff turnover at the NSU and 
NCSP over the last six months, particularly at senior levels. This has led to a loss of 
corporate knowledge for the NCSP, in their relationships with the NCSP-R and for the 
programme as a whole. 
 
HPV vaccination and cervical screening – NCSP-Register linkages 
HPV immunisation programmes are being implemented worldwide, with the aim of 
reducing the incidence of, and deaths from, cervical cancer. Significant resourcing is 
being invested by governments, including the New Zealand Government, in introducing 
these immunisation programmes. 
 
The single most important element of monitoring the success of New Zealand’s 
Immunisation Programme is evaluating whether its objective is being achieved. To 
make this assessment, the screening histories of women being screened, combined 
with their vaccination status, must be monitored and evaluated. The full benefit of 
immunisation will not be realised for many years, until entire generations of girls and 
women have been vaccinated. However, monitoring of the vaccinated cohort and 
evaluating their screening results will inform any future decisions regarding both the 
immunisation and the screening programmes. 
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A very early study on the impact of HPV vaccination (Brotherton et al 2011) reported on 
the introduction of the Australian HPV vaccination programme with the quadrivalent 
HPV vaccine for all women aged 12–26 years between 2007 and 2009, and the impact 
on women’s cervical screening results. Trends in cervical abnormalities in women in 
Victoria, Australia, before and after introduction of the vaccination programme, were 
analysed by linking vaccination programme data with those women’s data on the 
Victorian Cervical Cytology Registry between 2003 and 2009. The study compared the 
incidence of histopathologically defined high-grade cervical abnormalities (HGAs, 
lesions coded as cervical intraepithelial neoplasia of grade 2 or worse or 
adenocarcinoma in situ; primary outcome) and low-grade cytological abnormalities 
(LGAs) in five age groups before (1 January 2003 to 31 March 2007) and after (1 April 
2007 to 31 December 2009) the vaccination programme began. 
 
The study found that, after the introduction of the vaccination programme, incidence of 
HGAs decreased by 0.38% (95% confidence interval 0.61–0.16) in girls younger than 
18 years. This decrease was progressive and significantly different to the linear trend in 
incidence before the introduction of the vaccination (incident rate ratio 1.14, 1.00–1.30, 
p = 0.05). No similar temporal decline was recorded for LGAs or in older age groups. 
 
This very early study linking cervical screening results with women’s vaccination status 
identified the importance of linkage between vaccination and screening registers to 
confirm that the decrease in HGAs continues as expected subsequent to the 
introduction of the HPV immunisation programme; and to enable ongoing monitoring of 
participation in screening, and screening results, among vaccinated women. 
 
The Brotherton et al (2011) findings reinforce the need for cervical screening 
programmes to adapt and respond to a post-vaccination environment and the 
requirement to define workable screening algorithms, especially in vaccinated 
populations. For this to occur, HPV vaccination status must be captured and recorded 
with the woman’s screening history, or both registers must be linked to enable 
confirmation of vaccination status. 
 
Any future planning for the NCSP-R must include options for linking the HPV 
Immunisation Register with the NCSP-R, so that a woman’s vaccination status forms 
part of her cervical screening history. 
 
Key issues 
 Having the ability to populate the NCSP-R with population-level data and issue 
invitations to all eligible women to screen would enable proactive approaches to 
unscreened and under-screened women, and should be a strategic priority for the 
NCSP to investigate. 
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 The majority of issues with electronic transfer of colposcopy reports to the NCSP-R 
appear to be due to operating system incompatibilities. However, other reasons 
contributing to the incompleteness of the required data fields may be the competing 
priorities of clinicians’ time, and difficulties in completing the e-colposcopy form. 
Timely access to and timely reporting of colposcopy findings are critical to the 
outcomes of the NCSP. 
 Consistent feedback from screening providers was that the system could not match 
local health databases with the NCSP-R data to identify unscreened or under-
screened women. This was a primary concern for identifying women from ethnic 
groups who are at greatest risk of developing cervical cancer. 
 The 2011 Parliamentary Review Committee Report identified concerns that some 
colposcopy and test results were inconsistent with those recorded on the Register. 
The NCSP-R audit in 2014 did not include a random audit of coding on the NCSP-R 
and correlation with laboratory and colposcopy records. This quality assurance 
intervention should be considered for future audits. 
 The issue, action and outcome of complaints, regarding either the NCSP-R or the 
programme as a whole, must have robust follow-up processes. Complaints from 
consumers regarding the screening programme need to be regularly reviewed and 
monitored, and a summary report provided to the NCSP Advisory Group (and where 
relevant to the NCSP-R), so that any trends can be identified and addressed. 
 The routine reports from the NCSP-R to providers are well received and they are a 
valuable quality improvement opportunity for providers to enable personal 
performance benchmarking and monitoring. Reporting back to providers on their 
outcome data and reviewing the data and outcomes, in collaboration with lead clinical 
providers, should form part of the continuous feedback cycle for quality improvement, 
and should be a focus for the NCSP into the future. 
 Māori women are over-represented in cervical cancer statistics, and under-
represented in cervical screening participation. The mechanisms for applying to NKG 
for data appear to be an impediment to improving the health outcomes and reducing 
cervical cancer incidence and mortality for Māori women. 
 The NCSP-R understands HPV screening is on the horizon. It needs timely advance 
notice and clearly defined timeframes to manage its business and to ensure that 
business continuity for any transition is achievable. The NCSP-R currently has no 
links with the HPV immunisation data and there has been no discussion with the 
NCSP-R regarding this. 
 The NCSP-R identified concerns regarding the high staff turnover over the last six 
months at the NSU and NCSP, particularly at senior levels. This has led to a loss of 
corporate knowledge for the NCSP, in relationships with the NCSP-R and for the 
programme as a whole. 
 The full benefit of immunisation will not be realised for many years, until entire 
generations of girls and women have been vaccinated. However, monitoring of the 
vaccinated cohort and evaluating their screening results will inform any future 
decisions regarding both the immunisation and the screening programmes. 
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Recommendations 
28. Strong strategic governance and also IT expertise within the Ministry are needed 
to enable informed decisions regarding future HPV screening, data linkage with 
the National Immunisation Register, and the subsequent redesign of the NCSP-R 
and its functions that will be required. 
29. Decisions regarding the future directions of cervical screening must be 
strategically planned. Realistic and achievable timeframes and resourcing are 
needed so that robust registry systems can be developed to support any revised 
screening pathway. 
30. Issues impeding the successful completion of the e-colposcopy project to enable 
electronic uploading of colposcopy data must be resolved as a priority. This must 
include working with providers who are responsible for uploading colposcopy 
reports to ensure the colposcopy forms are user-friendly and able to be 
transmitted in a timely manner. A comprehensive national intervention to resolve 
the barriers to the successful completion of the e-colposcopy project is essential to 
ensure complete data for women referred for colposcopy is captured on the 
NCSP-R. It is recommended that an audit across all DHBs is undertaken by 
December 2015 to ensure colposcopy data is successfully being uploaded to the 
NCSP-R. 
31. Achieving the ability to populate the NCSP-R with population data and issue 
invitations to all eligible women to screen should be a strategic priority for the 
NCSP to investigate. 
32. It is noted the NCSP-R audit in 2014 did not include a random audit of coding on 
the NCSP-R and correlation with laboratory records. This quality assurance 
intervention should be considered for future audits. 
33. The issue, action and outcome of complaints, regarding either the NCSP-R or the 
programme as a whole, need to be regularly reviewed and monitored, and a 
summary report provided to the NCSP Advisory Group, so that any trends can be 
identified and addressed. 
34. A focus for the NCSP into the future should be reporting back to providers, and 
reviewing the data and outcomes in collaboration with lead clinical providers from 
DHBs as part of a continuous feedback cycle for quality improvement. 
35. It is strongly recommended the NCSP and NKG work in partnership to identify 
more streamlined processes that minimise the burdens the current processes for 
accessing data place on both parties. 
36. Any future planning for the NCSP-R must include options for linking the HPV 
Immunisation Register data with women’s cervical screening history on the 
NCSP-R, so that a woman’s vaccination status forms part of her cervical screening 
history. 
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37. The NCSP must ensure processes are in place to monitor compliance with the 
legislative requirement for all colposcopy clinics, including the private clinics, to 
send their colposcopy data to the NCSP-R. 
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Chapter 9: Ethnicity data 
Overview 
This chapter reviews the quality and use of ethnicity data (particularly access to and use 
of Māori women’s data), the nature of efforts employed to gauge the accuracy of 




Data access and the National Kaitiaki Group 
New Zealand holds a unique position in the international health sector regarding the 
protection of research information that belongs to its indigenous people. In regard to the 
National Cervical Screening Programme (NCSP), Māori women’s cervical screening 
data is deliberately and purposefully guarded by a specific regulation – the Health 
(Cervical Screening [Kaitiaki]) Regulations 1995, Regulation 4 – and by the Health Act 
1956, section 112J(h). 
 
The legislation enabled the establishment of the National Kaitiaki Group (NKG), which is 
accountable to the Minister of Health. The NKG’s task is to consider applications for the 
release of Māori women’s data from the National Cervical Screening Programme-
Register (NCSP-R). 
 
In 2011 the Parliamentary Review Committee Report (Tan et al 2011) recommended 
that the NCSP take that review as an opportunity to amend the Kaitiaki Regulations. 
This recommendation was not upheld in its entirety. Instead, the Māori Business Unit 
(formerly the Māori Health Directorate) at the Ministry of Health, the National Screening 
Unit (NSU) and the NKG upheld the intent of the recommendation, which was to resolve 
to work together to make the NKG process appropriate for allowing access to data and, 
at the same time, assuring protection of Māori women’s data. This action is a continuing 
process that was confirmed in review discussions in 2015, with all parties involved. 
 
The NKG continues to approve (or not) the release of Māori women’s information. 
Frustrations abound with data analysts who through this role are also charged with 
monitoring the performance of the programme. A key informant commented: 
“It is frustrating that we have to apply to use the data that we collect for the 
purposes that we are employed to do, as enabled by section 112” 
(ie, section 112J(h) of the Health Act 1956). 
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The NKG meets quarterly and accepts applications electronically. However, these 
arrangements do not mitigate the issue for analysts who are under time constraints to 
use the data and produce the monitoring reports within Ministry of Health guidelines and 
timeframes, and before they must meet the NKG’s routine requirement to destroy the 
data after six months falls due. Should the NSU wish to retain the data beyond six 
months, it must make a further application to the NKG. The NSU has clarified that, while 
there is no stand-alone legal requirement to destroy data after six months, the NKG 
routinely places a condition, on all applications to access data, that the data be deleted 
after six months has elapsed. 
 
Ethnicity data and addressing the equity gap37 
 District Health Boards (DHBs) are required to report on cervical screening coverage 
and develop plans to improve this. 
 Cervical screening activities are monitored for inclusion in DHB Māori Health Plans. 
The NCSP team has reviewed all Māori Health Plans and provided feedback. Māori 
Health Plans are a good lever within DHBs to inform the Boards on cervical 
screening and to help them address the equity gap. 
 The NCSP has strengthened its connections with the Māori Health Business Unit 
within the Ministry of Health. Quarterly meetings are held to review progress against 
Māori Health Plans and whānau ora collective reports, and to discuss initiatives or 
policy developments. 
 Equity – Our Focus, an internal steering group, has been set up. Members include 
NSU staff and Māori and Pacific advisors from across the Ministry. This group 
provides operational advice and oversight to contribute toward achieving equitable 
national screening programmes. 
 The NSU has met with Tumu Whakarae, the collective of DHB Māori Health General 
Managers, to build relationships and discuss improving access to services. There 




Data in the NCSP-R is safe. The first audit of the NCSP-R38 was conducted by senior 
managers in the NCSP in July-August 2014. The Register is a database containing 
secure cervical screening information for more than 1.4 million women. The 
management of the Register has been the responsibility of New Zealand Post Health 
Services (NZPHS) since 2010. 
 
                                            
37
 Information provided by the NCSP for the Parliamentary Review Committee: What the NCSP has been doing to 
increase coverage in the last three years. 
38
 Performance Audit report: National Cervical Screening Programme, Register Management October 2014. 
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The audit of the NCSP-R aimed to provide assurance that the Register is being 
managed efficiently, effectively, and in line with best practice and the needs of the 
Ministry of Health’s National Screening Unit and the NCSP. Findings from the audit 
confirmed that relationships and governance, quality improvement, value for money, 
and IT systems management of the Register (and therefore women’s data, including 
that of Māori women) are well managed. The relationships between the Ministry and 
NZPHS are strong and working effectively for the benefit of New Zealand women. 
 
Ethnicity analysis 
All of the Ministry of Health’s monitoring reports explain (among other extrapolations) 
their process of analysis by ethnicity, which is considered in four groups – Māori, 
Pacific, Asian and European/Other – based on women’s priority two ethnicity codes 
recorded on the NCSP-R. Current analysis from the NCSP-R data (at March 2014) 
recorded ethnicity codes for approximately 98.4% of the 1.4 million women on the 
NCSP-R. 
 
The data is collected during encounters with the health system, such as when a woman 
is registering with primary care services, during an admission to hospital, or during 
surveys. The Ministry engages in a number of activities to improve the quality of 
ethnicity data, including by developing in 2004 protocols for the collection and recording 
of ethnicity data. Coding of ethnicity on the NCSP-R follows the classification used by 
the Ministry of Health (Ministry of Health 2004). 
 
The NCSP undertakes continuing work to improve the accuracy of ethnicity recording 
on the Register (NSU 2014b). 
 
In New Zealand, ethnic identity is an important dimension of health inequities. Māori and 
Pacific people experience lower life expectancy and health disadvantage across most 
mortality and morbidity indicators compared with Europeans, as well as socio-economic 
disadvantage in areas such as housing, education, income and employment (Harris 
et al 2012). 
 
Ethnic inequalities between Māori and non-Māori are the most consistent and 
compelling inequities in health (Robson and Harris 2007). An analysis of socio-
economic position and health status data identifies three distinct types of ethnic 
inequalities in health in New Zealand. These have been described as the distribution 
gap, the outcome gap and the gradient gap. New Zealand research suggests life 
expectancy and other measures of health status are similar in rural and urban areas.39 
 
                                            
39
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Data matching 
At the regional level, DHBs have their own databases for more localised and timely 
access to data on their screened populations and for results from their screening efforts. 
NCSP has regular contact with DHBs regarding their processes for data matching and 
tracing women for their screening participation. 
 
The NCSP reports the following: 
 PHOs can request data matching against the NCSP-R every six months to identify 
women who are overdue or who have been screened elsewhere and information 
from the other provider has not been provided to them. 
 An automated data matching pilot is underway with a large PHO in Auckland 
(ProCare) to identify PHO-enrolled women who are unscreened. This will inform 
further data matching for other PHOs. 
 Most DHBs are manually data matching with general practices to identify women who 
are overdue for a cervical smear and facilitating opportunities for them to be screened.40 
 
Use of ethnicity data 
Complexities proliferate where aggregated data is evidenced in coverage reporting but 
not in the biannually reported data. There are demands on the time limits for other 
provider functions to produce timely data to meet targets that are aligned to funding 
incentives. For example, PHO funding is tied to the Integrated Performance and 
Incentive Framework (IPIF), which relies on disaggregated data that can only be 
supplied twice per year (biannual reportage quotient) from the analysts in the NCSP and 
NSU. The NSU has confirmed that this data is being supplied on a monthly basis from 
May 2015. 
 
The NSU and NCSP continue to identify improvements in the relationship with the NKG. 
Applications have recently been written that make sense from an NKG perspective as well 
as not compromising the NCSP’s intent to obtain the data in a respectful manner. The 
NCSP has made efforts to present applications that adequately answer the key questions 
that NKG asks about the use of Māori women’s data. The NCSP ensures that the people 
who attend the meetings with the NKG understand the Health Act 1956 and related 
regulations and can respond to the NKG’s questions about the use of the data and how 
this aligns with this legislation. In the last round of applications for information, the NKG 
acknowledged an improvement in the manner in which applications are filled out. 
 
The Review Committee is encouraged to find that the NSU has undertaken a review to 
improve the process for the NKG applications for Māori women’s data, and has agreed 
that the NKG lead the work to develop a combined NSU and NKG application form for 
accessing and using Māori women’s cervical screening data. Questions and responses 
for access to Māori women’s data on the NCSP-R continue to follow the standard set by 
                                            
40
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the NKG. Applications to access Māori women’s data are made for monthly monitoring, 
and quarterly and biannual coverage reports. 
 
The function of the NCSP-Register 
Part 4A, section 112F(2) of the Health Act 1956 prescribes that every screening or 
diagnostic test result that is reported to the NCSP must be recorded on the NCSP-R if 
that result relates to a woman who is enrolled in the NCSP. 
 
Once screening records are stored within the Register, they can be used to provide: 
 screening histories to support smear takers, laboratories and colposcopists in their 
provision of screening services to women 
 a back-up service for women by generating overdue screening test letters and 
screening test result letters 
 statistical data for monitoring and evaluation of the programme.41 
 
To complete the NKG and NSU process for accessing Māori women’s data, the NCSP 
diligently provides its responses to six NKG queries on the Report Back template. The 
NKG asks for reports on how the data will be used to improve Māori women’s health 
and for confirmation that the data will be or has been destroyed. All NCSP monitoring 
reports are placed on the Ministry of Health website and are available publicly.42 
 
The NCSP response to the NKG requests includes the following points: 
 The NKG’s approval of NCSP requests to access Māori women’s data as part of 
routine monitoring of the programme is seen as invaluable. 
 Māori women are a priority group for the NCSP. 
 Māori women’s data: 
– helps to reduce inequities health for Māori women 
– enables complete analysis specifically in relation to participation rates for Māori 
women 
– informs the planning, funding and decision-making processes of government and 
providers (DHBs) to shape policy and drive initiatives to improve and increase 
coverage rates for Māori women at national and regional/district levels. 
 The findings show how specific initiatives to maintain Māori coverage rates within the 
regions (DHBs) achieve equitable coverage at or above the 80% NCSP target for 
Māori, Pacific, Asian, European/Other and overall. Individual DHBs can be identified 
as high performers in contributing to Māori coverage rates. 
 Coverage information is another key tool in the development and review of DHB 
Māori Health Plans, as these are used to monitor the performance of DHBs in 
providing cervical screening to the Māori population. 
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 Performance audit report: National Cervical Screening Programme – Register Management October 2014, p6. 
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 NKG Application, 5 January 2015. 
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 NCSP biannual reports are able to show timeliness for further referrals and tests 
such as colposcopies for Māori women with high-grade results from their smears. For 
example, 49.4% of Māori high-grade women were seen within the standard time of 
20 working days, compared with 65.0% for European/Other high-grade women. 
These statistics show the need for colposcopy services to improve their methods for 
seeing Māori women within the timeframe set by the Colposcopy Policies and 
Standards. The NCSP can then follow a process of consultation with colposcopy 
clinics and monitor progress for those women within the programme. 
 
Accuracy of ethnicity data 
The NCSP team works directly with providers to improve their service delivery models, 
with a focus on increasing coverage for women in priority groups. Included in this is 
information about the importance of correctly documenting ethnicity. 
 
A more intensive investigation was instigated to address reasons why the laboratories 
omitted recording accurate ethnicity data from their processes for handling women’s 
smears. The NCSP has worked with laboratories to discuss this and provide information 
on the importance of accurately recording ethnicity information in laboratory systems. 
The ethnicity recorded on laboratory systems is the same as the ethnicity that is 
recorded on the NCSP-R. 
 
Ethnicity adjusters for NCSP-Register 
The NSU also undertook a review to examine the issues with ethnicity data collection 
and potential solutions. A previous set of adjusters was developed in 2008 and used for 
a number of years to compensate for inaccuracies in ethnicity data on the NCSP-R, 
particularly the undercounting of Māori, Pacific and Asian women.43 
 
The NCSP has worked on developing the new set of ethnicity adjusters for the Register. 
Previously, adjusters were used to better estimate coverage for Māori women because 
using the ethnicity data held in the NCSP-R results in an undercount. It is likely that 
some, but not all, of the disparity between Māori and non-Māori is due to undercounting. 
Also noted were the new denominator counts from Census 2013, which means that 
coverage data is now more accurate, but there has been an apparent decrease in 
coverage for Māori women.44 NCSP-R management reports that there are issues with 
ethnicity data in terms of what is the most accurate. 
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Data completeness45 
Stakeholder comments have identified that the data shows persistent inequity or 
disparities in participation rates for cervical screening among Māori, Asian and Pacific 
women. This is considered a major concern for the NCSP and the sector, particularly in 
relation to Māori. The NSU and NCSP engage in a wide range of activities that support 
and enhance the completeness of ethnicity data and encourage broad-based 
approaches to data accuracy and data sharing that contribute to achieving this 
completeness. The following are some instances of such activities. 
 
NCSP are aware that: 
 there is a need to have greater scrutiny on the inequalities, similar to the provision 
and the process used by BreastScreen Aotearoa46 
 it is important for Māori to be part of any discussion and that the NCSP has 
ownership of any implementation processes. 
 
The NCSP-Register 
Management for the NCSP-R is unsure of how complete the data is if there is limited or 
no referral information provided. The NCSP is continuing with work to improve the 
accuracy of ethnicity recording on the Register.47 
 
Support to screening services funding review 
The model of this funding is being updated. The key goals of funding support to 
screening services were to: 
 provide funding that achieved intensive one-to-one support for priority women who 
are hard-to-reach 
 make a big difference to a small number of women and increase their access to 
cervical smears 
 support Māori and Pacific providers, who were well placed to offer culturally safe 
kanohi ki te kanohi (face-to-face) services. 
 
Social marketing 
According to a key informant, social marketing for NSU-wide activities will focus on 
Māori women. Qualitative research (focus groups and individual interviews) will be 
planned to understand women’s motivations for and barriers to participation in 
screening programmes. 
                                            
45
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 Māori representation is on the Social Marketing Governance Group. 
 Advice from the Māori Monitoring and Equity Group and contracted Māori advisors 
with communications experience will also inform the social marketing work. 
 
Data access and reducing disparities 
Issues encountered in regard to data access have highlighted that the process to obtain 
information from the Register is slow. This process is mainly influenced by: 
 the need for a correctly functioning database that would also help to access 
information in real time 
 concerns about obtaining up-to-date data and the need to have information, 
technology and reporting systems working more efficiently 
 the need to improve relationships between the NCSP and the NKG. 
 
The latest Monitoring Report (NSU 2014b) showed that the coverage target was met for 
European/Other women (81.9% screened within the previous three years), but was not 
met for Māori, Pacific or Asian women (62.6%, 68.6% and 64.8% respectively screened 
within the previous three years). 
 
Data access and sharing information 
Independent service providers (ISPs) have found it challenging to identify who the 
unscreened women are in their areas, particularly Māori women, who have a higher 
cervical cancer rate than the other priority groups. 
 
The 2012 NCSP Annual Report (NSU 2014a) reports that in 2010, there were 
52 women who died from cervical cancer, including 8 Māori women. The age-
standardised mortality rate was 1.7 per 100,000 women in the general population and 
3.3 per 100,000 for Māori women. This is after a reduction in the number of deaths from 
10.3 per 100,000 in 1998 for Māori women. 
 
Difficulties in screening are encountered where general practitioners (GPs) are not 
sharing information or data with ISPs. Information need to be shared more freely and 
transparently between GPs and other providers. This issue could be ameliorated by 
better communication between the DHB managers and the NSU. Given that the NCSP 
can only report on women who have been screened and a PHO can only report on 
patients who are enrolled with that PHO, there should be proactive planning and 
coordination between GPs and ISPs locally, supported by DHB managers and NSU 
nationally, to have strategies in place to assist with the identification of the unscreened 
women. Access to and identification of this information can be directly related to 
reducing disparities for priority women – and Māori women in particular. 
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Data accuracy and laboratory recording of ethnicity48 
The NCSP screening coverage data is taken from the NCSP-R, and the ethnicity 
recorded on the NCSP-R is the same as that entered by laboratories. The NCSP 
explained in its June 2014 newsletter that, while any person can have multiple 
ethnicities, the person’s ethnicity is self-identified and can change over time. Smear 
takers are responsible for providing accurate ethnicity data on laboratory request forms. 
 
The NCSP has provided two ways in which laboratories can improve the quality of 
ethnicity data on the NCSP-R: 
 Ensure that ethnicity is entered and/or updated at the laboratory, and the ethnicity 
recorded matches that on the latest laboratory request form. 
 If more than one ethnicity is listed on the laboratory request form, prioritise ethnicity 
according to the Ethnicity Data Protocol.49 
 
The NCSP ensures that sound systems are in place so that some ethnic groups are not 
undercounted. In addition, through these systems, quality ethnicity data is provided to 
measure how health services are working for specific (priority) populations and to assist 
in improving access to health services for people who need them. 
 
For instance: 
 coding of ethnicity on the NCSP-R follows the classification used by the Ministry of 
Health (Ministry of Health 2004) 
 work is continuing to improve the accuracy of ethnicity recording on the Register 
(NSU 2014b). 
 
Ethnicity data protocols for the health and disability sector require ethnicity to be 
recorded at Level two as the minimum level of specificity (Ministry of Health 2004). The 
category of Māori stands alone at all levels of the classification. This is in recognition of 
Māori as the tangata whenua (original inhabitants) of New Zealand and New Zealand’s 
unique position as the only country where there is a commitment to the status, 
preservation and continuity of Māori cultural traditions, including language (Ministry of 
Health 2004). 
 
Figure 9.1 shows the ethnicity data quality-improvement cycle. Collecting good-quality 
ethnicity data in the health and disability sector is important for many reasons, including 
the following: 
 Ethnicity data is part of a set of routinely collected administrative data used by health 
sector planners, funders and providers to design and deliver better policies, services 
and programmes. Better information helps improve every New Zealander’s health by 
providing a sound basis for decision making. 
                                            
48
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 In New Zealand, ethnic identity is recognised as an important dimension of health 
inequalities. The impact of those factors is particularly evident among Māori and 
Pacific peoples, whose health status is lower on average than that of other New 
Zealanders (Ministry of Health 2004). 
 












The three steps covered by these protocols
Training and education
 
Source: Ministry of Health (2004) 
 
The NCSP has produced for this 2015 review a range of strategies to increase 
coverage and reduce disparities between priority women – Māori, Pacific and Asian – 
and European/Others. Evaluation of these efforts will undoubtedly need to continue as 
part of the essential business for the NCSP. 
 The NCSP has included in its DHB contract reporting templates a requirement to 
report against actions in the DHB Māori Health Plans, since July 2014. 
 Some work has looked at funding free smears for more people but equally there is 
now a need to consider developments with primary human papillomavirus (HPV) 
screening and funding HPV development, as against whether or not a focus should 
remain on funding free smears. 
 Feedback regarding ISPs providing screening interventions was that they are very 
creative. Some are combined with breast screening promotion and some involve 
smears being taken in the home. 
 
Key issues 
 New Zealand holds a unique position in the international health sector arena 
regarding the protection of research information that belongs to its indigenous 
people. The NKG is accountable to the Minister of Health and considers applications 
for the release of Māori women’s data from the NCSP-R. The NSU and NCSP 
continue to voice their frustration with both the past relationship with the NKG and the 
process for obtaining access to Māori women’s data from the NCSP-R. 
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 Current analysis of the NCSP-R data (at March 2014) recorded ethnicity codes for 
approximately 98.4% of the 1.4 million women on the NCSP-R. The NCSP has 
continuing work to improve the accuracy of ethnicity recording on the Register. 
 In New Zealand, ethnic identity is an important dimension of health inequities. Māori 
and Pacific people experience lower life expectancy and health disadvantage across 
most mortality and morbidity indicators compared with Europeans, as well as socio-
economic disadvantage in areas such as housing, education, income and 
employment. Ethnic inequalities between Māori and non-Māori are the most 
consistent and compelling inequities in health. 
 The NCSP has worked with laboratories to provide information on the importance of 
accurately recording ethnicity information in laboratory systems. The ethnicity 
recorded on laboratory systems is the same as the ethnicity that is recorded on the 
NCSP-R. 
 Stakeholder comments have identified that the data shows persistent inequities in 
participation rates for cervical screening among Māori, Asian and Pacific women. 
This is considered a major concern for the NCSP and the sector, particularly in 
regard to Māori. Planning for primary HPV screening is seen as a critical opportunity 
to improve cervical screening coverage for Māori women. 
 Issues encountered with regard to data access have highlighted that the process to 
obtain information from the Register is slow. This process is mainly influenced by the 
need to improve relationships between NCSP and the NKG so that a process of 
obtaining information quickly can be established. A correctly functioning database is 
also important. 
 Independent service providers have found it challenging to identify the unscreened 
women in their areas, particularly Māori women, who have a higher cervical cancer 
rate than the other priority groups. 
 Difficulties in screening are encountered where GPs are not sharing information or 
data with ISPs. Information needs to be shared more freely and transparently 
between GPs and other providers. 
 Pacific interviewees reported that health literacy should be considered within a 
systems approach where the key message is about family and not just the women. 
Once women are aware about how they can access services, they respond well. All 
DHBs should be required to produce a Pacific Action Plan. 
 
Recommendations 
38. The Parliamentary Review Committee is encouraged by the progress made 
between the NCSP and the NKG in order to provide timely and accurate reporting 
information on Māori women. There is further room for the NCSP and NKG to 
continue to strive to improve relationships.50 
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39. The NSU, NCSP portfolio managers and DHB managers need to collaborate with 
ISPs and PHOs (general practices) regarding data sharing between the agencies 
to identify unscreened women in the regions. It is emphasised that this issue is 
related to reducing disparities for priority women and Māori women in particular. It 
is recommended that, as a result of this collaboration, the NCSP and NSU should 
issue clear national guidelines on sharing client data between agencies. 
40. The NCSP should ensure that DHBs provide Action Plans for each of the priority 
groups. In particular, DHBs should develop an annual Pacific Action Plan and an 
annual Asian Action Plan to address inequities and disparities in cervical 
screening for each of the priority groups.51 
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Chapter 10: Colposcopy 
Overview 
Colposcopy is a medical procedure where the cervix is visually examined. It is carried 
out using a colposcope, which is a low-powered microscope that provides an enlarged 
view of the cervix, enabling the diagnosis and treatment of cervical abnormalities. The 
colposcope can help guide the taking of biopsies for histological diagnoses, and can 
help visualise the cervix while using a range of treatment methods. 
 
Colposcopy is central to the successful diagnosis and treatment of cervical 
abnormalities. It allows a comprehensive visual examination of the cervix, and enables 
the location of possible lesions that may require treatment, in women referred with any 
of the following conditions: 
 cytological abnormalities detected on cervical sampling 
 visible abnormalities of the cervix 




Colposcopy services in New Zealand are contracted to District Health Boards (DHBs), 
where the service is usually part of a gynaecological or women’s health service. 
Colposcopy is also provided by gynaecologists working in private practice. 
 
Colposcopy service providers must comply with “duties of persons performing 
colposcopy procedures” as specified in section 112M of the Health Act 1956, as 
amended by Part 4A in 2004. Compliance with this Act includes providing data to the 
National Cervical Screening Programme (NCSP) as specified. 
 
Monitoring colposcopy services – compliance with legislation 
According to the Health (National Cervical Screening Programme) Amendment Act 
2004 (Part 4A, section 112D), the NCSP has a statutory obligation to: 
a) promote high-quality cervical screening, assessment and treatment services, while 
recognising and managing the differences between the various types of cervical 
cancer, with a view to reducing the incidence and mortality rate of cervical cancer 
b) inform women and the community of the risks, benefits and expected population 
health gains from participation in the NCSP 
c) promote the regular recall of women who are enrolled in the NCSP for screening 
tests 
d) facilitate continuous quality improvement by allowing and performing regular 
evaluations of the NCSP 
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e) ensure that information that is collected for the purposes of the NCSP is: 
i. available, in a reliable, accurate and timely manner, to persons authorised 
under this Part, or any other enactment, to have access to it 
ii. safely stored, including on the NCSP-Register 
f) provide information to women about the quality and effectiveness of the NCSP 
including, if it is appropriate, information based on the results of evaluations. 
 
To fulfil its statutory functions, the NCSP must collect and analyse data on colposcopy 
services. 
 
The National Cervical Screening Programme Policies and Standards 
The NCSP has produced a Policies and Standards document with agreed policies, 
guidelines and standards of practice for health professionals who provide cervical 
screening services (Ministry of Health 2013). The purpose of these Policies and 
Standards is to support all those involved in the NCSP to achieve the programme’s 
aims and objectives, by ensuring a high standard and national consistency of service at 
each step of the screening pathway. 
 
Colposcopy Quality Improvement Programme 
In 2009 the Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists (RANZCOG) led the development of Colposcopy Quality Improvement 
Program (C-QuIP), an education, certification, re-certification and audit programme for 
all health professionals performing colposcopy in Australia and New Zealand. The aim 
of C-QuIP is to improve the care of women who are referred for colposcopy and 
treatment of screen-detected abnormalities. A comprehensive online education 
programme is provided for all professionals performing colposcopy (C-QuIP 2015). 
 
District Health Board colposcopy services 
The colposcopy services within DHBs are audited every three years. The most recent 
audit revealed a number of high-risk Corrective Action Requests (CARs), as shown in 
Table 10.1. The most frequently reported high-risk CARs were in relation to timeliness 
of diagnosis and treatment, documenting colposcopy assessment, work practices 
policy, internal quality control policies and quality assurance activities. All CARs have 
now been closed (see Appendix H for more detail). 
 
  Report of the Parliamentary Review Committee 109 
 regarding the New Zealand Cervical Screening Programme 
Table 10.1: Frequency of high-risk CARS 
Standard/policy Number of DHBs with high-risk CARs 
602 – Timeliness of diagnosis 10 
603 – Documenting colposcopy assessment 7 
605 – Timeliness of treatment 6 
Internal quality control policy / quality assurance activities 5 
609 – Managing women who do not attend / failure to attend guidelines 4 
611 – Maintaining staff skill levels 4 
610 – Ensuring services are adequately staffed 1 
607 – Delivering appropriate outpatient treatment 1 
Work practices policy 6 
Referral for colposcopy policy 1 
Data collection for the development of new targets and reports 2 
Service components 1 
Source: Data provided by NCSP 2015 
 
A third round of audits commenced in 2015 for all 20 DHBs. The audit provider is Health 
and Disability Auditing New Zealand Limited and the audit team consists of a lead 
auditor, a colposcopist and a colposcopy nurse. 
 
All colposcopy service providers contracted to the NCSP are monitored using National 
Cervical Screening Programme-Register (NCSP-R) data against a range of indicators, 
including: 
 wait times for assessment for high- and low-grade abnormalities and urgent referrals 
 rates of women who do not attend appointments 
 total volumes of new assessments undertaken 
 rates of women with high-grade lesions who have had a biopsy 
 rates of biopsies suitable for histological interpretation 
 positive predictive value (PPV) of colposcopy for high-grade lesions 
 rates of high-grade treatment failures 
 use of high-risk HPV (hrHPV) testing to manage discordant results 
 follow-up of women with high-grade cytology, no histology. 
 
Colposcopy units must ensure the maintenance of skill levels of staff performing 
colposcopy through: 
 attaining at least the minimum volume of new cases (see Standard 610, Appendix I) 
 participating once every three years in an activity recognised by C-QuIP (see 
Standard 610, Appendix I) 
 for nursing staff, participating in continuing education activities appropriate to their 
practice. 
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For a summary of the National Cervical Screening Programme Policies and Standards, 
Section 6: Providing a Colposcopy Service, see Appendix I. 
 
Colposcopists 
Colposcopists should be certified by C-QulP or be practising under the supervision of a 
certified colposcopist, while working towards certification by C-QulP. 
 
Colposcopists must: 
 be registered to practise in New Zealand and hold a current annual practising 
certificate with the New Zealand Medical Council or Nursing Council of New Zealand 
 practise according to the Guidelines for Cervical Screening in New Zealand (NSU 
2008) and subsequent updates 
 maintain a minimum volume and spectrum of new referrals as per the standards 
 work closely with other health professionals and participate in multidisciplinary 
meetings in accordance with New Zealand guidelines. 
 
Nurse colposcopists 
There are three practising nurse colposcopists and one treating colposcopist in New 
Zealand. Plans are in place for nurse colposcopists to practise in the community, rather 
than only in the DHB colposcopy clinics; this approach will allow access by women who 
have difficulty attending DHB clinics. 
 
Results from this approach will help to decide if training more nurse colposcopists will 
help to address the challenging issues for the NCSP in some ethnic communities in 
New Zealand. 
 
National colposcopy meetings 
National colposcopy meetings have been re-convened since the last Parliamentary 
Review in 2011 in order to improve the networking of DHBs and information sharing. 
The NCSP held national colposcopy meetings in June 2012 and November 2014. 
 
In addition, the Australian Society for Colposcopy and Cervical Pathology (ASCCP) held 
its Annual Scientific Meeting in 2013 in Wellington, and an ASCCP course in 2014 in 
Auckland. These educational meetings provide a professional update on all aspects of 
cervical screening and management of screened abnormalities. 
 
Follow-up after high-grade cytology 
Compared with other ethnic groups, there is a higher proportion of women from the 
Pacific community (16.3%), followed by women from the Māori population (8.8%), for 
whom there is no evidence that they received follow-up tests after a high-grade cytology 
report. Table 10.2 shows the number of women who did not receive any follow-up within 
90 days and within 180 days of a high-grade cytology report, by ethnicity. 
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Table 10.2: Women without any follow-up test within 180 days of a high-grade cytology 
report, by ethnicity 
Ethnicity High-grade cytology Without follow-up by 90 days Without follow-up by 180 days 
n n % n % 
Māori 400 59 14.8 35 8.8 
Pacific 123 30 24.4 20 16.3 
Asian 174 16 9.2 11 6.3 
European/Other 1,793 175 9.8 101 5.6 
Total 2,490 280 11.2 167 6.7 
Source: NCSP Monitoring Report Number 40 (NSU 2014b) 
 
Colposcopy data 
Currently, colposcopy data is sent to the NCSP-R (*see page 112) by various 
modalities: by completing paper forms, electronically and, since late 2014, by e-
colposcopy. 
 
Colposcopy indicators are an important quality measure of the NCSP, and reporting on 
them should not be unduly delayed. The 2011 Parliamentary Review into the NCSP 
identified an urgent need to ensure colposcopy data in the NCSP-R was complete and 
to include colposcopy indicators in the monitoring reports (Tan et al 2011). It is 
anticipated that completeness of colposcopy data on the NCSP-R will continue to 
improve over time. 
 
Colposcopy data has been recorded on the NCSP-R for a short time relative to cytology 
and histology data. It is possible that reporting of colposcopy data to the NCSP-R is 
incomplete and therefore results for these indicators may need to be interpreted with 
some caution (NSU 2014b). Electronic reporting from DHBs would reduce the likelihood 
of incomplete reporting in the future. Colposcopy data from the private sector will need 
to be monitored to ensure these colposcopists are complying with the Health Act 1956. 
The NCSP has a responsibility to assist the private sector colposcopists in this process, 
and to provide feedback of clinical indicators to them rather than just to the DHBs. The 
issue of completeness of colposcopy data is a high priority for the NCSP to address. 
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* The National Cervical Screening Programme-Register (NCSP-R) is the national 
repository for information relating to cervical screening events and is a key 
component of the National Cervical Screening Programme. The purpose of the 
Register is to support the NCSP to reduce the incidence of and mortality rate 
from cervical cancer, and to enable access to information by those operating or 
evaluating the programme. The requirements and functions of the Register are 
prescribed in Part 4A of the Health Act 1956. Under this legislation, every result 
that is reported to the NCSP from a screening test, or from a diagnostic test, 
must be recorded on the NCSP-R, if that result relates to a woman who is 
enrolled in the NCSP. This information is stored securely by the Register in 
Wellington and can be accessed only by those authorised to do so. Information 
can only be provided outside the programme to health practitioners and/or 
evaluators or a review committee appointed by the Minister of Health to 
evaluate the programme. The NCSP-R is operated by New Zealand Post, with 
some Register duties carried out by DHBs. 
 
Almost all the DHBs now utilise colposcopy software in their colposcopy clinics. By the 
end of 2015, it is planned that all DHBs will be utilising the Gynaecology Plus 
colposcopy software (proprietor Solutions Plus). The need to collect important data 
means that there are more mandatory fields that the colposcopist must input. There is a 
need to ensure this task is not too onerous to distract from clinical activities. There 
should be periodic reviews of what mandatory data is necessary to ensure 
colposcopists are meeting the NCSP standards. 
 




The electronic transfer of colposcopy data to the NCSP-Register is known as e-
colposcopy. Colposcopy software is used by DHBs colposcopy clinics. The key 
stakeholders behind electronic reporting are the NCSP, DHB colposcopy clinics, 
NCSP-R, SolutionsPlus, clinicians and IT departments. 
 
Conversion to e-colposcopy commenced in July 2014, but it has involved delays as a 
result of problems encountered with software and linkage from DHBs to the NCSP-R. 
These problems are being overcome with support from the NCSP team, and with 
governance and reporting through the Screening Information Governance Group. In 
March 2015 the NCSP undertook a re-scoping project to ensure the e-colposcopy 
project had the appropriate level of senior oversight within the Ministry of Health and 
linkages back to the Information Group within the Ministry. 
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Two DHB clinics were using e-colposcopy by March 2015. The NCSP team, together 
with its stakeholders, will work through the challenges and will support users in DHB 
colposcopy clinics as they familiarise themselves with the smooth operation of the 
software. The goal will be to ensure all 20 DHBs are using e-colposcopy in the near 
future. The importance of e-colposcopy is also discussed in Chapter 8: NCSP-Register. 
 
C-QuIP 
Since December 2012, medical practitioners and nurses wanting to practise colposcopy 
in New Zealand must have obtained C-QuIP certification (under the auspices of 
RANZCOG) as a practising colposcopist (or be working towards this certification). 
 





Diagnostic colposcopists are required to undertake 75 colposcopies in each three-year 
period, from commencement of audit, in women who have not been treated in the last 
12 months. The practitioner is required to provide evidence of a minimum number of 
colposcopies annually, with 25 being the minimum level required to maintain skill to a 
satisfactory standard. Audit for this standard is mandatory. 
 
Therapeutic colposcopists 
Therapeutic colposcopists are required to lodge all treatments with histology in each 
three-year period from commencement of audit. The practitioner should aim to have 
histological evidence of high-grade changes (punch biopsy and/or loop specimen) in 
80% of cases. Audit for this standard is mandatory. 
 
NCSP Policies and Standards 
In addition to the C-QuIP standards, colposcopists in New Zealand need to meet more 
stringent criteria and colposcopy indicators outlined in the NCSP Policies and Standards 
(see Appendix I). 
 
Under the NCSP Policies and Standards, colposcopists need to: 
 maintain a minimum of 50 new cases per annum in New Zealand (the ideal number 
is 100 per annum), or a minimum of 150 cases over a three-year period (note: this 
total differs from the minimum C-QuIP volumes required for certification, and has 
been discussed with RANZCOG; case volumes can be a combination of cases from 
different practices (eg, combined DHB and private) but evidence is required for each 
practice) 
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 maintain a minimum number of 10 treatments per year, as per C-QulP guidance (or 
30 treatments in each three-year period) 
 Maintain certification and demonstrate participation in the C-QulP Professional 
Development Programme (recertification and audit) as per the C-QulP website 
(www.cquip.edu.au). 
 
It was determined that New Zealand maintains a higher number of cases and that 
colposcopy audits by International Accreditation New Zealand did request and include 
cases from both DHB and private practice. 
 
The last RANZCOG C-QuIP accreditation cycle has been extended until the end of 
2015 for New Zealand colposcopists seeking re-accreditation. The first accreditation 
cycle involved collecting numbers of colposcopy and treatment performed over three 
years from 2012. It is important that the next accreditation cycle after 2015 involves 
more than documenting the number of procedures. Colposcopy indicators already 
collected in the NCSP-R colposcopy data should be included in the next C-QuIP 
accreditation cycle. The NCSP will need to discuss the accreditation process with 
RANZCOG. 
 
Data collection for promoting best practice in colposcopy 
Purpose 
It is important to analyse and report on complete data sets from colposcopy services to 
promote best practice, emphasising safety and quality. 
 
Quality improvement 
Data held on the NCSP-R that has been received from colposcopy services is analysed 
to support practitioners with quality improvement. For example, analyses may include: 
 correlation for high-grade lesions (CIN2 or worse) between colposcopy findings and 
histology results (in order to calculate the positive predictive value of colposcopy for 
high-grade abnormalities) 
 the proportion of biopsies suitable for histological interpretation 
 the number of residual high-grade abnormalities, 12 months after treatment 
 the reason no biopsy was taken, when a woman with a high-grade abnormal smear 
has been referred 
 the outcome for women who had a high-grade abnormal smear but no biopsy taken. 
 
Feedback from the DHBs’ colposcopy clinics suggests that most of the colposcopists do 
not have difficulties achieving the number of colposcopy required each year by the 
NCSP. Most of the clinics now have colposcopy software that allows them to generate 
the above analyses. However, it is not routine for these analyses to be generated for 
individual colposcopists annually. Feedback on the quality of colposcopy performance is 
not provided to colposcopists by the NCSP either. Feedback on colposcopy 
performance annually is important to assist the colposcopists in maintaining their skills. 
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It is vital for the private colposcopists as most do not have colposcopy software in their 
practice to generate these analyses. They submit their colposcopy data to the NCSP-R 
by paper format; the NCSP should take responsibility for providing them with the 
analyses of it. 
 
Colposcopy in population with an HPV vaccination programme 
As HPV infection decreases in a HPV-vaccinated population, the need for colposcopy 
will decrease and the number of high-grade abnormalities will also drop, as early 
observations in Australia show (Brotherton et al 2011). In addition, positive predictive 
value of colposcopy will drop as the prevalence of high-grade disease falls. 
 
Primary HPV screening is being introduced into countries with an HPV vaccination 
programme and New Zealand has started the process of evaluating the introduction of 
primary HPV screening. It is expected that, although the number of colposcopies is 
likely to increase in the initial change-over to HPV screening, it will drop by the second 
round of HPV screening as the incidence of high-grade disease will be substantially 
lower (Ronco et al 2014). The initial increase in the number of colposcopies will also be 
limited if the initial age of screening is moved to 25 years of age. 
 
Key issues 
 Electronic reporting from DHBs would reduce the likelihood of incomplete reporting of 
colposcopy to the NCSP-R. It is important to ensure e-colposcopy is functioning well 
in all DHB colposcopy clinics in the near future. 
 Colposcopy data submitted from the private sector will need to be monitored to 
ensure these colposcopists are complying with the Health Act 1956. 
 Medical practitioners and nurses wanting to practise colposcopy in New Zealand 
must have obtained C-QuIP certification. Colposcopy indicators already collected in 
the NCSP-R colposcopy data should be included in the next C-QuIP accreditation 
cycle. 
 It is important to analyse and report on complete data sets from colposcopy services 
to promote best practice, emphasising safety and quality. 
 National colposcopy meetings should take place on an annual basis to improve 
networking of DHBs and information sharing. 
 
Recommendations 
41. There is an urgent need to ensure that colposcopy data in the NCSP-R is 
complete. The NCSP can facilitate this process by making available e-colposcopy 
to all DHB colposcopy clinics. 
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42. The NCSP should ensure that colposcopy data submitted from the private sector 
fully complies with the Health Act 1956.52 
43. Data held on the NCSP-R that is received from colposcopy services should be 
analysed annually to support practitioners in their quality improvement.53 
44. The NCSP and the Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists will need to address the discrepancy between the C-QuIP and 
NCSP colposcopy standards. This recommendation is to ensure New Zealand 
colposcopists accredited by C-QuIP meet the same standards as those required 
by the NCSP. 
 
                                            
52
 See also recommendation 37 
53
 See also recommendation 34 
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Chapter 11: Human papillomavirus (HPV) and cervical 
cancer 
Overview 
Human papillomavirus (HPV) is one of the most common causes of sexually transmitted 
disease worldwide. HPV belongs to the Papovaviridae family of deoxyribonucleic acid 
(DNA) viruses, many of which are oncogenic or potentially oncogenic. HPV is a 
relatively small virus consisting of a 72-capsomere capsid, which contains the viral 
genome, a double-stranded DNA. 
 
Over 200 papillomavirus types have been described, around 100 of which infect 
humans and are, therefore, classified as HPV (Burd 2003). Types HPV 6 and HPV 11 
cause around 90% of the anogenital warts diagnosed and are not associated with 
cancer, but have been linked to 10% of low-grade squamous intraepithelial lesions 
(LSIL). They are considered as low-risk types. Fifteen subtypes (16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68, 73, 82).are recognised as potentially oncogenic and are 
considered as high-risk types. Types HPV 16 and HPV 18 are responsible for 
approximately 70% of cervical cancers worldwide (Muñoz et al 2003; Bosch et al 2008) 
(see Figure 11.1). Information about cervical cancer incidence and mortality can be 
found in Chapter 1: Introduction and methods. 
 
Figure 11.1: Cumulative percentages of cervical cancer cases attributable to the most 
frequent HPV genotypes 
 
Source: Muñoz et al (2003) 
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HPV-attributable disease in humans 
HPV is one of the most important infectious agents in cancer causation. With respect to 
cancer of the cervix, it is generally accepted that HPV is necessary for the development 
of cancer, and all cases of this type of cancer can be attributed to the infection (Parkin 
2006). However, although HPV infection is necessary, it is not sufficient alone to cause 
cervical cancer, and other factors may also play a part. For anal cancer, it has been 
estimated around 90% are positive for oncogenic HPV, as shown in Table 11.1, and 
approximate estimates suggest that prevalence of HPV in cancers of the vulva, vagina 
and penis is around 40%. HPV also plays a role in a fraction of cancers of the oral 
cavity and pharynx. 
 

















Cervix 100 83,400 83,400 1.7 409,400 409,400 7.0 
Penis 40 5,200 2,100 0.04 21,100 8,400 0.14 
Vulva/vagina 40 18,300 7,300 0.2 21,700 8,700 0.2 
Anus 90 14,500 13,100 0.3 15,900 14,300 0.2 
Mouth 3 91,100 2,700 0.1 183,000 5,500 0.1 
Oro pharynx 12 24,400 2,900 0.1 27,700 3,300 0.1 
All sites  5,016,100 111,500 2.2 5,827,500 449,600 7.7 
Source: Parkin (2006) 
 
There is compelling evidence to suggest that cervical HPV infection is acquired as a 
result of sexual intercourse and that, for many women, infection occurs shortly after 
beginning their first sexual relationship (Collins et al 2002). Lifetime number of male 
partners is a major risk factor (Karlsson et al 1995). One study, using longitudinal data 
from 242 women who had had only one sexual partner, found that the risk of acquiring 
cervical HPV infection was 46% (95% confidence interval (CI) 28–64) at three years 
after intercourse. The median time from first intercourse to first detection of HPV was 
only three months (Collins et al 2002). 
 
The vast majority of HPV infections are transient, with only a small proportion becoming 
persistent (Karlsson et al 1995; Burk et al 1996; Strauss et al 2002). Among 
asymptomatic women in the general population, the prevalence of HPV infection ranges 
from 2% to 44%. The adjusted global prevalence, from a meta-analysis of 78 studies, 
was estimated to be 10.41% (95%CI 10.2–10.7), with considerable variation by region 
(Burchell et al 2006). Progression of HPV infection to invasive disease is rare (less than 
2% in most series). However, the data emphasises the importance of follow-up 
surveillance in treated patients (Burd 2003). 
 
The high-risk HPV types 16 and 18 are the most persistent types of HPV infection and 
can last many times longer than low-risk types, such as HPV 6 (Ho et al 1998; 
Woodman et al 2001; Richardson et al 2003, Muňoz et al 2004). 
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HPV and pathogenesis of cervical disease 
Cervical cancer is one of the best understood examples of how viral infection can lead 
to malignancy (Burd 2003). After the cervix is infected with HPV, infection may cause 
mild Pap cytology abnormalities and/or mild cervical intraepithelial neoplasia (CIN1) or 
LSIL. This usually clears spontaneously. 
 
It has become apparent that persistence of high-risk HPV (hrHPV) is a key factor in the 
progression to precancerous lesions (CIN2 or CIN3) or high-grade squamous 
intraepithelial lesions (HSIL). These lesions have a greater likelihood of progressing to 
invasive cancer (Solomon et al 2002; Burd 2003). The progressive development of 
cellular changes from HPV infection to cervical cancer generally takes 10 to 20 years, 
although, in very few cases, it may only take one to two years. CIN1 changes can arise 
within three months of infection, CIN2 within six months, and CIN3 within one to two 
years. 
 
An Australian study assessed the HPV genotype prevalence among a cohort of 1,676 
women who had been referred due to cytological abnormalities (Stevens et al 2009). 
Overall, 83.9% of women were HPV positive. Of those with histological diagnosis at the 
time of treatment (n = 899), HPV positivity increased significantly with disease severity. 
Results showed: 62.4% (normal), 77.6% (CIN1), 92.6% (CIN2) and 97.9% (≥ CIN3) 
(p < 0.006). The five most prevalent genotypes were HPV 16 (35.1%), 31 (12.6%), 
51 (11.1%), 52 (9.9%) and 18 (8.5%). Multiple HPV infections, including multiple hrHPV 
infections, declined significantly with age. 
 
A New Zealand study of 594 women with high-grade abnormal cytology and a valid 
HPV test showed that, of those recruited, 356 (60%) had confirmed CIN2/3 and 6 (1%) 
had confirmed adenocarcinoma-in-situ (AIS) or glandular dysplasia. Positivity rates for 
any oncogenic HPV infection and for HPV16 and/or 18 within confirmed CIN2/3-AIS 
were 95% (95%CI 92–97%) and 60% (95%CI 54–65%) respectively; in all women with 
ASC-H/HSIL+/AGC/AIS cytology it was 87% (95%CI 84–89%) and 53% (95%CI 
49–57%), respectively. The most common reported HPV types in women with CIN 2/3 
were 16 (51%), 52 (19%), 31 (17%), 33 (13%) and 18 (12%). A trend for higher rates of 
HPV 16/18 infection compared with other oncogenic types was observed in younger 
women (p = 0.0006) (Simonella et al 2013). 
 
Co-factors that increase the risk of progression to cervical cancer 
Persistent HPV infection is necessary, but insufficient alone, to cause cervical cancer 
(Bosch et al 2002). Other factors are associated with the development of cervical 
cancer following oncogenic HPV infection (Burd 2003; Baseman and Koutsky 2005) 
including: 
 environmental factors such as smoking 
 sexual exposure, for example, age at first intercourse or first marriage, parity, number 
of sexual partners 
 hormonal factors, such as long-term use of oral contraceptives 
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 immunosuppressive factors, such as human immunodeficiency virus (HIV) infection, 
or being a transplant recipient 
 long-term systemic use of steroids. 
 
Although these co-factors are well described, it is still not possible to predict who will 
develop cervical cancer. 
 
Guidance on appropriate HPV testing 
HPV testing is recommended for: 
1. women aged 30 years or older who have not had an abnormal cytology report in 
the previous five years following atypical squamous cells of unknown significance 
(ASC-US) or LSIL cytology 
2. management after treatment for HSIL – includes ‘historical testing’ for women on 
annual smears for previous high-grade lesions and with negative smears since, to 
assess whether they can return to routine three-yearly screening 
3. women where colposcopy has shown discordant results from cytology, to help 
interpret these results. 
 
According to NCSP Monitoring Report Number 40 (NSU 2014b), among women aged 
30 years or older with valid HPV triage test results, 26.2% of women with ASC-US 
results and 60.1% of women with LSIL results were positive for high-risk HPV. There is 
a need to determine whether there is any benefit in continuing HPV triage in women 
with LSIL results, if more than 60% of women with LSIL results are positive for HPV. 
 
Test accuracy 
A recent evidence review by the Australian Medical Services Advisory Committee 
(MSAC 2013) drew the following conclusions: 
 The HPV triage test is more sensitive than a single repeat cytology test for the 
detection of CIN2+ and CIN3+ lesions in women with possible LSIL and has similar 
specificity. 
 The HPV triage test is more sensitive than a single repeat cytology test for the 
detection of CIN2+ lesions (but not CIN3+) in women with LSIL and has lower 
specificity. 
 A significant proportion of additional CIN2+ lesions that would be detected by HPV 
triage of LSIL and possible LSIL are likely to regress when a strategy of repeat 
cytology is used. 
 The colposcopy rate following HPV triage is higher in women aged < 35 years than in 
women aged ≥ 35 years. 
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Specific monitoring of the other uses of HPV testing is not yet included. These other 
uses include: 
 management of women previously treated for CIN2/3 
 management of women with a high-grade squamous cytology result in the past, 
followed by negative cytology 
 resolution of discordant cytology, colposcopy and histology. 
 
In New Zealand, it was estimated that 3,126 (15.5%) HPV tests were for triage of low-
grade cytology in women aged 30 years or older; 2,247 (11.2%) were for post-treatment 
management for women treated in the past four years; 7,744 (38.5%) were for follow-up 
management of women with high-grade squamous cytology or histology more than 
three years previously (historical testing); and 1,090 (5.4%) were on samples collected 
at a colposcopy visit that did not fit into a previous category (possibly for resolution of 
discordant results). Another 5,904 (29.4%) HPV tests did not fit into any of the 
previously described categories (NSU 2014b). 
 
hrHPV testing policy 
hrHPV testing of liquid-based cytology (LBC) samples must be carried out using 
approved and validated processes and in accordance with manufacturer instructions. 
 
The test procedure must be endorsed by an internationally recognised accreditation 
agency, such as the United States Food and Drug Administration (FDA), or must be 
Conformité Européenne (CE) marked and/or internally clinically validated to meet at 
least the performance of internationally validated tests. The sensitivity of the test for the 
detection of CIN2 or worse in women aged 30 years or older must be at least 90%. The 
hrHPV test must test for a minimum of the 14 most common hrHPV subtypes. More 
detailed criteria are in the NCSP Policies and Standards – Section 5: Providing a 
laboratory service. 
 
Accreditation of HPV laboratories 
The NCSP has a memorandum of understanding with International Accreditation New 
Zealand (IANZ) for accrediting NCSP laboratory service providers. 
 
Seven laboratories currently provide combined cytology screening and HPV testing. 
NCSP policy and quality standards dictate that hrHPV testing is only permitted at a 
laboratory where gynaecological cytology is reported. 
 
IANZ accredits medical laboratories against ISO15189 and the NCSP audits against 
NCSP Policies and Standards – Section 5: Providing a laboratory service. 
 
Accreditation involves a site visit to each laboratory annually, which consists of an IANZ 
assessor and a National Screening Unit (NSU) representative (surveillance visit). Every 
four years there is a peer review assessment, which also includes both a scientist and a 
pathologist technical expert for each discipline. The annual round is January to December. 
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A laboratory section assessment takes place over the duration of one day, and the 
report is subsequently issued by IANZ, with input from the NSU representative. IANZ is 
also responsible for follow up of Corrective Action Requests (CAR) and Strong 
Recommendations (SR). The NCSP also undertakes follow-up as part of its contractual 
meetings with service providers. 
 
The assessments of each laboratory section can occur on the same day, or be spread 
across a week, so the NSU representative always attends the cytology section 
assessment. The relevant sections of the NCSP Policies and Standards are provided to 
the IANZ assessors (and peer reviewers if present) for the laboratory section that 
undertakes HPV testing. The outcome of the HPV laboratory section is fed back by 
IANZ to the NSU representative and any issues that arise against the NCSP Policies 
and Standards are discussed. 
 
From the 2014 round, four CAR/SR arose from two laboratories for HPV testing, which 
related to aliquoting and cross-contamination checks. 
 
The rate of HPV testing will vary between laboratories for a number of reasons. One 
reason is that laboratories differ in their general volume of work. Another reason may be 
differences in the population that laboratories serve, because HPV testing is performed 
in specific subgroups of women. For example ,HPV triage testing is performed in 
women with low-grade (ASC-US/LSIL) cytology results (but without recent 
abnormalities), therefore laboratories reporting higher rates of low-grade abnormalities 
may also have higher rates of triage testing. Conversely, laboratories reporting on a 
larger proportion of cytology from colposcopy clinics may be less likely to perform HPV 
triage testing, because women attending colposcopy have generally had a recent 
abnormality. These issues may, for example, partly explain differences in rates between 
Canterbury Health Laboratories (where rates of low-grade cytology results are 
comparatively high) and LabPLUS (where a larger proportion of cytology comes from 
colposcopy clinics) (NSU 2014b). 
 
HPV vaccination 
Most developed countries have now implemented an HPV vaccination programme for 
pre-adolescent girls. This development has been supported by a recent cost-
effectiveness analysis, which concluded that vaccination of girls is cost-effective in the 
vast majority of countries in the world (Jit et al 2014). In this analysis, vaccination of a 
cohort of 58 million 12-year-old girls, in 179 countries, prevented 690,000 cases of 
cervical cancer and 420,000 deaths during their lifetime. HPV vaccination was very 
cost-effective in 156 (87%) of the 179 countries. 
 
HPV immunisation was first implemented in New Zealand in 2008 and is currently 
available to females under the age of 20 years. The HPV vaccine does not offer 
complete protection against cervical cancer, as the vaccine does not include all 
genotypes of the virus, and not all women receive or respond to the vaccine. The 
current three-dose coverage level in girls aged 12–13 years in New Zealand is 48–56%. 
The coverage is higher among the Māori and Pacific populations. 
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Table 11.2 provides a comparison of HPV immunisation coverage at each eligible 
cohort since the start of the programme on 1 September 2008 through to 28 February 
2014, using the Census estimated population projection as denominator to assist in 
assessing the progress towards the targets for HPV immunisation. Girls have up to their 
20th birthday to commence the publicly funded programme. Girls born from 1991 to 
1993 will have now passed their 20th birthday and are no longer eligible for the funded 
HPV programme. 
 
Modelling results suggest that, in countries like New Zealand, the health sector would 
achieve the best value for money in reducing incidence of cervical cancer by further 
improving HPV vaccination coverage for girls, rather than adding in the vaccination of 
boys (Pearson et al 2014). Nevertheless, vaccination of boys could become cost-
effective, and could help reduce incidence of other cancers caused by HPV, if the 
vaccine was supplied at very low prices and administration costs were minimised. 
 
A strategy is needed to ensure every woman’s HPV vaccination status is captured as 
part of her screening history. This may be achieved through data linkage with the HPV 
Immunisation Register. This information can then be used to help assess the success of 
the Immunisation Programme in preventing cervical cancer. 
 
For discussion regarding linking the HPV Immunisation Register to the National Cervical 
Screening Programme-Register (NCSP-R), see Chapter 8: NCSP-Register. 
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Table 11.2: HPV immunisation coverage by ethnicity, vaccination and eligible birth 
cohort, 1991 to 2000 
 Immunisation coverage (%) 
HPV birth cohort 
(born during the year) 
Vaccination Māori Pacific Other* All 
2000 HPV-1 Quadrivalent 69 77 55 60 
HPV-2 Quadrivalent 66 76 53 58 
HPV-3 Quadrivalent 60 69 50 54 
1999 HPV-1 Quadrivalent 71 84 54 61 
HPV-2 Quadrivalent 69 83 53 59 
HPV-3 Quadrivalent 64 77 51 56 
1998 HPV-1 Quadrivalent 67 77 50 56 
HPV-2 Quadrivalent 65 76 49 55 
HPV-3 Quadrivalent 60 72 47 52 
1997 HPV-1 Quadrivalent 69 79 51 58 
HPV-2 Quadrivalent 67 77 50 56 
HPV-3 Quadrivalent 63 74 48 54 
1996 HPV-1 Quadrivalent 70 79 54 60 
HPV-2 Quadrivalent 68 77 53 58 
HPV-3 Quadrivalent 64 73 51 56 
1995 HPV-1 Quadrivalent 63 75 51 56 
HPV-2 Quadrivalent 60 73 50 54 
HPV-3 Quadrivalent 55 66 48 51 
1994 HPV-1 Quadrivalent 63 74 54 57 
HPV-2 Quadrivalent 59 71 52 55 
HPV-3 Quadrivalent 53 64 50 52 
1993 HPV-1 Quadrivalent 62 76 55 58 
HPV-2 Quadrivalent 57 72 53 56 
HPV-3 Quadrivalent 50 66 50 52 
1992 HPV-1 Quadrivalent 55 74 57 58 
HPV-2 Quadrivalent 50 69 55 55 
HPV-3 Quadrivalent 44 64 52 51 
1991 HPV-1 Quadrivalent 50 64 56 56 
HPV-2 Quadrivalent 45 57 54 52 
HPV-3 Quadrivalent 38 50 51 48 
Note: Estimated HPV eligible population includes females only and is based on the selected denominator. 
* Other includes all ethnicities except Māori or Pacific. 
Source: National Immunisation Register database 
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Currently in New Zealand, three doses of the vaccine are given, as shown in 
Table 11.2, although there is some drop-off in coverage after the first dose. This dosage 
is different to the United Kingdom, where since 2014 just two doses of the vaccine have 
been administered (Public Health England 2014). The United States FDA (2014) has 
also approved a human papillomavirus 9-valent vaccine, recombinant for the prevention 
of certain diseases caused by nine types of HPV. Covering nine HPV types, five more 
HPV types than Gardasil® (previously approved by the FDA), Gardasil®9 has the 
potential to prevent approximately 90% of cervical, vulvar, vaginal and anal cancers. 
 
Within the Ministry of Health, the NCSP needs to work closely with the Immunisation 
team, who are part of the Sector Capability and Implementation Business Unit, to 
enhance the benefit of the HPV Immunisation Programme in cervical cancer prevention. 
An ongoing dialogue between the NCSP and New Zealand Immunisation focused on 
ways of increasing vaccination coverage is important. 
 
Primary HPV screening 
When the Papanicolaou (Pap) test was first introduced in the 1940s, cervical cancer 
was the number one cause of death among women. Since the introduction of cervical 
screening programmes using the Pap test in the 1970s and 1980s, much has been 
achieved in reducing the incidence of and mortality from cervical cancer. Scientific 
understanding of the natural history of cancer of the cervix and its relationship with the 
human papillomavirus has led to even further improvements in the prevention of cervical 
cancer. Recent population interventions in developed countries with the introduction of 
HPV immunisation programmes for 12- and 13-year-old girls will, over the coming 
decades, see cervical cancer incidence and the prevalence of cervical high-grade 
abnormalities decline even further. Science is now telling us that there are different 
ways to prevent, test for and manage the precursors to cervical cancer. 
 
The following information provides some background context, as well as evidence from 
two recent international reports (USA and Australia) regarding the introduction of 
primary HPV screening for cervical cancer. The evidence for a transition to primary HPV 
screening is compelling. 
 
In September 2010, the External Review Group of the World Health Organization 
(WHO) met to decide on the update of Comprehensive Cervical Cancer Control: 
A guide to essential practice,. One of the major conclusions of the External Review 
Group was that the chapter on screening and treatment of precancerous lesions for 
cervical cancer prevention needed to be updated. In 2013, WHO released the updated 
WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical 
Cancer Prevention (WHO 2013). 
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The guidelines state that: 
“Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that may 
exist at any one of three stages: CIN1, CIN2, or CIN3. If left untreated, CIN2 
or CIN3 (collectively referred to as CIN2+) can progress to cervical cancer. 
Instead of screening and diagnosis by the standard sequence of cytology, 
colposcopy, biopsy, and histological confirmation of CIN, an alternative 
method is to use a ‘screen-and-treat’ approach in which the treatment 
decision is based on a screening test and treatment is provided soon or, 
ideally, immediately after a positive screening test. Available screening tests 
include a human papillomavirus (HPV) test, visual inspection with acetic acid 
(VIA), and cytology (Pap test). Available treatments include cryotherapy, 
large loop excision of the transformation zone (LEEP/LLETZ), and cold knife 
conization (CKC).” 
 
The document provides recommendations for strategies for a screen-and-treat 
programme, and it is intended primarily for policy makers, managers, programme 
officers, and other professionals in the health sector who have responsibility for 
choosing strategies for cervical cancer prevention. For countries that already have a 
cervical cancer prevention and control programme, the recommendations were 
developed to assist decision makers in determining which screening test or tests and 
treatment to provide (WHO 2013). 
 
A number of countries, including Australia and the Netherlands, are moving to modify 
their cervical screening programmes – or, as in the USA, to modify their cervical 
screening guidelines – to implement a primary HPV screening test. 
 
On 14 April 2014 the United States FDA approved the use of one HPV DNA test (cobas 
HPV test, Roche Molecular Systems, Inc.) as a first-line primary screening test for use 
alone for women aged 25 years or older. This test detects each of HPV types 16 and 18 
and gives pooled results for 12 additional high-risk HPV types. 
 
The new approval was based on long-term findings from ATHENA, a clinical trial that 
included more than 47,000 women. The results showed that the HPV test used in the 
study performed better than the Pap test in identifying women at risk of developing 
severe cervical cell abnormalities. 
 
The greater assurance against future cervical cancer risk with HPV screening has also 
been demonstrated by a cohort study of more than a million women(Gage et al 2014). 
This study found that, after three years, women who tested negative on the HPV test 
had an extremely low risk of developing cervical cancer − about half the already low risk 
of women who tested negative on the Pap test. 
 
First-line HPV screening has not yet been incorporated into the current professional 
cervical cancer screening guidelines. Professional societies are developing interim 
guidance documents, and some medical practices may incorporate primary HPV 
screening (National Cancer Institute 2014). 
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In Australia, after an extensive review of global evidence and modelling of a range of 
screening pathways that commenced in 2011, the Australian Health Ministers Advisory 
Council (AHMAC) endorsed in early 2014 the recommendation of the Medical Services 
Advisory Committee (MSAC) that a new ‘cervical screening test’ should replace the 
current Pap smear (AHMAC 2014). 
 
Cervical cancer is the 12th most common cancer affecting Australian women (excluding 
basal and squamous cell carcinoma of the skin). There were 682 new cases of cervical 
cancer diagnosed in 2010, and 152 women died from cervical cancer in 2011. This is 
equivalent to 9.6 new cases and 2.0 deaths per 100,000 women, respectively. 
Incidence of cervical cancer and mortality rates are much higher in Aboriginal and 
Torres Strait Islander women, with incidence at 22.3 cases and deaths at 10.6 per 
100,000 women in the period 2004 to 2008 (AIHW 2014a). 
 
Evaluating new cervical screening options in Australia 
The evidence assessment 
The MSAC evidence review provided a systematic review of available literature 
addressing the primary and secondary questions outlined in a Decision Analytic 
Protocol as follows. 
 
A modelled evaluation was undertaken of the effectiveness and cost-effectiveness of six 
different primary screening approaches, using different technologies or technology 
combinations, as described in the Decision Analytic Protocol, compared with the current 
screening pathway. The approaches evaluated were: 
1. conventional cytology with International Agency for Research on Cancer (IARC) 
age range and intervals 
2. manually read LBC with IARC age range and intervals 
3. automated image-read LBC with IARC age range and intervals 
4. HPV primary testing with cytology (LBC) triaging of all oncogenic HPV-positive 
women 
5. HPV primary testing with partial HPV genotyping (ie, differential identification and 
subsequent management of HPV 16/18 positive women [colposcopy] compared 
with women with other oncogenic HPV genotype infections [reflex LBC]) 
6. HPV primary testing with adjunctive co-testing with LBC (ie, performing both LBC 
and HPV testing at the primary screening stage and managing on the basis of both 
tests for all women). 
 
For each of these six potential primary screening approaches, the effects of a number of 
possible variants, based on differences in screening behaviour and compliance 
assumptions and accounting for the secondary evaluation questions, were also 
evaluated. These included: 
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(i) moving from the current reminder-based screening system in which reminders are 
sent to eligible women who have not attended for screening at the recommended 
interval, to a call-and-recall system in which invitations are sent before the 
re-screening due date (two different sets of attendance assumptions were used for 
future compliance in the context of longer intervals for reminder-based strategies 
and alternate assumptions were used for call-and-recall strategies) 
(ii) moving from an assumed ‘slower uptake’ scenario for screening initiation after age 
25 years (if the recommended age of starting was changed without issuing 
invitations to women on their 25th birthday) to a ‘faster uptake’ scenario which 
assumed women were sent invitations on their 25th birthday 
(iii) for LBC options, use of reflex HPV triage testing for low-grade cytology instead of 
management according to current National Health and Medical Research Council 
recommendations (which involve either cytology follow-up or immediate 
colposcopy depending on the age and screening history of the woman) 
(iv) for LBC options using HPV triage and for primary HPV screening options involving 
cytology triage, two different alternatives for managing triage-test-positive women 
thereafter (via either recommended 12-month follow-up or direct colposcopy 
referral) 
(v) introducing HPV ‘exit testing’ for women attending screening at age 64 years or 
older, to assess and manage the group of women at very low risk of subsequent 
disease with a view to potential discharge of this group from screening. 
 
In total, over 130 specific potential cervical screening strategies were evaluated and 
compared with current practice for cervical screening. 
 
The MSAC report found that cervical screening using a primary HPV test with partial 
HPV genotyping will detect HPV infections that are associated with abnormal cellular 
changes at risk of progressing to cervical cancer. Differential management of women 
who test positive for HPV genotypes 16, 18 ± 45 will allow more intensive management 
of HPV infections that are at a higher risk of progressing to cervical cancer. 
 
The screening interval 
In regard to the screening interval, the evidence review found longer screening intervals 
would be appropriate for HPV screening due to its high negative predictive value. In 
addition to the randomised controlled trial evidence (range of three- and five-yearly 
intervals), two cohort studies suggested screening intervals of up to five years may be 
appropriate (Katki et al 2011; Kitchener et al 2011). In their recent study, Ronco et al 
(2014) recommended extending screening intervals to at least five years for HPV 
screening to avoid over-diagnosis of regressive CIN. 
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Elfström et al (2014) analysed 13 years of follow-up from a randomised controlled trial 
on HPV screening in Sweden and found the longitudinal sensitivity of cytology for 
CIN2+ in the control arm at three years (85.9%, 95%CI 76.9–91.8%) was similar to the 
sensitivity of HPV screening in the intervention arm at five years (86.4%, 95%CI 
79.2–91.4%). They concluded that the increased sensitivity of screening for HPV 
reflects earlier detection rather than over-diagnosis, and the low long-term risk of CIN3+ 
among women who tested negative in HPV screening supports an HPV screening 
interval of five years. 
 
The evidence review found that increasing the interval for conventional cytology to three 
years did not result in any change in effectiveness in a pooled analysis by an IARC 
working group in 1986 and two recent modelling studies (Creighton et al 2010; 
Kulasingam et al 2011). 
 
Colposcopy referral rates 
The evidence review found that while HPV screening resulted in increased referral rates 
to colposcopy compared with conventional cytology, this increased referral rate is higher 
in women ≤ 35 years of age (HPV arm: 13.1% vs conventional cytology arm: 3.6%; 
relative risk 3.29, 95%CI 2.88–3.75) (Vesco et al 2011). The difference in referral rates 
among women > 35 years of age between conventional cytology and HPV screening 
was not as great (HPV arm: 5.8% vs conventional cytology arm: 2.5%; relative risk 2.37, 
95%CI 2.13–2.65) (Vesco et al 2011). Referral rates to colposcopy were expected to 
decrease as the size of the HPV-vaccinated cohort increases and subsequent treatment 
rates were not expected to increase. 
 
Similarly, the colposcopy referral rate was higher among women younger than 35 years 
of age compared with older women when HPV screening was used to triage women 
with LSIL or possible LSIL from a primary LBC test (Dillner et al 2011; ALTS 2003a, 
2003b; Bjerre et al 2008) (HPV triage age < 35 years: 70.9%, 95%CI 63.6–77.3% 
versus HPV triage age > 35 years: 52.9%, 95%CI 45.5–60.2%). 
 
All scenarios lacked evidence for vaccinated populations. 
 
Cost-effectiveness 
 The MSAC modelled evaluation found a number of potential new screening 
strategies that were predicted to reduce cervical cancer incidence and mortality 
rates further than the current levels. These all involved replacing conventional 
cytology with newer technologies as the primary screening test. 
 Modelling of the HPV screening strategies predicted an 8% to 18% decrease in 
cervical cancer mortality and savings of $33.8 to $52.8 million to the health 
system. 
 Modelling projected that the volumes of cytology tests undertaken would fall 
from 2.4 million to 340,000 annually. 
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The University of New South Wales Cancer Modelling Group also undertook a 
sensitivity analysis for the primary HPV (with partial HPV genotyping) screening 
pathway to assess the threshold cost at which HPV screening would remain a cost 
saving: 
 For both unvaccinated and vaccinated cohorts, the preferred pathway remained a 
cost saving when compared with current practice for all likely levels of HPV test cost. 
 The overall costs decreased further as the test cost was reduced. 
 The cost-effectiveness ratio of the preferred pathway did not exceed $30,000 per Life 
Year Saved until the HPV test cost was well above likely levels. 
 
The modelled evaluation found that, compared with current practice, primary HPV 
screening with partial HPV genotyping reduced cervical cancer incidence by 18% 
(95%CI 13–21%) and cervical cancer mortality by 18% (95%CI 14–21%) in an 
unvaccinated population. Of all the strategies modelled, partial HPV genotyping resulted 
in the greatest reductions in incidence and mortality. 
 
Primary HPV strategies with partial HPV genotyping resulted in cost savings compared 
with current practice, ranging from $33.8 to $52.8 million, and from $41.7 to 
$58.5 million, in unvaccinated and vaccinated populations respectively. It is assumed 
these savings are inclusive of general practitioner (GP) and specialist visits as well as 
the costs of HPV partial genotyping and LBC triage. To provide some perspective, in 
2012–13 an estimated $89.3 million was spent in Australia on cervical screening 
pathology tests alone, excluding the costs of GP and specialist visits (AIHW 2015). 
 
MSAC supported reflex LBC testing to triage women with positive HPV test results. In 
supporting reflex LBC testing, MSAC noted that, for women with HPV genotypes other 
than 16/18 (or possibly 45), the results of LBC would determine the need for referral for 
colposcopy. For individuals with HPV16/18 (or possibly 45), referral for colposcopy is 
required, and must be accompanied by LBC results. MSAC did not support HPV and 
LBC co-testing. 
 
New Zealand is currently undertaking some modelling work with the University of New 
South Wales in relation to primary HPV screening for women aged 25–69 years. 
Results should be available in late 2015. 
 
Under-screened strategy 
There was strong evidence that self-collected HPV tests for under-screened or never-
screened women would be feasible and effective for supplementing an organised 
screening programme that uses clinician-collected samples and examination of the 
cervix. Facilitation by or on behalf of a medical practitioner who also offers mainstream 
testing is important to provide appropriate counselling and interpretation, a safe 
environment for collection, timely sending of samples to a pathology laboratory and 
follow-up when required. Women who test positive for HPV would need to return to the 
clinician to obtain a new sample for LBC triage. 
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MSAC supported the self-collection of an HPV sample, for an under-screened or never-
screened woman, which has been facilitated by a medical or nurse practitioner (or on 
behalf of a medical practitioner) who also offers mainstream cervical screening. 
 
The information above has been obtained from the Australian Government Medical 
Services Advisory Committee’s Outcomes Report on Application No. 1276 – Renewal of 
the National Cervical Screening Program. Further detail on the MSAC 
recommendations may be found at: www.msac.gov.au. 
 
In summary, the following points outline the key recommendations for the ‘renewed’ 
cervical screening programme, which will commence in Australia from May 2017: 
 Five-yearly cervical screening should be conducted using an HPV test with partial 
HPV genotyping and reflex LBC triage, for HPV vaccinated and unvaccinated women 
aged 25–69 years, with exit testing of women aged 70–74 years. 
 Self-collection of an HPV sample, for an under-screened or never-screened woman, 
should be facilitated by a medical or nurse practitioner (or on behalf of a medical 
practitioner) who also offers mainstream cervical screening. 
 Invitations and reminders should be sent to women aged 25–69 years, and exit 
letters sent to women aged 70–74 years, to ensure the effectiveness of the 
programme. 
 An HPV test every five years is more effective than, and just as safe as, screening 
with a Pap test every two years. 
 An HPV test every five years can save more lives and women would need fewer tests 
than in the current two-yearly Pap test programme. 
 HPV-vaccinated women would still require cervical screening as the HPV vaccine 
does not protect against all the types of HPV that cause cervical cancer. 
 The recommendation to commence cervical screening at 25 years of age is based on 
evidence that shows: 
– cervical cancer in young women is rare 
– screening women younger than 25 years of age has not changed the number of 
cases of cervical cancer or deaths from cervical cancer in this age group 
– commencing screening at 25 years of age would prevent investigation and over-
treatment of common cervical abnormalities in young women that usually resolve 
spontaneously 
– HPV vaccination has already been shown to reduce cervical abnormalities among 
women younger than 25 years and will continue to reduce the risk of cervical 
abnormalities in this age group. 
 
Over the next two years, until the ‘renewed’ screening programme is implemented in 
Australia, the Steering Committee for the Renewal Implementation Project will be 
overseeing the development of the revised screening pathways and programme 
redesign. This will include the establishment of a new Cervical Screening Register, 
which will issue invitations and reminders to all eligible women in the target age group, 
as well as receiving screening test results, HPV immunisation status and colposcopy 
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reports (± histology). Negotiations are also underway for the approval of the HPV test/s 
with partial genotyping that will ensure the sensitivity and specificity required for the 
programme to achieve the predicted improvements in cervical cancer prevention. 
 
With many countries moving to modify their cervical screening programmes, New 
Zealand with the advantage of having transitioned to liquid based cytology, is also in a 
position to consider primary HPV screening in combination with its existing HPV 
Immunisation Programme. The following are potential benefits to New Zealand women: 
 The screening interval is longer without any loss of benefit. The low long-term risk of 
CIN3+ among women who tested negative in HPV screening supports an HPV 
screening interval of five years compared with the current three years. 
 Commencement of screening from 25 years of age, rather than from 21 years as 
under the current system, will realise benefits for the health system as a whole, as 
well as for young women, who could be considered to be ‘over-treated’ in the current 
regime, with resultant morbidity effects such as incompetent cervices. 
 Women gain psychosocial benefits with this new screening paradigm. 
 International evidence suggests a primary HPV screening protocol is more cost-
effective and can realise savings for the NCSP relative to the current regime. 
 
Key issues 
 The current three-dose coverage level in girls aged 12–13 years in New Zealand is 
48–56%. The coverage is higher among the Māori and Pacific population. Efforts are 
needed to increase this coverage to levels achieved in countries like Australia and 
the United Kingdom. 
As part of New Zealand’s progress towards assessing the feasibility of implementing 
a new screening regime, it will be vital to have strong collaboration, communication, 
partnerships and change management processes with stakeholders from across 
government departments (including immunisation stakeholders), screening providers, 
District Health Board representatives, laboratories, colposcopists and consumers to 
enable the successful development and implementation of a revised screening 
programme. A key partner in the development of the best model of care for the New 
Zealand Cervical Screening Programme should be the National Health Committee. 
 Linkage with the National Immunisation Register and/or the ability to accurately 
record women’s HPV vaccination status with the screening history are essential for 
the New Zealand Government to be able to determine whether HPV immunisation is 
achieving its objectives, and to monitor the effectiveness and cost-effectiveness of 
the HPV Immunisation Programme. 
– According to NCSP Monitoring Report Number 40 (NSU 2014b), among women 
aged 30 years or older with valid HPV triage test results, the proportion who were 
positive for high-risk HPV was 26.4% for women with ASC-US results, and 60.1% 
for women with LSIL results. There is a need to see if there is any benefit in 
continuing HPV triage in women with LSIL results, if more than 60% of women 
with LSIL results are positive for HPV. 
  Report of the Parliamentary Review Committee 133 
 regarding the New Zealand Cervical Screening Programme 
– There were 5,904 (29.4%) HPV tests that did not fit into any of the described 
categories (NSU 2014b), situations that warrant HPV testing. Appropriate use of 
HPV tests need to be monitored to educate clinicians. 
– There is strong evidence that self-collected HPV tests for under-screened or 
never-screened women would be feasible and effective for supplementing an 
organised screening programme that uses clinician-collected samples and 
examination of the cervix. 
 
HPV summary 
The New Zealand Government needs to be confident that the New Zealand Cervical 
Screening Programme is delivering maximum benefit for New Zealand women in 
reducing morbidity and mortality attributable to cervical cancer. It needs to be confident 
that the programme design and delivery are comparable with international best practice, 
and are effective, cost-effective and efficient in achieving the programme’s objectives 
and in view of the Government’s investment in the initiative. 
 
Internationally, clinical evidence has shown convincingly that primary HPV testing can 
deliver greater gains in reducing morbidity and mortality from cervical cancer, and 
national screening programmes are transitioning to new testing regimes and follow-up 
protocols. New Zealand must give priority to reviewing the evidence and developing 
recommendations to transition to a primary HPV screening protocol that will deliver a 
more effective and efficient programme for the investment. 
 
The assessment and future recommendations must include a strategy for ensuring 
every woman’s HPV vaccination status is captured as part of her screening history. This 
may be achieved through data linkage with the HPV Immunisation Register, or through 
an alternative methodology for direct capture of the woman’s HPV vaccination status. 
 
Recommendations 
45. New Zealand must give priority to reviewing international evidence and developing 
a process for the introduction and implementation of a revised contemporary best-
practice screening programme that will realise further improvements in reducing 
morbidity and mortality attributable to cervical cancer and its precursors. Evidence 
shows that a screening protocol employing primary HPV screening with partial 
HPV genotyping will result in the greatest reductions in incidence and mortality 
from cervical cancer. 
46. It is recommended the Ministry of Health requests the engagement of the National 
Health Committee to support the National Screening Unit in developing the 
business plan and recommendations for the design and implementation of the new 
model of care for cervical screening in New Zealand. This process must be 
appropriately resourced and funded. 
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47. Within the existing programme, the benefits of HPV triage for LSIL cytology should 
be reviewed. 
48. Within current screening guidelines, the use of HPV tests by clinicians should be 
monitored. Feedback from this monitoring should be provided to non-compliant 
clinicians to improve practice. 
49. As per recommendations in Chapter 8: NCSP-Register, to enable monitoring and 
evaluation of the effectiveness and cost-effectiveness of the HPV Immunisation 
Programme, it is necessary to develop strategies to capture and record a woman’s 
HPV vaccination status with her screening history, or link data with the National 
Immunisation Register.54 
50. In reviewing evidence for a revised screening protocol, consideration should be 
given to screening options that would encourage participation by unscreened and 
under-screened women. Self-sampling has been identified as a strategy to reduce 
inequities and barriers for women at highest risk who are not screening, or not 
screening regularly. 
 
                                            
54
 See also recommendation 36. 
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Chapter 12: Future directions for the National Cervical 
Screening Programme 
Technology 
Molecular markers for cervical screening 
Human papillomavirus (HPV) testing is available based on a number of technologies. 
The technology for which most clinical evidence is available is Qiagen’s Hybrid 
Capture®. Research has shown that testing based on the Hybrid Capture® technology 
is capable of specifically detecting the most important carcinogenic HPV types: 16, 18 
and 45 (Thai et al 2009). 
 
Other HPV testing platforms include the COBAS 4800 technology (Roche Molecular 
Systems Inc, Pleasanton, California, USA) and the Abbott RealTime PCR (Abbot 
Molecular Inc, Des Plaines, Illinois, USA). 
 
The United States-based ATHENA trial of COBAS 4800 technology among HPV 
positive women has found that in women who had colposcopy, the COBAS HPV test 
was more sensitive than liquid-based cytology for detection of CIN3 or worse; 92.0% 
(95% CI 88.1–94.6) versus 53.3% (95% CI 47.4–59.1), a difference of 38.7% (95% CI 
31.9–45.5; p < 0.0001) (Castle et al 2011). The authors conclude that HPV testing with 
separate HPV16 and HPV18 detection could provide an alternative, more sensitive and 
efficient strategy for cervical cancer screening than methods based solely on cytology. 
 
The Abbott RealTime PCR high-risk HPV (hrHPV) test is also highly sensitive for 
detection of high-grade cervical disease and cancer. One study using this test to 
determine its clinical sensitivity showed that this test detected 97.2% of CIN3 specimens 
and 98.5% of cancer specimens (Tang et al 2009). 
 
One project, which the National Cervical Screening Programme (NCSP) has recently 
endorsed, is being undertaken in the Auckland region to align with testing technologies 
being used in Australia. Conducted in collaboration with the Victorian cytology service 
and the University of New South Wales, the study is evaluating whether testing for 
certain types of HPV is a more effective cervical cancer screening test than the Pap 
smear test. In Australia, this is known as the Compass study, a three-armed 
randomised controlled trial of image-read cytology screening versus primary HPV 
deoxyribonucleic acid (DNA) testing in Australian women aged 25–64 years (Canfell 
et al 2014). This project in Auckland has completed the recruitment of 500 participants 
(aged 25–64 years) who presented for routine cervical smears from local practices. The 
women were randomised to three study arms, two of which will use HPV screening as 
the primary screening test and either HPV 16/18 or dual stained cytology with p16/Ki67 
as management options. The next phase is qualitative focus group activity plus analysis 
of study data. The results will be pooled with Australian data as well as being analysed 
separately. 
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Few HPV tests are approved for clinical use and it is important that clinicians 
understand which test can be utilised, in what circumstances, with which specimens, 
and the meaning of the report issued. An overview of HPV tests is available in 
Appendix J (Cubie and Cuschieri 2013). 
 
Management of screened abnormalities 
Two adjunctive colposcopy technologies for examination of the uterine cervix were 
recently examined by the National Institute for Health and Care Excellence (NICE 
2012). The systems evaluated were DySIS (DySIS Medical) and the Niris Imaging 
System (Imalux Corporation). 
 
DySIS comprises a digital video colposcope and dynamic spectral imaging (DSI) 
technology that are used in combination with each other during clinical examination. 
This technology evaluates the blanching effect of applying acetic acid to the epithelium 
(acetowhitening). It produces a quantitative measurement of the rate, extent and 
duration of the acetowhitening. The dynamic map (DySISmap) produced can be 
overlaid on a colour image of the tissue to help the clinician determine the presence and 
grade of any lesion. 
 
The Niris Imaging System uses optical coherence tomography as an adjunct to a 
standard colposcope. It is a non-invasive device, designed to aid in the detection and 
diagnosis of early-stage disease. It is used for guidance of biopsy and surgery, and in 
post-treatment surveillance in various clinical applications, one of which is as an adjunct 
to colposcopy. It uses optical coherence tomography, with near-infrared light to produce 
real-time, high-resolution, cross-sectional imaging of tissue microstructure. 
 
The aim of the NICE evaluation was to determine whether using adjunctive colposcopy 
technologies such as these is cost-effective and whether the health outcomes and 
quality of life in women referred for colposcopy are improved, compared with the 
outcomes when using conventional colposcopy. 
 
Soutter et al (2009) found DySIS is more sensitive than colposcopy in detecting high-
grade lesions and can provide improved guidance for biopsy. A further study by 
Louwers et al (2011) found that the sensitivity of DSI colposcopy to identify women with 
high-grade (CIN2+) lesions was 79% (95%CI 70–88%) and the sensitivity of 
conventional colposcopy was 55% (95%CI 44–65%) (p = 0.0006, asymptotic McNemar 
test). When the DSI colour-coded map was combined with conventional colposcopy, the 
sensitivity was 88% (95%CI 82–95%). 
 
NICE concluded that the modelling of DySIS colposcopy showed that it is robustly cost-
effective (possibly even cost saving) compared with conventional colposcopy. However, 
no reliable estimates of the sensitivity and specificity of the Niris Imaging System for 
CIN 2+ were identified in the assessment, and a full economic analysis was therefore 
not possible. 
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NICE has also developed a Medtech Innovation Briefing on ZedScan as an adjunct to 
colposcopy in women with suspected cervical intraepithelial neoplasia (NICE 2015). 
ZedScan uses electrical impedance spectroscopy (EIS) to detect pre-cancerous and 
cancerous cells in the cervix of women who have suspected cervical intraepithelial 
neoplasia. It is a diagnostic tool intended as an adjunct to colposcopy in women who 
are referred for colposcopy by the National Health Service’s Cervical Screening 
Programme in the United Kingdom because of an abnormal cervical cytology result. A 
study by Tidy et al (2013) indicates EIS used as an adjunct to colposcopy improves 
colposcopic performance. The addition of EIS could lead to more appropriate patient 
management with lower intervention rates. The use of the ZedScan is not currently 
planned for any NICE guidance programme. 
 
Other adjunct technologies 
Spectroscopy is a non-invasive method in which light or electric current is used to study 
the biochemical composition as well as the metabolic and structural features of tissue. 
Components of the electromagnetic spectrum relevant to diagnostic spectroscopy 
include the ultraviolet A range (315–400 nm), the visible light range (400–700 nm) and 
the near infrared range (700–900 nm). When light strikes tissue, it will be absorbed with 
or without re-emission of the light or it is scattered by (sub)surface interactions (Parker 
2005). 
 
In 1999 Mitchell et al presented a review concluding that fluorescence spectroscopy 
performs better than colposcopy and other techniques, including cervicography, 
speculoscopy, cytology and HPV testing (Mitchell et al 1999). 
 
A comprehensive review by Louwers et al (2009) indicated some larger trials performed 
in the field of spectroscopy have demonstrated relatively high sensitivities in the 
diagnosis of squamous intraepithelial lesions. The authors believe that of all currently 
available objective-data-producing alternatives or adjuncts to colposcopy, spectroscopy 
has the potential to emerge as the technique of choice and that one day it might 
become incorporated into routine clinical practice. 
 
A summary of the various modalities of spectroscopy and their efficacy has been 
adapted from Louwers et al’s publication (Tan and Wrede 2011), as shown in 
Table 12.1. 
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Use of light to study the 
features of the tissue 
Sensitivity (%) Specificity (%) References 




Fluorescence and reflectance 
spectra from the cervix in vivo 
95 55–83 Ferris et al 2001 
DeSantis et al 2007 
LUMA Combination of fluorescence, 
white light back scattered 
spectroscopy and video imaging 
92 50 Huh et al 2004 






Soutter et al 2009 
Louwers et al 2011 
Trimodal Combination of fluorescence, 
diffuse reflectance and light 
scattering spectroscopy 
92** 71** Georgakoudi et al 
2002 
Impedance Impedance spectrum is measured 
through a contact probe that uses 
electrical current 
74 53 Abdul et al 2006 
Truscreen® A probe in contact with the cervix 
collects spectrometric data 
70 – Singer et al 2003 
Note: 
* DySIS + conventional colposcopy 
** Normal versus abnormal cervix 
Source: Adapted from Louwers et al (2011) 
 
Summary 
New technologies are being evaluated continuously, and the NCSP will need to keep 
abreast of these ongoing developments. 
 
Research 
The NCSP has an ethical obligation to ensure the National Cervical Screening 
Programme is meeting its aims and objectives. Research is an important discipline and 
screening programmes should be involved in ongoing research to support the quality 
improvement culture. Research and evaluation activities within the NCSP include: 
 cost-effectiveness and cost–benefit evaluations 
 feasibility studies 
 outcome studies and evaluations 
 programme evaluations. 
 
Areas outside the scope of the research strategy include auditing and monitoring, 
literature reviews and policy development based on scientific literature. However, the 
results from the six-monthly monitoring reports and annual reports do form the basis of 
evaluation and help to inform research endeavours. 
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The NCSP, as a centre of excellence, strives to meet international obligations by 
publishing work that has international relevance. The research needs of the existing 
programme are prioritised and outcome-based research that focuses on ensuring equity 
and informed consent is promoted. A fair and transparent process ensures researchers 
can access screening data. 
 
Research that is underway, or proposed, is reviewed on a quarterly basis by the NCSP. 
An internal clinical group prioritises research, accesses requests for data, identifies 
areas in which NCSP should publish and reviews the literature. The NCSP has a 
relationship with the Health Research Council in New Zealand, which also helps to 
inform funding decisions. In addition, annual meetings between the NCSP and the 
research community help to identify areas that would benefit from research. 
 
Current research on cervical screening and management of screened 
abnormalities in New Zealand 
One recently published study looked at type-specific oncogenic human papillomavirus 
infection in high-grade cervical disease in New Zealand (Simonella et al 2013). Women 
on the National Cervical Screening Programme-Register (NCSP-R), aged 20–69 years 
between August 2009 and February 2011 with a cytology record of ASC-
H/HSIL+/AGC/AIS, were invited to participate in the study. A total of 594 women were 
recruited; of these, 356 (60%) had confirmed CIN2/3 and 6 (1%) had confirmed AIS or 
glandular dysplasia. The most commonly reported HPV types in women with CIN 2/3 
were 16 (51%), 52 (19%), 31 (17%), 33 (13%) and 18 (12%). A trend for higher rates of 
HPV 16/18 infection compared with other oncogenic types was observed in younger 
women (p = 0.0006). The prevalence of HPV 16/18 in New Zealand was comparable 
with that observed in Australia and Europe. 
 
A further study, which is still in progress, is the PRINCess study. This is a prospective 
multicentre trial of conservative management of CIN2 among women who are under 
25 years of age (Simcock and Sykes 2014). The objective of this trial is to provide 
clinically relevant information on the practicality of conservative management of CIN2. 
The safety of observational conservative management will be evaluated and clinical and 
biological markers predictive of outcome will be identified. The trial is being undertaken 
in large colposcopy centres in New Zealand and Australia; patients are being monitored 
by the local centre, with data collated and analysed centrally at the University of Otago’s 
Department of Obstetrics and Gynaecology in Christchurch. 
 
Further, two projects have been commissioned by the New Zealand Ministry of Health 
that will inform future policy change to primary HPV screening. The work is being 
undertaken by an expert modelling team based at the University of New South Wales, 
who are part of a wider research group led by Associate Professor Karen Canfell. See 
‘Molecular markers for cervical screening’ above for more detail. 
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Screening 
Over the last 40 years, the implementation of organised cervical screening programmes 
using conventional Pap smear cytology screening has delivered significant reductions in 
the burden of cervical cancer across western countries. New Zealand has been one of 
the more successful countries in reducing the incidence of and mortality from cervical 
cancer. Between 1996 and 2012 cervical cancer incidence declined from 10.5 to 6.2 per 
100,000 for women of all ethnicities. Between 1998 and 2010 cervical cancer mortality 
declined from 3.2 to 1.7 per 100,000 women of all ethnicities (NSU 2014a). 
 
The New Zealand mortality rates from cervical cancer are lower than those in the United 
Kingdom (3 deaths per 100,000 women in 2010),and USA (approximately 2.4 deaths 
per 100,000 women in 2010). New Zealand and Australia have the lowest rates of 
cervical cancer incidence in the world (Cancer Research UK 2014). 
 
However, cervical cancer is a largely preventable disease, and it is the responsibility of 
governments and health experts to ensure that any screening programme is able to 
achieve maximum benefits, in accordance with contemporary evidence, for the 
population it serves. 
 
HPV vaccination and screening 
Much has been learned about the natural history of cervical cancer and its causative 
factors over recent years. This knowledge has led to the implementation of HPV 
immunisation programmes across most of the western world, as well as in many second 
and third world countries, over the last 10 years in efforts to prevent the development of 
cervical cancer from the main causative HPV strains. There is also high-level evidence 
of the benefits of different screening methodologies (including HPV primary screening) 
that will deliver even better outcomes than the current Pap-smear-based programmes. 
 
The World Health Organization (WHO), in its report Comprehensive Cervical Cancer 
Control: A guide to essential practice (WHO 2014), states that new technological 
developments offer the potential to tackle cervical cancer in a more comprehensive way 
and build a healthier future for girls and women. As HPV vaccination programmes target 
girls between the ages of 9 and 13, before they become sexually active, there is the 
opportunity to launch a life-course approach to cervical cancer prevention and control, 
starting from childhood and continuing through adulthood. 
 
Essential information for future screening directions will come from the ability to identify 
and record both vaccinated and unvaccinated women as they are screened. This 
information will enable appropriate monitoring, so it is possible to confirm whether the 
decreases in high-grade abnormalities continue as expected subsequent to the 
introduction of the HPV Immunisation Programme. 
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WHO states that it will monitor how many countries change their national screening 
guidelines based on the publication of the new (2014) WHO guidelines. It anticipates 
that in approximately five years after the publication of the 2014 recommendations, 
sufficient new evidence will be available to update these guidelines and potentially add 
new ones. 
 
Internationally, some countries have already moved to guidelines that recommend, or 
are in the planning stages for, the implementation of HPV primary screening. 
Commencement age and screening intervals vary across countries. The new 
Netherlands screening programme will have a commencement age of 30 years and 
screen women for hrHPV to the age of 60 years at five-yearly intervals (Meijer 2015). 
The Australian programme will change to become an invitation and recall process 
commencing at the age of 25 years, with exit between the ages of 70–74 years, and 
screening at five-yearly intervals. 
 
In a United States study of more than one million women (Gage et al 2014), the 
estimated cervical cancer risks among women who tested HPV-negative alone, 
Pap-negative alone and co-test-negative were compared with the risk estimates of 
Pap testing every three years and co-testing every five years. 
 
The researchers found that the risk of developing cervical cancer within three years 
following a negative HPV test result was about half of the already low risk following a 
negative Pap test. Cervical cancer risk within three years of a negative HPV test was 
similar to the risk of developing cancer within five years following a negative co-test. 
The researchers estimated that the following number of women would go on to develop 
cervical cancer after a negative test: 
 Pap-negative: 20 per 100,000 women over three years 
 HPV-negative: 11 per 100,000 women over three years 
 co-test-negative: 14 per 100,000 women over five years. 
 
Self-testing 
Some countries are also considering the benefits and merits of primary HPV self-
testing. The Australian Medical Services Advisory Committee report (MSAC 2014) 
found that the acceptability of a screening test for people having the test should be 
considered (issues such as convenience, ease of use, discomfort, embarrassment, cost 
and real and perceived risks) and that another important consideration should be equity 
of access to the test regardless of rurality, ethnicity, socio-economic status or 
disadvantage status. The report found strong evidence that self-collected HPV tests for 
under-screened or never-screened women would be feasible and effective for 
supplementing an organised screening programme that uses clinician-collected 
samples and examination of the cervix. The Netherlands is also implementing a self-
testing alternative for unscreened or under-screened women (Meijer 2015). 
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Although not specifically discussed or considered in any published documents to date, it 
is a subject of more general discussion and highly conceivable that the future directions 
for cervical screening could move towards a primary HPV self-test for all women. Those 
found to have a positive test would then be advised to attend their health care provider 
for a clinician-administered follow-up test. This pathway could realise benefits for both 
women and the health system. 
 
Urine testing 
One recent study combined the results of 14 clinical trials of urine testing and compared 
the results with those from the cervical HPV DNA test (Pathak et al 2014). Urine tests 
correctly identified 87 per cent of HPV positive samples and 94 per cent of negative 
samples. A New Scientist report on the research suggests that, as cervical HPV DNA 
testing is already known to be more sensitive than microscope-based methods, it may 
be that the urinary HPV test is as good as a cytology sample (Geddes 2014). However, 
there are no other studies at this time that might support this early research. 
 
Genetics 
In a paper in the WHO Bulletin, ‘Revisiting Wilson and Jungner in the genomic age: a 
review of screening criteria over the past 40 years’, authors Andermann et al (2008) 
note that governments are faced with the difficult task of managing the use of new 
genetic information and technologies while balancing the many different perspectives 
and needs of society. With the recent sequencing of the entire human genome, genetic 
screening is being proposed as a major vehicle for translating genetic and genomic 
advances into population health gains. However, what is technologically possible is 
creating pressure to introduce or expand screening programmes, often before adequate 
safeguards and regulatory frameworks are in place. Even beyond the field of genetics 
and genomics, there is a growing understanding that population-level policy decisions 
should be based both on high-quality evidence and on the values of the population, as 
well as contextual considerations. 
 
Management 
The screening pathway 
The NCSP is one of five nationally organised screening programmes in New Zealand, 
where all activities along the screening pathway are planned, coordinated, monitored 
and evaluated. The National Screening Unit (NSU) is the coordination centre 
responsible for managing the country’s national screening programmes, including the 
NCSP. The NCSP is responsible for delivering the programme. The vision of the NSU is 
for high-quality, equitable and accessible national screening programmes. Planning 
over the past five years has included a range of specifically focused strategies and 
actions to achieve this vision (NSU 2010). 
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The National Cervical Screening Programme Strategic Plan 2009–2014 identified a key 
management issue of the NCSP and, therefore, a remaining challenge for the National 
Screening Unit. Namely, the work ahead must focus on reducing the disproportionate 
number of Māori women developing and/or dying from cervical cancers (NCSP 2009). 
 
In the context of screening, equity requires that all people within the target population 
have a fair opportunity to participate in the programme. The NCSP identifies four groups 
in the target population as requiring equitable access to quality services: Māori, Pacific, 
Asian and European/Others. Screening providers have a responsibility to ensure that all 
barriers to screening are minimised for participants. 
 
Since its establishment, the NSU has demonstrated its management contributions to 
health outcomes for New Zealanders (NSU 2010) through a cervical screening focus for: 
 increasing the coverage of cancer screening programmes 
 implementing the new NCSP-R, which has centralised data entry, includes 
colposcopy reporting and provides online access for stakeholders 
 implementing the new NCSP Guidelines for Cervical Screening in New Zealand 
(NSU 2008), including HPV testing and liquid-based cytology technology 
 establishing quality and performance management systems 
 raising awareness of screening through a range of health promotion initiatives 
 implementing a number of workforce initiatives, including development of training for 
smear takers and cytology laboratories. 
 
In the United Kingdom and elsewhere in Europe, findings on and experiences of the 
lower socio-economic population groups are similar to those for the priority groups of 
the NCSP in New Zealand, in that awareness and uptake of health services has shown 
a range of harder-to-reach groups have unmet need relating to information, support and 
cancer services. There is evidence of inequalities at each stage of the patient pathway, 
from information provision through to palliative care. 
 
In the United Kingdom, appropriate and targeted service provision has been shown to 
be central to the reduction of cancer inequalities (Gordon-Dseagu 2006). It is, therefore, 
essential to provide information and support that effectively meet the needs of harder-
to-reach groups. 
 
Baker and Middleton (2003) found reduced uptake of cervical screening among lower 
socio-economic groups and those living in deprived areas in England from 1991 to 
1999. Target levels of 80% uptake were reached by a higher proportion of providers in 
wealthy areas than providers in deprived areas. 
 
A study in Belgium (Lorant et al 2002) found that women from lower socio-economic 
groups were less likely to have had a test for cervical cancer. Reasons for these 
differing uptake rates were felt to be related to: 
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 cost (financial and psychological) 
 beliefs (attitudes of both patients and physicians) 
 behaviours (support and information seeking). 
 
It is important that screening programmes are not exacerbating health inequalities by 
being less accessible to groups with poorer health status while at the same time 
depriving those groups of resources for other services that would improve their health. 
In practice, a service can be judged to be equitable when people are treated in as fair a 
manner as possible by ignoring irrelevant differences between them, but taking into 
account relevant differences (Cabell et al 1992). In New Zealand there is a diverse 
range of cultural groups, and cultural factors can be relevant differences. Thus a 
screening programme needs to operate from a cultural context that makes sense to 
participants (Te Manawa Hauora 1993). 
 
Māori and Pacific populations have poorer health outcomes for breast and cervical 
cancer. These outcomes result from both under-screening of the population and higher 
mortality statistics for these particular diseases within these populations. Inconsistent 
practice and variable access to some screening activities reduce the efficacy of national 
screening programmes. Finding ways to realise Māori and Pacific potential to help 
improve screening outcomes will be key in addressing these inequities (NSU 2010). 
 
Current and future challenges 
To maximise value for money and to ensure the maximum benefits from screening 
accrue to the populations served, the NSU must recognise there are expectations of an 
increasing range of patient-centric and tailored services and treatments, and that 
efficient and effective purchase and delivery of screening will be required. The 
contributions that are essential to achieving the maximum benefits from screening 
include: reducing cancer incidence, ensuring priority groups have access to the 
information they need and reducing cancer inequalities (NSU 2010). 
 
Leadership of screening 
The NSU Strategic Plan (NSU 2010) identifies that a whole-of-screening view is needed 
for the ongoing development of national screening. This would incorporate further 
infrastructure planning and workforce development, account for screening in the wider 
sector and population, and have strong clinical governance and leadership at a national 
level. To support an improved focus on clinical and cultural safety, quality and 
competent performance, there would also need to be a greater emphasis on cervical 
screening and health literacy where the onus is on health professionals to remove the 
barriers to priority groups participating in the programme. The whole-of-screening 
approach must recognise the complex processes involved along the screening pathway 
and integrate health literacy practices into strategic and operational planning, service 
delivery, and leadership and management. These efforts need to ensure priority groups 
are involved in planning and monitoring the (cervical) screening programme. 
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As set out in its Strategic Framework to address these challenges while working 
towards the NSU vision of high-quality, equitable and accessible national screening 
programmes, the NSU plans to focus its work over the next five years on the five 
strategic objectives shown in Table 12.2 (NSU 2014c). 
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NSU: New and future developments 
Recent years have also seen significant developments in cervical cancer prevention. 
The advent of the cervical cancer vaccine as a primary prevention strategy, as well as 
new technologies in cytology and high-risk human papillomavirus detection are 
changing the face of cervical screening by improving efficiency and effectiveness as 
well as our ability to categorise each woman’s risk. The programme will continue to 
refine existing services as well as to adapt to incorporate the benefits of newer 
technologies to improve cost-effectiveness and further reduce the burden of cervical 
cancer for New Zealand women (NSU 2009e). 
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Glossary of terms and abbreviations 
AHB Area Health Board 
AGC Atypical glandular cells 
AIS Adenocarcinoma-in-situ 
ASCCP Australian Society for Colposcopy and Cervical Pathology 
ASC-H Atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion 
ASC-US Atypical squamous cells of unknown significance 
Asian The definition of ‘Asian’ by Statistics New Zealand includes people with origins in the Asian 
continent, from Afghanistan in the west to Japan in the east, and from China in the north to 
Indonesia in the south. Asian New Zealanders largely comprise Chinese and Indians, who 
also have long histories of settlement in New Zealand. 
ASR Age-standardised rate 
BSA BreastScreen Aotearoa 
CAR Corrective Action Request 
Cervical Cancer 
Audit 
Cervical Cancer Audit Report: Screening of Women with Cervical Cancer, 2000–2002 was 
published, with 31 recommendations, in November 2004. 
CI Confidence interval 
CIN Cervical intraepithelial neoplasia 
CSI Cancer Screening Inquiry. The Ministerial Inquiry into the Under-reporting of Cervical 
Smear Abnormalities in the Gisborne Region (2000-01), known as the ‘Cervical Screening 
Inquiry’ (CSI), released its report containing 46 recommendations in 2001. 
C-QuIP Colposcopy Quality Improvement Program 
DALY disability-adjusted life year 
DHB District Health Board 
DNA Deoxyribonucleic acid 
DSI Dynamic spectral imaging 
e-colposcopy The electronic transfer of colposcopy data to the NCSP-Register 
EIS Electrical impedance spectroscopy 
FDA Food and Drug Administration 
GP general practitioner 
HDC Health and Disability Commissioner 
HGA High-grade cervical abnormalities 
HPCA Act Health Practitioners Competence Assurance Act 2003 
HPV Human papillomavirus 
hrHPV High-risk HPV 
HSIL High-grade squamous intraepithelial lesions 
HWNZ Health Workforce New Zealand 
IANZ International Accreditation New Zealand 
IARC International Agency for Research on Cancer 
Ibid (Latin, short for ibidem, meaning the same place) In a footnote or endnote, means the 
same source as the one cited in the preceding footnote or endnote. 
ISP Independent service provider 
IT Information technology 
LBC Liquid-based cytology 
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LGA Low-grade abnormalities 
LSIL Low-grade squamous intraepithelial lesions 
MMEG Māori Monitoring and Equity Group 
NCSP National Cervical Screening Programme. The national programme for cervical screening in 
the National Screening Unit 
NCSP Advisory 
Group 
An independent group of expert advisors to the National Cervical Screening Programme 
NCSP-R National Cervical Screening Programme-Register, or ‘NCSP-Register’. A database that 
holds details of all participants enrolled in the NCSP. It stores and maintains screening 
details and manages data about participants with abnormal screening tests 
NHB National Health Board. The national services, purchasing and strategic planning division of 
the Ministry of Health 
NHC National Health Committee 
NICE National Institute for Health and Care Excellence 
NKG National Kaitiaki Group 
NSU National Screening Unit. The national unit for all cancer screening programmes within the 
Ministry of Health 
NZHIS New Zealand Health Information Services 
NZPHS New Zealand Post Health Services 
OAG Office of the Auditor General. The first review was undertaken in October 2001 on progress 
to implement the CSI recommendations, and the report was released in February 2002. 
The second follow-up review on progress to implement Dr McGoogan’s recommendations, 
and the second report with 10 recommendations, were released in December 2003. 
OECD Organisation for Economic Co-operation and Development 
PDCA cycle Plan-Do-Check-Act cycle 
PHO Primary health organisation 
PRC Parliamentary Review Committee. The parliamentary or ministerial review committee 
established under Part 4A section 112O of the Health Act 1956 
RANZCOG Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
WHO World Health Organization 
 
 148 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Glossary of Māori words and sayings 
Hauora Māori 
providers 
Māori health (service) providers 
Kaimahi Health worker or helper 
Wahine Woman 
Whakapapa The recitation of genealogies or stories which create a base or foundation of meaning for 
people. 
whānau ora Family health and wellbeing. Also the name of the national Māori health strategy, Whānau 
Ora, led by the Associate Minister of Health from 2010 to 2014 to address health, social, 
cultural and economic disparities between Māori and non-Māori in New Zealand. It 
complements the Ministry of Health’s Māori Health Strategy, He Korowai Oranga, which 
also has whānau ora as its conceptual basis 
whānau ora 
collectives 
Groupings of whānau or family health and wellbeing service providers (usually a 
combination of Hauora Māori providers who also deliver a mix of social, educational, media, 
housing, justice services etc)  
 
  Report of the Parliamentary Review Committee 149 
 regarding the New Zealand Cervical Screening Programme 
Appendix A: Timeline of significant events for the 
National Screening Unit and the NCSP 
1988 The Cartwright Inquiry (Cervical Cancer Inquiry at National Women’s Hospital) recommends 
the National Cervical Screening Programme (NCSP) be established. Prior to this, there was 
only ad hoc cervical screening in New Zealand (Cartwright 1988). 
1988 The NCSP is established in 14 Area Health Boards (AHBs). The Department of Health 
provides guidance and support. 
1991 The National Cervical Screening Programme-Register (NCSP-R) is introduced into 14 AHBs. 
1993 The NCSP is divided between the Ministry of Health, Public Health Commission and the 
purchasing units of four Regional Health Authorities (RHAs). 
1994 The NCSP-R operates out of 14 AHBs, which input data. 
1996–1997 The NCSP-R is reconfigured to a national database, but operations remain in AHBs. 
1997 The NCSP (including the Register) is moved into the Health Funding Authority (HFA), which 
replaces the four RHAs. 
1998 NCSP national coordination role is transferred from HFA to Auckland, Public Health 
Directorate. 
1998 The NCSP-R team is located in Information Directorate in HFA. 
October 1999 The Gisborne Inquiry into Under-reporting of Cervical Smear Abnormalities in the Gisborne 
Region is established. 
July 2000 The National Screening Unit (NSU) is established in the Ministry of Health as a separate unit 
with a Clinical Director and a Group Manager. The Clinical Director reports to the Group 
Manager – at Tier 3. 
April 2001 The Gisborne Inquiry report is published (Duffy et al 2001). 
December 2001 Dr Euphemia McGoogan reports on progress in implementing the CSI recommendations and 
makes further recommendations on clinical improvements. She noted a serious risk of clinical 
exclusion from decisions and of clinical input being sidelined (McGoogan 2001). 
2002 The Office of Auditor General (OAG) reports on action undertaken to implement the Cervical 
Screening Inquiry’s 46 recommendations (OAG 2002). 
June 2003 Dr McGoogan produces a second report on progress in implementing the CSI 
recommendations and makes further recommendations (McGoogan 2003). 
2002 In an NSU structural review, the Clinical Director position is disestablished following the 
incumbent’s resignation. Under the restructure there are three Clinical Leaders, for breast and 
cervical screening and public health. The Clinical Leaders for breast and cervical screening 
report to the Group Manager. The public health leader reports to the Director of Public Health, 
with dotted line reporting to the Group Manager. 
2002 The new Health Bill is developed to address safety and effectiveness of the NCSP. This 
subsequently becomes the Health (National Cervical Screening Programme) Amendment Act 
2004. 
2002 Data input to the NCSP-R is reduced from 14 to 6 District Health Boards (DHBs). 
2002–2003 Further NSU structural changes are made. The QMAA (a separate quality group in the NSU) is 
disestablished and its quality functions are incorporated within NCSP and BreastScreen 
Aotearoa (BSA) teams. 
Dec 2003 The OAG publishes a second report, which includes a review of CSI and makes 126 other 
recommendations. 
July 2004 The Health (National Cervical Screening Programme) Amendment Act 2004: section 112C 
comes into force 1 July 2004. The rest of the Act comes into force 12 months later. 
November 2004 The Cervical Cancer Audit Report, on screening of women with cervical cancer from 2000 to 
2002, is published (Cervical Cancer Audit and University of Auckland 2004). 
July 2005 The Bethesda 2001 coding system is integrated into the NCSP-R. 
2006 Redevelopment of new NCSP-R begins. 
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May 2006 The Health and Disability Commissioner report reviews colposcopy services at Waitemata DHB 
(NSU 2006). 
2006 A review and audits of all DHB colposcopy services take place. 
2007 In further Ministry restructuring, the NSU moves to the Health and Disability National Services 
Directorate. 
2007–2008 A further NSU restructure aimed at “strengthening foundations” takes place. New screening 
initiatives (antenatal and newborn) are coordinated. A separate Quality and Equity team is re-
established in NSU. The NSU also reintegrates with the Ministry, but retains direct purchasing 
of services. 
July 2008 The NCSP-R is centralised in the Ministry of Health. A new Register Central team is formed. All 
data input is central, with 13 regional Register services. 
September 2008 The newly developed NCSP-R is implemented with the Guidelines for Cervical Screening in 
New Zealand (NSU 2008). 
2008–2009 A Ministerial review of the health system is undertaken, resulting in the Ministerial Review 
Group’s Report, also known as The Horn Report (Ministry of Health 2009). 
2009–2010 The Ministry of Health is restructured. A National Health Board (NHB) is established in the 
Ministry of Health. The NSU is under the National Services Purchasing of the NHB. Some NSU 
positions are affected. The Māori Advisor role is moved from the NSU to the Māori Health 
Directorate. 
2009 A further NSU restructure takes place following the appointment of a new Group Manager. As a 
result: 
 the ‘equity’ oversight becomes a Quality team function 
 clinical leadership drops to Tier 6 
 a Clinical Governance Group for the NSU is established 
 the Senior Leadership team becomes the Management team with fewer members. Clinical 
leaders are not included as clinical input is to be achieved prior to management meetings 
 additional performance management analysts are appointed to NCSP and BSA 
 some reporting lines change. 
September 2009 The NSU Strategy and Policy team, which provides advice on wider screening issues, is 
moved out of the NSU. 
March 2010 Ministry of Health restructuring occurs. 
July 2010 NCSP-R is outsourced to DATAM (a New Zealand Post subsidiary with approximately 28 staff). 
July 2010 The NCSP-R implements HL7 messaging, so that laboratory results go directly to the Register. 
February 2011 Further Ministry of Health restructuring is undertaken. The NHB and NSU are not directly 
affected. 
June 2011 The report of the Parliamentary Review Committee regarding the National Cervical Screening 
Programme is completed (Tan et al 2011). 
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Appendix B: Areas for review 
1.1 Coverage, participation, equity, access and disease burden 
 Coverage and participation by region, age, ethnicity and socio-economic status. 
 Adherence to screening guidelines. 
 Retention rates and loss to follow-up rates. 
 Trends in rates and processes related to these measures. 
 Work undertaken to improve these measures and impact of these activities. 
 Key facilitators and barriers to future improvements. 
 Work undertaken (or proposed) by the NSU or its providers to evaluate its 
activities in these areas. 
 
1.2 Quality and monitoring 
 Review Independent Monitoring Group reports and other documentations held 
by NSU or relevant groups in relation to quality across the programme. 
 Work undertaken (or proposed) by NSU or its providers to evaluate its activities 
in these areas. 
 New Zealand Cervical Cancer Audit. 
 
1.3 Organisational and structural issues 
 Structural (ie, National Cervical Screening Programme (NCSP) structure) and 
infrastructural issues that may impact on the quality of the NCSP and services it 
delivers. 
 Work undertaken (or proposed) by NSU or its providers to evaluate its activities 
in these areas. 
 Role and performance of NCSP Advisory Group. 
 
1.4 Workforce issues 
 Current and possible issues for the future. 
 NCSP planning and actions around current and future workforce issues. 
 
1.5 Ethnicity data – quality, completeness and use 
 Includes access to and use of Māori data. 
 What work has been done to assess the accuracy and completeness of 
ethnicity data and to bring about improvements in this data? 
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1.6 NCSP-Register 
 Integrity of data, integration with laboratories. 
 Processes for invitation, recall of those overdue for screening and follow-up of 
those with abnormal results. 
 Access to online screening histories. 
 Support to regional services and any possible issues. 
 Collection of colposcopy data and any possible issues. 
 
1.7 Colposcopy 
 Colposcopists (medical) – Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists’ Colposcopy Quality Improvement Program 
(C-QuIP). 
 Nurse colposcopists – accreditation and practice improvement. 
 
1.8 Human papillomavirus (HPV) vaccination 
 Impact of HPV immunisation on the NCSP. 
 Assess impact from the evaluation of the HPV Immunisation Programme on 
how well the programme has achieved its goals, objectives and implementation 
priorities. 
 
1.9 HPV screening 
 Guidance on using HPV screening by detecting high-risk type HPV. 





Adjunct technology to improve colposcopy performance. 
 Screening 
Using HPV screening as primary screening. 
 Management 
Outcomes on conservative management of screened abnormalities. 
 Research 
Future research to be undertaken. 
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Appendix C: Individuals, agencies and organisations 
contacted by the Parliamentary Review Committee 
National Cervical Screening Programme (NCSP) Senior Management team 
National Screening Unit Senior Management team 
NCSP team 
National Screening Advisory Committee 
Office of the Health and Disability Commissioner 
Register Central Team DATAM / New Zealand Post 
NCSP Advisory Group 
Māori Advisory Group 
Māori Monitoring and Equity Group 
Pacifica (Pacific Advisory Group) 
Women’s groups: 
 Women’s Health Action Group 
 Federation of Women’s Health Councils 
Other government groups 
 Health and Disability Commissioner Office 
Lead pathologist and lead scientists 
 Six laboratories reporting cytology and human papillomavirus (HPV) screening 
Regional service managers / coordinators 
Independent service providers 
Pacific providers 
Public health representatives/services 
Other groups 
 Cancer Control Council 
 Cancer Control Council (New South Wales – monitoring) 
 Cancer Society of New Zealand 
Research scientist, University of Otago 
District Health Board (DHB) lead colposcopists, nurses and managers 
Public health physicians 
Immunisation and HPV experts 
Mainstream primary health organisations 
Pacific primary health organisations 
Family Planning Association 
Extra interviews requested with: 
 Ministry of Health 
 University of Otago 
 Kaitiaki Group 
 Retired individuals 
 Waikato DHB 
 University of Auckland, Population Health, Māori and Pacific Department 
 National Health Committee 
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Appendix D: Semi-structured interview guide 




New Zealand Cervical Screening Programme 2015 
 
Introduction 
The National Cervical Screening Programme (NCSP) Review Committee is a ministerial 
review committee established under Part 4A section 112O of the Health Act 1956 (“the 
Act”). 
 
The NCSP Review Committee’s statutory functions are to review: 
 the operation of the NCSP 
 evaluation activities of the kind described in section 112T of the Act that have been 
carried out or are proposed to be carried out. 
 
The focus of the Review Committee is the continuous quality improvement of 
components of the NCSP, with a view to reducing the incidence and mortality rates of 
cervical cancer. 
 
The Review Committee members are: 
 Dr Jeffrey Tan (Chair) 
 Ms Linda Thompson 
 Ms Gail Ward. 
 
One way the Committee wishes to elicit feedback is by semi-structured interviews. This 
will involve a series of questions with emphasis on your expertise in the NCSP and that 
will be followed by an opportunity for you to offer your own comments, feedback and 
concerns. 
 
The Review Committee is most appreciative of the time that you have taken to be 
involved in this process. 
1. Can you tell us how you are involved in cervical cancer screening? 
(Please check all that apply – please number each in order of priority.) 
 Laboratory    Nurse Practitioner    Health Promotion  
 Public Health    Scientist    Screening Participant  
 Other (please specify)  
 Advisory Committee   Please specify Committee Name  
Physicians:  General Practice    OB/GYN    Colposcopy  
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2. What are the most important matters for the Review Committee to understand 
about cervical screening in New Zealand? 
 
3. What do you know about quality improvements that have been underway within 
the Screening Programme? 
 
4. What is your opinion as to the success of these efforts? 
 
5. At an overall level, do you believe that the Screening Programme is providing a 
valuable and high-quality service for New Zealand women? 
 Yes 
 No 
Please explain your reasons. 
 
6. In your opinion, what has been the biggest single challenge that the Screening 
Programme faces? 
 
7. In your opinion, what has been the most significant accomplishment of the 
Screening Programme? 
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8. In your opinion, what is the most important issue that the Screening Programme 
must address and resolve in the next three years? 
 
9. Please identify what, if any, other issues the Review Committee should be aware of. 
 
10. Is there any other information that you wish to share with the Review Committee 
for their consideration? 
 
 
Thank you so much for your time and contribution. 
 
If you later have anything else that you wish to share with the Review Committee, 
please feel free to notify us by contacting: 
Dr Jeffrey Tan 
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NATIONAL CERVICAL SCREENING PROGRAMME (NCSP) 2014/15 
REVIEW 
January 2015 
The National Cervical Screening Programme (NCSP) Review Committee is a ministerial 
review committee established under Part 4A section 112O of the Health Act 1956 (“the 
Act”). 
 
The NCSP Review Committee is an independent body appointed by the Minister of 
Health, whose statutory functions are to review: 
 the operation of the NCSP 
 evaluation activities of the kind described in section 112T of the Act that have been 
carried out or are proposed to be carried out. 
 
The focus of the Review Committee is the continuous quality improvement of 
components of the NCSP, with a view to reducing the incidence and mortality rates of 
cervical cancer. 
 
Dr Jeffrey Tan (Australia) has been appointed to chair the committee and the other 
members are Ms Linda Thompson (New Zealand) and Ms Gail Ward (Australia). 
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As key stakeholders in the Programme, we very much appreciate receiving your input 
regarding functions of and any issues relating to the NCSP. 
 
Within your area of expertise, we would like to hear your initial response regarding key 
issues that you think the Review Committee should consider. 
 










If possible, please submit details of the weaknesses or challenges as attachments. 
 
Please forward to: 
Dr Jeffrey Tan 
NCSP Review 
 
Further information if required 










This form will remain confidential to the Ministry of Health and the 2014 NCSP 
Parliamentary Review Committee. 
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Appendix F: Feedback 
Following are some views of participants external to the Ministry of Health, including the 
advisory groups of the National Screening Unit (NSU) and the National Cervical 
Screening Programme (NCSP); and staff members from the Ministry of Health. These 
views come through submissions and Parliamentary Review Committee interviews. 
 
Chapter 1: Introduction and methods 
“In the first instance we would like to comment on the structure of the 
feedback form. Its format of encouraging three comments only into issues, 
which have been considerably condensed in the accompanying NATIONAL 
CERVICAL SCREENING PROGRAMME (NCSP) 2014/15 REVIEW, Areas 
for review. It does not encourage comprehensive feedback, particularly from 
consumers, who may believe they are constrained to comment briefly and 
only on the issues described. Inclusion of the full review would have been 
more helpful as would an explanation of the roles of the NCSP and the NSU.” 
 
Chapter 3: Coverage, participation, equity and access 
“While we note recent research indicates improved rates of cervical 
screening amongst Māori and Pacific, there are still significant disparities in 
screening participation between Māori, Pacific and Asian women compared 
to the rest of the population. We believe there are still concerns about women 
being lost to follow-up and that responses to this need to be community 
specific. We also believe that not enough effort has been made to identify 
populations or communities, which have low screening participation rates 
such as new migrant or refugee communities or groups such as lesbian or 
transgender people or women with disabilities. We agree it is particularly 
important that the number of smear takers who are attuned to cultural 
sensitivities and the preferences of diverse groups of women are extremely 
important.” 
“Currently the funding for ‘free’ cervical screens to the DHBs [District Health 
Boards] is insufficient to cover the additional primary care work to reach 
unscreened or under-screened women. Whilst the volume of the screens has 
increased which is a positive move, the funding per screen has not. The 
DHBs’ fund to the PHOs [primary health organisations] per screen needs to 
be ‘topped up’ by the DHBs; this is putting pressure on financially constrained 
DHBs.” 
“The Ministry of Health should explore options for providing a fully funded 
screening programme for cervical cancer, as all other national screening 
programmes are. This would negate the issues of DHBs having to fund the 
PHOs and would help reduce the disparities that exist in access for women.” 
 
 160 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Chapter 4: Monitoring and evaluation 
“The monitoring reports that are currently provided by the UNSW [University 
of New South Wales] Australia has caused concern particularly for Māori. It 
would be more useful to have a greater scrutiny on the inequalities, similar to 
the provision and the process used by the BSA [BreastScreen Aotearoa], for 
the BSA Māori Monitoring Report and including consultation on 
recommendations for addressing disparities. It is important for Māori to be 
part of the discussion and to be able, where possible, to take ownership of 
implementing solutions.” 
“The monitoring reports lack Māori input. It is important to create a picture so 
people understand what the issues are and to have more context. More 
anecdotal commentary rather than just an analysis of the data would be 
useful.” 
“I find the ‘Cervical Screening Guidelines’ and the associated documents 
‘NCSP Best Practice Guidance on HPV Testing’ and ‘Guidance on HPV 
Testing Update 1: April 2010’ poorly organised and not integrated, which 
makes them difficult to use. I consider them in need of review and updating.” 
 
Chapter 5: Quality assurance 
“We should be conducting clinical audits of women who do get invasive 
cervical cancer in New Zealand, not in the hugely expensive way that the last 
Audit was conducted around 2000, but more as a data-gathering rolling audit 
of cases as they occur. The numbers are small enough in New Zealand to do 
this. We would see a lot of the same lessons gleaned from audits overseas 
(unscreened, under-screened women) but there may be particular issues 
unique to New Zealand.” 
 
Chapter 6: Organisational and structural issues 
Equity issues 
“Overall it is obvious in the last three years things haven’t moved much. The 
rates for Māori and Pacific (priority) groups have not made significant 
change. Participation numbers show complacency (regarding low rates 
demonstrated in DHB figures). 
“This may show that they’ve lost momentum, leadership, or need a push.” 
“There needs to be a halt on continuing to do the same thing if it has not 
made any difference over the last five years. Many of the public health units 
(within DHBs and PHOs) who have accountability over this area are not 
doing anything to excite the interests of the priority (women’s) communities”. 
“Māori health units and public health need to work together – take the lead 
from other successful programmes such as Suicide Prevention and have 
better engagement of Māori community organisations (eg, the iwi).” 
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“Very disappointing that the TV adverts are no longer being broadcast, these 
were impressive and had a great deal of impact.” 
“Education is important. The TV adverts were a great way of addressing this 
as they highlighted that it isn’t just the woman herself who matters but the 
whole whānau (whānau ora strategies are needed).” 
“Apart from difficulties in accessing services, the other issue is that the 
priority women do not consider cervical screening a priority in their lives.” 
 
Risks to the screening programme 
“Māori and Pacific are not able to access the programme at the same rates 
as other ethnicities – this is a risk.” 
“Introduction of HPV [human papillomavirus] – there is a risk of public 
confusion if timing and messaging are not well coordinated and aligned with 
excellent social marketing strategies for instance.” 
“High turnover of staff in the NSU leads to loss of continuity and experience 
within the team.” 
“There has been a loss of identity, networking opportunities with the 
cessation of regular face to face NCSP Programme Managers meetings. 
Teleconferences just do not do it. National meetings were not an issue if 
given at least 6–12 months’ advanced notice.” 
“Within the NCSP there has been a high turnover of staff and this has 
created difficulties, communications is not very good with regional sites and 
ISPs [independent service providers] especially for kaimahi. There are 
regular steering meetings but this is for the high level managers only.” 
 
Successes at regional level with ISPs and DHBs 
“Good communication and encouraging women as well as workers to 
‘continue on this journey and keep over-delivering’.” 
“Staff don’t give up, they keep looking for women who have moved. Fetch 
and find – talk to family members, ask where they are.” 
“Accountability of the DHBs – depends on good people. Where there are 
good people, there are good service delivery models.” 
 
Clinical leadership 
“Renewed or more effective clinical leadership is essential to drive 
appropriate changes in the NCSP and to ensure the programme remains in 
line with current evidence.” 
“Most importantly the new Clinical Leader needs to drive a significant change 
with Primary HPV screening – this includes the relevant policy work, sector 
collaboration across the pathway including priority groups and consumers, 
communicating with smeartakers and women and working in a transparent 
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(and visible) way across the Ministry and relevant other departments 
(Imms/NIR [National Immunisation Register] (just getting the NIR permissions 
to be able to routinely update the NCSP register with accurate HPV 
vaccination data will require a significant amount of work), HPV vaccination 




“We believe that a more diverse range of consumer and women’s 
organisations must be afforded more opportunities to provide both feedback 
and guidance at all levels of policy development and service provision. 
Screening is an important and sometimes life saving activity. However, 
screening programmes must take into account emerging research, consumer 
concerns, and unintended negative effects as well as consider the important 
issues of confidentiality and informed consent.” 
“A one stop shop for BSA and NCSP would be useful. There are barriers to 
accessing services including difficulties with travel and financial difficulties.” 
 
Advisory group appraisal 
“The NCSP Advisory Group performs a vital role and functions relatively well, 
for the purposes of reviewing Monitoring Reports and providing a place for 
professionals to raise issues and receive feedback about developments in 
the NCSP. The committee largely operates as an Advisory Group ie, 
members provide advice about issues raised. It is not a powerhouse of 
clinical leadership.” 
“A Professional Board which has some relationship to the screening 
programme, where key people can provide leadership. We can raise things 
but it doesn’t go anywhere particularly.” 
 
Social marketing programmes 
“Having social marketing programmes that make women visible – is highly 
beneficial.” 
“Social media and web-based culture should be considered as a means to 
disseminate information.” 
“Health promotion and literacy is essential for quality assurance and data 
access. It is important that the results from programmes are easily accessible 
to consumers and understandable in layman terms. This is seen as 
improving engagement. If people trust programmes, they are more likely to 
be engaged.” 
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Chapter 7: Workforce issues 
Addressing disparities for NCSP priority groups, particularly Māori 
“Trying to work in a more integrated way with stakeholders such as PHOs is 
important and encouraging the use of the support to screening services 
contract so community workers can talk to women and health to overcome 
barriers.” 
“In order to engage Māori stakeholders, and put them (strategies) in the 
community, they seem to work when you have people in strategic places who 
can make it work for them/you: Cultural competence; How you talk to Māori 
community; Health literacy – How you break down complicated issues; 
Cultural understandings.” 
“There have been many staff leave the NSU which has resulted in a huge 
loss of knowledge, experience and the relationships that have been built of 
the years. There has been no Māori portfolio manager for many years and 
most recently 2013 the Pacific portfolio manager left and neither of these 
positions has been replaced.” 
“Important to maintain relationships with ISPs; provide timely information to 
all providers i.e. ensure data is continually updated and available; support 
and value the work that ISPs do to contribute to engaging Priority Women 
(PW) into the screening programme.” 
“They need to retain the ISP contracts as it is the ISPs who are the only ones 
who can reach the really hard Priority Women (PW) and engage them into 
screening. Other services are more restricted.” 
 
Pacific comments 
“Support more Pacific people coming into senior leadership roles, either 
within the Ministry or in positions; and those who are not Pacific who are in 
leadership roles, also are aware of the discrepancy in the Pacific population.” 
“Training around Pacific providers to take smears.” 
“You can set up strategies and policies, but unless you have the workforce to 
engage with the people/communities, it doesn’t make a difference.” 
“The Ministry of Health is now aware that the Pacific/Māori audience needs 
things done differently (equity focus) eg, interaction with key Pacific people.” 
“For Pacific, get everyone who was involved in any sort of screening, to make 
sure there was cultural competency delivery. Knowing how to best engage 
with Pacific.” 
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Impacts of primary HPV screening on the laboratory workforce 
“Cytology will probably drop by 85% – even if reflex cytology are done for 
HPV positive tests.” 
“Fearful of the cytology (workforce) group, not getting graduates taking 
cytology because they don’t see a career in it. The expertise will be ‘lost’.” 
“Cytology: This is a small (workforce) pool of key individuals who make a 
huge difference.” 
“Labs are going to close, and where will they be? If you close a whole lab, 
the best screeners will go.” 
 
Training 
“HPV online course is very slow, got to be designed for primary care to be 
able to do it in their own environment. Designed for their needs.” 
“We need updated information in primary care – it should be available online. 
Role of the clinical leader should be to address the education and facilities 
that are needed for staff. There’s no regulation, and if the practice nurse has 
to pay and do it in her own time, they won’t do it.” 
 
Chapter 8: NCSP-Register 
“There are long reporting delays on coverage rates which can lead to a loss 
of confidence and frustration for health professionals when working to 
increase coverage rates. This applies particularly to PHOs who now have 
cervical screening as a target in their Integrated Performance Incentive 
Framework, and are working with DHBs to use data-matched lists to target 
women for screening invitation and recall. The largest PHOs need these lists 
monthly.” 
“Data is not extracted from the NCSP-Register in a timely manner (currently 
only six-monthly), therefore ongoing monitoring is difficult to achieve.” 
“Smear takers cannot access the Register electronically, therefore limiting 
their ability to access current information on the woman’s screening history.” 
“The lack of a population register limits the effectiveness in targeting women 
who have never been screened or who are not enrolled in primary care. This 
may be up to 20–30% of women in high-risk groups.” 
“We are building a data warehouse at the moment, working with the IT Board 
to look at the cancer IT screening pathway for the future and how this looks. 
Modelling what this looks like in 2025 and working backwards from that.” 
“Dubious data quality and lack of response to data requests from DHBs. 
Ongoing issues with data collection/warehouse ... national data does not 
compare well with our local data.” 
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“There is a wealth of information on the NCSP-Register. It is a huge resource 
which we are not maximising. If new technologies and new techniques are to 
be introduced to New Zealand, relatively small nationally directed research 
projects would be highly useful to determine an appropriate role in the New 
Zealand context.” 
 
Chapter 9: Ethnicity data 
NSU and NCSP relationship with the National Kaitiaki Group 
“It is frustrating that we have to apply to use the data that we collect for the 
purposes that we are employed to do, as enabled by section 112 ... 
[section 112J(h) of the Health Act 1956].” 
“It has not been a good relationship ... we have tried to strengthen that 
relationship. It is getting better. We want to share the information in a way 
that is helpful and want to ensure that information is open and transparent.” 
 
Social marketing 
“... qualitative research (focus groups and individual interviews) will be 
planned to understand women’s motivations and barriers to participation in 
screening programmes.” 
“The only way women will be picked up if they have not been screened is by 
a community initiative. Some of the ISPs face the complexity of the women 
they’ve tried to contact for smears. They’ve had to sort out other issues; such 
as domestic violence because it’s not until a woman is in a stable situation 
that a smear is a possibility.” 
“To increase coverage and improve health literacy for women and their 
whānau a national proactive campaign needs to be reinstated, with targeted 
interventions to address disparities among ethnic groups in terms of 
participation and retention. This could include the use of social media.” 
 
Chapter 10: Colposcopy 
“Most of our colposcopists have no trouble maintaining the minimal numbers 
[colposcopy numbers as per NCSP Standards].” 
“I don’t think absolute numbers are very reflective on quality, maybe it needs 
to be considered only when there are concerns in terms of quality??” 
“Analyses of colposcopy data to support quality improvement are produced 
for the department as a whole annually for the annual clinical report. 
Individuals can pull their own data if wished.” 
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“Analyses of colposcopy data to support quality improvement could be 
obtained by audit of Gynae-Plus data – but audit and time to do this has been 
an issue in our department. We certainly are not provided this info by the 
NCSP-Register.” 
“Increasing nursing colposcopies would be good and increasing access.” 
 
Chapter 11: Human papillomavirus (HPV) and cervical cancer 
Primary HPV screening 
“The introduction of any such programmes must be preceded by information 
and education for both the public and health professionals. The evidence for 
such a programme and the support or treatment that can be provided to 
those testing positive should also be considered. We agree this will have 
workforce implications and such a programme should not proceed without 
attention to there being an adequate workforce in place both in laboratories 
and in health professionals who are trained to give information and support to 
those being tested and those who test positive.” 
 
HPV immunisation 
“I am unsure which agencies are the key stakeholders for implementation of 
HPV vaccination, but uptake in New Zealand has been disappointing 
compared to Australia. I have heard all sorts of reasons given why the New 
Zealand rate is lower than that in Australia, but I wonder if New Zealand 
agencies are doing enough to learn from successful strategies used in 
Australia.” 
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Appendix G: Agreement between the New Zealand 
Government and Southern Community Laboratories 
Ltd for Laboratory Training Services 
Provider No: 420619 / Contract No: 347182/00. 28.06.2013 
 
Section C Service Specification to: 
 develop and maintain a well-informed quality workforce for the cervical screening 
laboratory services 
 provide comprehensive training in four to eight regions to all laboratory sector groups 
 establish an Independent Training Committee 
 scope a national laboratory workforce training needs assessment 
 provide an informative annual newsletter 
 provide a scholarship fund 
 provide training plans for each of the laboratory sector groups 
 provide a plan for the HPV screening programme. 
 
Agreement: NZ Govt. and Southern Community Laboratories Ltd. Laboratory Training 
Services. Provider No: 420619 / Contract No: 347182/00. 30.04.14 
 
Section C Service Specification: 
C.1.1. To enable histoscientists, molecular scientists and cytoscientists/technicians 
attend the 2014 New Zealand Institute of Medical Laboratory Science 
(NZIMLS) annual scientific meeting in Dunedin on 14 August 2014 
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Appendix H: Colposcopy audit status 
Corrective Action Request (CAR) status 1 April 2015 
District Health Boards 
audited in current 
round (by audit date) 
Date final report 
received 
Corrective Action Requests Corrective Action 
Request status 
Total High CARs closed 
Waitemata 2 June 2011 7 5 7 All CARs cleared 
Counties Manukau 13 June 2011 10 2 10 All CARs cleared 
Auckland 15 July 2011 4 2 4 All CARs cleared 
Waikato 1 August 2011 14 6 14 All CARs cleared 
Hutt Valley 9 February 2012 13 6 13 All CARs cleared 
Lakes 9 February 2012 18 6 17 All CARs cleared 
Bay of Plenty 8 March 2012 13 9 11 All CARs cleared 
West Coast 26 March 2012 8 3 8 All CARs cleared 
Capital & Coast 26 March 2012 12 6 0 All CARs cleared 
Wairarapa 26 March 2012 15 6 15 All CARs cleared 
Hawke’s Bay 4 July 2012 9 3 9 All CARs cleared 
Canterbury 5 July 2012 9 1 9 All CARs cleared 
Southern (Southland) 9 July 2012 6 2 5 All CARs cleared 
MidCentral 15 November 2012 11 1 11 All CARs cleared 
Taranaki 2 November 2012 8 3 8 All CARs cleared 
Southern (Otago) 26 November 2012 4 1 4 All CARs cleared 
Tairawhiti 5 February 2013 5 2 5 All CARs cleared 
Whanganui 7 March 2013 6 1 6 All CARs cleared 
Northland 12 June 2013 11 2 5 All CARs cleared 
South Canterbury 3 July 2013 10 2 10 All CARs cleared 
Nelson Marlborough 29 July 2013 12 9 11 All CARs cleared 
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Appendix I: Summary of Standards in Section 6: 
Providing a Colposcopy Service, of NCSP Policies and 
Standards 
Source: Ministry of Health (2013) 
 
Standard 603: One hundred percent of medical notes accurately record colposcopic 
findings at first and subsequent assessments (as per the data requirements listed in 
Appendix 2 of Section 6), and these are sent electronically to the National Cervical 
Screening Programme-Register (NCSP-R). 
 
Standard 604: Ninety percent or more of women will have been sent, and/or will have 
had discussed with them, their definitive diagnosis within 30 working days of their 
colposcopy visit. 
 
Standard 606: Eighty percent of women receiving large loop excision of the 
transformation zone (LLETZ) treatment are managed as outpatients/day patients under 
local analgesia. 
 
Standard 607: One hundred percent of women who have ablative treatment have had 
an adequate biopsy taken for histological diagnosis. 
 
Standard 608: Ninety percent or more of women treated for CIN2-3 should: 
 have a colposcopy and smear within the nine-month period post-treatment 
 be discharged back to the smear taker as appropriate. 
 
Standard 610: One hundred percent of colposcopy clinics and colposcopists 
participating in the NCSP must meet the requirements outlined in this standard to 
ensure colposcopy services are adequately staffed. 
 
Standard 611: One hundred percent of colposcopists: 
 maintain a minimum of 50 new cases per annum in New Zealand (the ideal number 
is 100 per annum), or a minimum of 150 cases over a three-year period 
 participate in continuing education activities, including peer review (including MDMs, 
audits, collegial review, Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists requirements, case presentations) and attendance at a national 
or international colposcopy meeting at least every three years. 
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The following standards apply to the provision of colposcopy services by District Health 
Boards, and colposcopists should be aware of these: 
 Standard 601: Recording referrals and informing women about colposcopy. 
 Standard 602: Ensuring timeliness of colposcopic assessment. 
 Standard 605: Ensuring the timeliness of, and appropriate selection for, treatment. 
 Standard 609: Managing women who did not attend. 
 Standard 612: Providing an adequate clinical environment. 
 Standard 613: Provision of colposcopy data to the NCSP-R. 
 
Typically all of the above Standards are monitored through audits undertaken by the 
NCSP and some regular reporting through the contract monitoring process. 
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Appendix J: Overview of HPV tests (a) signal and 
(b) target amplification 
Sub-division Technology Supplier Comments and applications 
(a) Hybridisation In situ hybridisation INFORM HPV III 
(Roche) 
Kits with cocktails of HPV Family 6 or 
HPV Family 16 probes for both 
cytology and tissue applications 
 Solution hybridisation 
and capture of RNA 
probes complementary 
to L1 DNA sequences 
hc2 (Qiagen) Detects 13 hrHPV types in 
aggregate. 
Well-established assay for cervical 
screening and disease management 
 As above Care 
HPV (Qiagen) 
Simplified version of hc2 suitable for 
field testing in low-resourced 
countries 
 Solution hybridisation 
with probe oligo and 
‘Invader’ oligo 
Cervista HPV HR 
(Hologic) 
Novel approach using cleavase 
enzyme; detects 14 hrHPV types 
across three species-specific wells. 
Approved for cervical screening an 
disease management 





Degenerate / multiplex / 
consensus primers 
MY09/11; PGMY Generalised amplification against L1 
sequences 
  GP5+/6+ GP5+/6+used extensively clinically 
for cervical screening especially in 
the Netherlands 
Consensus DNA 
real-time PCR with 
limited genotyping 




RealTime HR HPV 
(Abbott Molecular, IL, 
USA); Cobas 4800 
HPV (Roche) 
Detect HPV 16 and 18 individually 
and other hrHPVs in aggregate; 
suitable for cervical screening with 
risk stratification beyond 





Aptima HPV (GenProbe 
now Hologic) 
Detection of E6/E7 HPV mRNA 
(14 hrHPV types); evidence for 
increased specificity, particularly in 
triage contexts 
RNA amplification 
with limited typing 
NASBA and type 
specific resolution using 
molecular beacons for 
5 hrHPV types 
HPV Proofer (Norchip, 
Klokkarstua, Norway) 
High specificity but lower sensitivity 
due to limited type range (HPV 16, 
18, 31, 33, 45) 
  Nuclisens HPV 
(Biomerieux, Marcy 
L’Etoile, France) 
Note: HPV Proofer is available in 
Scandinavia and UK; Nuclisens HPV 
is a similar test in mainland Europe 
Full genotyping CR with hybridisation 
using enzyme 
immunoassay (EIA) 
GP5+/6+-PCR-EIA As with all full genotyping assays – 
suitable for epidemiology and 
surveillance; R&D including 
detection in new conditions 
 PCR with reverse 
hybridisation of 
amplicons on nylon 
strips with immobilised 
probes 
Linear Array (Roche) Line blot based on PGMY primers 33 
  InnoLiPA (Innogenetics, 
Gent, Belgium) 
Line blot based on SPF10 primers; 
validated on FFPE sections and can 
be automated 
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Sub-division Technology Supplier Comments and applications 




PCR with microarray reverse 
hybridisation; targets 1 gene and 
involves simultaneous detection and 
genotyping of 24 low-risk and high-
risk types 
  CLART Â HPV2 
(Genomica, Coslada, 
Spain) 
Hybridisation to each probe in array 
in triplicate; detecting up to 35 types 
with visualisation using low-density 
arrays 




Sensitive, can be used to detect up 
to 100 different targets 
Mid range typing Multiplex real-time PCR BD Viper Assay (BD, 
NJ, USA) 
Recently developed by BD; offers 
consensus test result plus individual 
typing of 16, 18, 45, 31, 51 52, 
33/58, 59/56/66, 35/39/68 
Note: DNA = deoxyribonucleic acid; FFPE = formalin-fixed, paraffin-embedded; HPV = human papillomavirus; 
hrHPV = high-risk human papillomavirus; PCR = polymerase chain reaction; R&D = research and development; 
RNA = ribonucleic acid. 
Source: Cubie and Cuschieri (2013) 
 
  Report of the Parliamentary Review Committee 173 
 regarding the New Zealand Cervical Screening Programme 
References 
Abdul S, Brown BH, Milnes P, et al. 2006. The use of electrical impedance spectroscopy in the 
detection of cervical intraepithelial neoplasia. International Journal of Gynecological Cancer 16: 
1823–32. 
AHMAC (Australian Health Minister’s Advisory Council Government). 2014. Application No. 1276 – 






SAUGVidW_m4xj2g&bvm=bv.90790515,d.dGc&cad=rja (accessed April 2015). 
Ahmad OB, Boschi-Pinto C, Lopez AD, et al. 2001. Age Standardization of Rates: A new WHO 
standard. Geneva: World Health Organization. 
AIHW (Australian Institute of Health and Welfare). 2014. Cervical Screening in Australia 2011–2012. 
Cancer series no. 82. Cat. no. CAN 79. Canberra: AIHW. 
AIHW (Australian Institute of Health and Welfare). 2015. Cervical Screening in Australia 2012–2013. 
Cancer series no 93. Cat no. CAN 91. Canberra: AIHW. 
ALTS (ASCUS-LSIL Triage Study Group). 2003a. A randomized trial on the management of low-
grade squamous intraepithelial lesion cytology interpretations. American Journal of Obstetrics and 
Gynecology 188(6): 1393–1400. 
ALTS (ASCUS-LSIL Triage Study Group). 2003b. Results of a randomized trial on the management 
of cytology interpretations of atypical squamous cells of undetermined significance. American 
Journal of Obstetrics and Gynecology 188(6): 1383–392. 
Andermann A, Blancquaert I, Beauchamp S, et al. 2008. Revisiting Wilson and Jungner in the 
genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health 
Organization 86(4): 241–320. 
Auckland Regional Public Health Service. 2014. Maori Public Health Workforce Development 
Project. Report to Public Health Directorate Ministry of Health. URL: 
http://www.publichealthworkforce.org.nz/Data/media/documents/Maori%20PHWD/Maori%20PH%20
workforce%20development%20project-%20Tunks%2020%20Sept%2004.doc (accessed May 2015). 
Australian Population Health Development Principal Committee, Screening Subcommittee. 2008. 
Population Based Screening Framework. URL: 
http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/16AE0B0524753EE9C
A257CEE0000B5D7/$File/Population%20Based%20Screening%20Framework.docx (accessed April 
2015). 
Baker D, Middleton E. 2003. Cervical screening and health inequality in England in the 1990s. 
Journal of Epidemiology and Community Health 57: 417–23. 
Baseman JG, Koutsky LA. 2005. The epidemiology of human papillomavirus infections. Journal of 
Clinical Virology 31(1): 16–24. 
Bjerre P, Silfverdal L, Dillner L, et al. 2008. A randomized trial of basing treatment on human 
papillomavirus and/or cytology results in low-grade cervical lesion triage. American Journal of 
Obstetrics and Gynecology 199(1): 24. 
 174 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Bosch FX, Burchell AN, Schiffman M, et al. 2008. Epidemiology and natural history of human 
papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 19: 26 
(Suppl 10: K1–16). 
Bosch FX, Lorincz A, Muñoz N, et al. 2002. The causal relation between human papillomavirus and 
cervical cancer. Journal of Clinical Pathology 55(4): 244–65. 
Brotherton JML, Fridman M, May CL, et al. 2011. Early effect of the HPV vaccination programme on 
cervical abnormalities in Victoria, Australia: an ecological study. The Lancet 377 (9783): 2085–92. 
Burchell AN, Winer RL, de Sanjosé S, et al. 2006. Chapter 6: Epidemiology and transmission 
dynamics of genital HPV infection. Vaccine 24 (3):52–61. 
Burd EM. 2003. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews 
16(1): 1–17. 
Burk RD, Ho GY, Beardsley L, et al. 1996. Sexual behavior and partner characteristics are the 
predominant risk factors for genital human papillomavirus infection in young women. Journal of 
Infectious Diseases 174(4): 679–89. 
Cabell A, Gillett G, Gareth J. 1992. Practical Medical Ethics. Auckland: Oxford University Press. 
Canadian Partnership Against Cancer. 2013. Cervical Cancer Screening in Canada: Monitoring 
Program Performance 2009–2011. Toronto: Canadian Partnership against Cancer. 
Cancer Research UK. 2014. Cervical cancer mortality statistics. URL: 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/cervix/mortality/uk-cervical-cancer-
mortality-statistics (accessed April 2015). 
Canfell K, Castle P, Caruana M, et al. 2014. Protocol for Compass: A randomised controlled trial of 
primary HPV vs. cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women 
in Australia. URL: 
http://www.compasstrial.org.au/site/Compass/filesystem/documents/main/Compass%20Main%20Tri
al%20Protocol%20Exec-PP-12%20V1.pdf (accessed April 2015). 
Cartwright S. 1988. The Report of the Committee of Inquiry into Allegations Concerning the 
Treatment of Cervical Cancer at National Women’s Hospital and into Other Related Matters. 
Auckland: Government Printing Office. 
Castle PE, Stoler MH, Wright TC, et al. 2011. Performance of carcinogenic human papillomavirus 
(HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 
years and older: a subanalysis of the ATHENA study. Lancet Oncology 12 (9): 880–90. 
Cervical Cancer Audit and the University of Auckland. 2004. Cervical Cancer Audit Report: 
Screening of Women with Cervical Cancer, 2000–2002. Wellington: Ministry of Health. 
Chapman S. 2013. Paper to the National Health Board, Ministry of Health: NCSP Parliamentary 
Review Committee Free Smears Recommendation (unpublished). Wellington: National Screening 
Unit. 
Collins S, Mazloomzadeh S, Winter H, et al. 2002. High incidence of cervical human papillomavirus 
infection in women during their first sexual relationship. British Journal of Obstetrics and 
Gynaecology 109(1): 96–8. 
Colposcopy Quality Improvement Programme (C-QuIP). 2015. URL: 
http://www.cquip.edu.au/maintaining-certification.html (accessed April 2015). 
  Report of the Parliamentary Review Committee 175 
 regarding the New Zealand Cervical Screening Programme 
Creighton P, Lew JB, Clements M, et al. 2010. Cervical cancer screening in Australia: modelled 
evaluation of the impact of changing the recommended interval from two to three years. BMC Public 
Health 10: 734. 
Cubie HA, Cuschieri K. 2013. Understanding HPV tests and their appropriate applications. 
Cytopathology 24: 289–308. 
DeSantis T, Chakhtoura N, Twiggs L, et al. 2007. Spectroscopic imaging as a triage test for cervical 
disease: a prospective multicenter clinical trial. Journal of Lower Genital Tract Disease 11: 18–24. 
Dillner L, Kemetli L, Elfgren K, et al. 2011. Randomized health services study of human 
papillomavirus-based management of low-grade cytological abnormalities. International Journal of 
Cancer 129(1): 151–9. 
Duffy AP, Barrett DK, Duggan MA. 2001. Report of the Ministerial Inquiry into the Under-reporting of 
Cervical Smear Abnormalities in the Gisborne Region. Wellington: Ministry of Health. 
Duke University Medical Centre. 2014. Patient Safety – Quality Improvement. URL: 
http://patientsafetyed.duhs.duke.edu/module_a/introduction/contrasting_qi_qa.html (accessed April 
2015). 
Elfström KM, Smelov V, Johansson AL, et al. 2014. Long term duration of protective effect for HPV 
negative women: follow-up of primary HPV screening randomised controlled trial. British Medical 
Journal 16: 348: g130. 
FDA (Food and Drug Administration). 2014. FDA News Release: FDA approves Gardasil 9 for 
prevention of certain cancers caused by five additional types of HPV. URL: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm (accessed April 
2015). 
Ferris DG, Lawhead RA, Dickman ED, et al. 2001. Multimodal hyperspectral imaging for the 
noninvasive diagnosis of cervical neoplasia. Journal of Lower Genital Tract Disease 5: 65–72. 
Gage JC, Schiffman M, Katki HA, et al. 2014. Reassurance against future risk of precancer and 
cancer conferred by a negative human papillomavirus test. Journal of the National Cancer Institute 
106(8): dju153 doi: 10.1093/jnci/dju153. 
Geddes L. 2014. Simple urine test detects cervical cancer virus. New Scientist. URL: 
http://www.newscientist.com/article/dn26218-simple-urine-test-detects-cervical-cancer-
virus.html#.VT7G55Mx_CY (accessed April 2015). 
Georgakoudi I, Sheets EE, Muller MG, et al. 2002. Trimodal spectroscopy for the detection and 
characterization of cervical precancers in vivo. American Journal of Obstetrics & Gynecology 186: 
374–82. 
Gordon-Dseagu V. 2006. Cancer and Health Inequalities: An introduction to current evidence. 
Cancer Research UK. URL: 
http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/general
content/crukmig_1000ast-3344.pdf (accessed May 2015). 
Hale M. 2012. Essential Components of Organised Screening Programmes (unpublished). 
Wellington: National Screening Unit. 
Harris R, Cormack D, Tobias M, et al. 2012. The pervasive effects of racism: experiences of racial 
discrimination in New Zealand over time and associations with multiple health domains. Social 
Science & Medicine 74(3): 408–15. 
 176 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Health Foundation. 2009. Quest for Quality and Improved Performance. URL: 
http://www.health.org.uk/public/cms/75/76/313/563/QQUIP%20brochure.pdf?realName=LepS6D.pdf 
(accessed April 2015). 
Health Workforce New Zealand. 2014. Health of the Health Workforce 2013 to 2014. Wellington: 
Ministry of Health. 
Ho GY, Bierman R, Beardsley L, et al. 1998. Natural history of cervicovaginal papillomavirus 
infection in young women. New England Journal of Medicine 388(7): 423–8. 
Huh WK, Cestero RM, Garcia FA, et al. 2004. Optical detection of high-grade cervical intraepithelial 
neoplasia in vivo: results of a 604-patient study. American Journal of Obstetrics & Gynecology 190: 
1249–57. 
International Agency for Research on Cancer (World Health Organization). 2013. Global Cancer 
Burden. Press Release. URL: http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf 
(accessed April 2015). 
Jit M, Brisson M, Portnoy A, et al. 2014. Cost-effectiveness of female human papillomavirus 
vaccination in 179 countries: a PRIME modelling study. Lancet Global Health. e406–14. DOI: 
10.1016/S2214-109X(14)70237-2 (accessed March 2015). 
Karlsson R, Jonsson M, Edlund K, et al. 1995. Lifetime number of partners as the only independent 
risk factor for human papillomavirus infection: a population-based study. Sexually Transmitted 
Diseases 22(2): 119–27. 
Katki HA, Kinney WK, Fetterman B, et al. 2011. Cervical cancer risk for women undergoing 
concurrent testing for human papillomavirus and cervical cytology: a population-based study in 
routine clinical practice. Lancet Oncology 12(7): 663–72. 
Kitchener HC, Gilham C, Sargent A, et al. 2011. A comparison of HPV DNA testing and liquid based 
cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. 
European Journal of Cancer 47(6): 864–71. 
Kulasingam SL, Havrilesky L, Ghebre R, et al. 2011. Screening for Cervical Cancer: A decision 
analysis for the US Preventive Services Task Force. AHRQ Publication No. 11-05157-EF-1. 
Rockville, MD: Agency for Healthcare Research and Quality. 
Lorant V, Boland B, Humblet P, et al. (2002) Equity in prevention and health care. Journal of 
Epidemiology and Community Health 56: 510–16. 
Louwers JA, Kocken M, ter Harmsel WA, et al. 2009. Digital colposcopy: ready for use? An overview 
of literature. British Journal of Obstetrics and Gynaecology 116: 220–9. 
Louwers J, Zaal A, Kocken M, et al. 2011. Dynamic spectral imaging colposcopy: higher sensitivity 
for detection of premalignant cervical lesions. British Journal of Obstetrics and Gynaecology 118(3): 
309–18. 
McGoogan E. 2001. Progress in Implementing the Cervical Screening Inquiry Recommendations. 
URL: http://www.csi.org.nz/other_reports/McGooganReport1.pdf (accessed March 2015). 
McGoogan E. 2003. Final Report on the Review of Progress to Implement the Recommendations of 
the Gisborne Cervical Screening Inquiry. URL: 
http://www.csi.org.nz/other_reports/FinalReportOnTheReviewOFProgressGisborneCSI2003.pdf 
(accessed March 2015). 
Meijer C. 2015. Preventing Cervical Cancer Conference, Melbourne, Australia, 20–22 February 
2015. 
  Report of the Parliamentary Review Committee 177 
 regarding the New Zealand Cervical Screening Programme 
Milne BJ, Byun U, Lee A. 2013. New Zealand Socio-economic Index 2006. Wellington: Statistics 
New Zealand. 
Ministry of Health, Māori Health Group. 1994. Kia Whai Te Maramatanga: The Effectiveness of 
Health Messages to Māori. Wellington: Ministry of Health. 
Ministry of Health. 2002. Reducing Inequalities in Health. Wellington: Ministry of Health. 
Ministry of Health. 2003. A guide to developing health promotion programmes in primary health care 
settings. Wellington: Ministry of Health. 
Ministry of Health. 2004. Ethnicity Data Protocols for the Health and Disability Sector. Wellington: 
Ministry of Health. 
Ministry of Health. 2006. Health Workforce Development: An overview. Wellington: Ministry of 
Health. 
Ministry of Health. 2009. Meeting the Challenge: Enhancing sustainability and the patient and 
consumer experience within the current legislative framework for health and disability services in 
New Zealand. Report of the Ministerial Review Group (also known as The Horn Report). Wellington: 
Ministry of Health. 
Ministry of Health. 2010. Kōrero Mārama: Health Literacy and Māori. Results from the 2006 Adult 
Literacy and Life Skills Survey. Wellington: Ministry of Health. 
Ministry of Health. 2013. National Cervical Screening Programme Policies and Standards: Section 6 
– Providing a Colposcopy Service. Wellington: Ministry of Health. URL: 
https://www.nsu.govt.nz/system/files/page/ncsp_policies_and_standards_section_6_providing_a_col
poscopy_service_june_2014_0.pdf (accessed March 2015). 
Ministry of Health. 2014a. National Cervical Screening Programme Policies and Standards: 
Section 1 – NCSP Overview. Wellington: Ministry of Health. 
Ministry of Health. 2014b. PHO Performance Management Programme. URL: 
http://www.health.govt.nz/system/files/documents/pages/phoperfmagmtsummaryinfo.pdf (accessed 
April 2014). 
Ministry of Health and University of Otago. 2006. Decades of Disparity III: Ethnic and socioeconomic 
inequalities in mortality, New Zealand 1981–1999. Wellington: Ministry of Health. 
Mitchell MF, Cantor SB, RamanujamN, et al. 1999. Fluorescence spectroscopy for diagnosis of 
squamous intraepithelial lesions of the cervix. Obstetrics & Gynecology 93(3): 462–70. 
MSAC (Medical Services Advisory Committee). 2013. National Cervical Screening Program 
Renewal: Evidence review. MSAC application no 1276. Assessment report. Canberra: MSAC. 
MSAC (Medical Services Advisory Committee). 2014. Errata: Amendments to the Combined 
Executive Summary and the main report for the Evidence Review 
http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/E6A211A6FFC29E2C
CA257CED007FB678/$File/15%20May%202014%20Errata%20for%20the%20Renewal%20Evidenc
e%20Review%20and%20Combined%20Executive%20Summary.pdf (accessed March 2015). 
Muñoz N, Bosch FX, de Sanjosé S, et al. 2003. Epidemiologic classification of human papillomavirus 
types associated with cervical cancer. New England Journal of Medicine 348: 518–27. 
Muñoz N, Bosch FX, Castellsague X, et al. 2004. Against which human papillomavirus types shall 
we vaccinate and screen? The international perspective. International Journal of Cancer 
111: 278–85. 
 178 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
National Cancer Institute. 2014. URL: http://www.cancer.gov/cancertopics/types/cervical/pap-hpv-
testing-fact-sheet (accessed April 2015). 
National Health Committee. 2015. An Overview of Screening in New Zealand. Wellington: National 
Health Committee. 
NCPTS (National Cervical Pathology Training Service). 2014. National Cervical Pathology Training 
Service Annual Report (1 July 2013 – 30 June 2014). 
NCSP (National Cervical Screening Programme). 2009 Today and into the Future. A strategic plan 
for 2009 to 2014. URL: https://www.nsu.govt.nz/system/files/page/ncsp_strategic_plan_2009-
2014.pdf (accessed May 2015). 




%20Programme-Register? (accessed April 2015). 
NCSP (National Cervical Screening Programme). 2014b. National Cervical Screening Programme 
Register Stack Upgrade Project Business Case (unpublished). Wellington: Ministry of Health. 
NICE (National Institute for Health and Care Excellence). 2012. Adjunctive Colposcopy 
Technologies for Examination of the Uterine Cervix – DySIS and the Niris Imaging System. URL: 
http://www.nice.org.uk/guidance/dg4/resources/adjunctive-colposcopy-technologies-for-examination-
of-the-uterine-cervix-dysis-and-the-niris-imaging-system-29272302277 (accessed April 2015). 
NICE (National Institute for Health and Care Excellence). 2015. The ZedScan as an adjunct to 
colposcopy in women with suspected cervical intra-epithelial neoplasia. URL: 
http://www.nice.org.uk/advice/mib20/chapter/Summary (accessed April 2015). 
NSU (National Screening Unit). 2006. Report on the findings of a review of District Health Board 
Colposcopy Services. URL: https://www.nsu.govt.nz/system/files/resources/dhb-colposcopy-
services_review.pdf (accessed March 2015). 
NSU (National Screening Unit). 2008. Guidelines for Cervical Screening in New Zealand. URL: 
https://www.health.govt.nz/system/files/documents/publications/cervical-screening-guidelines-
aug08.pdf (accessed June 2015). 
NSU (National Screening Unit). 2010. Strategic Plan 2010 to 2015. Wellington: National Screening 
Unit. 
NSU (National Screening Unit). 2012a. National Cervical Screening Programme Monitoring Report 
Number 34. 1 July to 31 December 2010. URL: 
https://www.nsu.govt.nz/system/files/page/ncsp_monitoring_report_34_final_errata_oct_2012.pdf 
(accessed April 2015). 
NSU (National Screening Unit). 2012b. Discussion Document: Proposal for Organisational Change 
for the National Screening Unit (unpublished). Wellington: National Screening Unit. 
NSU (National Screening Unit). 2014a. National Cervical Screening Programme Annual Report 
2012. URL: https://www.nsu.govt.nz/system/files/page/annual_report_2012.pdf (accessed March 
2015). 
NSU (National Screening Unit). 2014b. National Cervical Screening Programme Monitoring Report 
Number 40. 1 July to 31 December 2013. URL: 
https://www.nsu.govt.nz/system/files/page/monitoringreport40_final.pdf (accessed March 2015). 
  Report of the Parliamentary Review Committee 179 
 regarding the New Zealand Cervical Screening Programme 
NSU (National Screening Unit). 2014c. National Screening Unit Quality Framework 2014: Delivering 
screening programmes (in publication). 
NSU (National Screening Unit). 2014d. Understanding HPV, HPV Testing, Cervical Cancer and the 
HPV Vaccine. URL: https://www.nsu.govt.nz/national-cervical-screening-programme/hpv-and-
cervical-cancer (accessed April 2015). 
NSU (National Screening Unit). 2014e. New and Future Developments. URL: 
https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/new-and-
future-developments (accessed May 2015). 
OAG (Office of the Auditor-General). 2002. Ministry of Health: Progress in Implementing the 
Recommendations of the Cervical Screening Inquiry. Wellington, New Zealand: Controller and 
Auditor General. 
OAG (Office of the Auditor-General). 2003. Ministry of Health: What further progress has been made 
to implement the recommendations of the Cervical Screening Inquiry? Wellington, New Zealand: 
Controller and Auditor General. 
OECD (Organisation for Economic Co-operation and Development). 2013. Cervical cancer 
screening in women aged 20-69, 2001 to 2011 (or nearest year). In Health at a Glance 2013. Paris: 
OECD Publishing. DOI: http://dx.doi.org/10.1787/health_glance-2013-graph114-en 
Parker MF. 2005. Emerging technology in cervical cancer screening: spectroscopy. Clinical 
Obstetrics and Gynecology 48(1): 209–17. 
Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. 
International Journal of Cancer 118: 3030–4. 
Pathak N, Dodds J, Zamora J, et al. 2014. Accuracy of urinary human papillomavirus testing for 
presence of cervical HPV: systematic review and meta-analysis. British Medical Journal 349: g5264. 
Pearson AL, Kvizhinadze G, Wilson N, et al. 2014. Is expanding HPV vaccination programs to 
include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an 
existing school-girl program. BMC Infectious Diseases 14: 351. DOI: 10.1186/1471-2334-14-351 
(accessed March 2015). 
Public Health Advisory Committee. 2004. The Health of People and Communities. A way forward: 
Public health policy and the economic determinants of health. Wellington: Public Health Advisory 
Committee. 
Public Health Agency of Canada. 2009. Report from the Screening Performance Indicators Working 
Group, Cervical Cancer Prevention and Control Network (CCPCN): January 2009. URL: 
http://www.phac-aspc.gc.ca/cd-mc/cancer/pmccspc-srpdccuc/index-eng.php (accessed April 2015). 
Public Health England, Department of Health, NHS England. 2014. Change from three to two doses 
in the HPV vaccination programme schedule. URL: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/310958/HPV_Joint_Le
tter_14_May.pdf (accessed April 2015). 
Richardson H, Kelsall G, Tellier P, et al. 2003. The natural history of type-specific human 
papillomavirus infections in female university students. Cancer Epidemiology, Biomarkers & 
Prevention (6):485–90. 
Robson B, Harris R (eds). 2007. Hauora: Māori Standards of Health IV. A study of the years 
2000–2005. Wellington: Te Rōpū Rangahau Hauora a Eru Pōmare. 
 180 Report of the Parliamentary Review Committee 
regarding the New Zealand Cervical Screening Programme 
Ronco G, Dillner J, Elfström K, et al. 2014. Efficacy of HPV-based screening for prevention of 
invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 
383(9916): 524–32. 
Scally G, Donaldson LJ. 1998. Clinical governance and the drive for quality improvement in the new 
NHS in England. British Medical Journal 317: 61. 
Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services 
Task Force [Internet].Evidence Syntheses, No. 86.Vesco KK, Whitlock EP, Eder M, et al.Rockville 
(MD): Agency for Healthcare Research and Quality (US); 2011 May. 
Simcock B, Sykes P. 2014. Protocol: PRINCess, The Prediction of Regression in CIN2 A 
prospective multicentre trial of conservative management of CIN2 in women under the age of 25. 
University of Otago and Canterbury District Health Board. URL: 
http://www.otago.ac.nz/christchurch/otago073807.pdf (accessed April 2015). 
Simonella LM, Lewis H, Smith M, et al. 2013. Type-specific oncogenic human papillomavirus 
infection in high grade cervical disease in New Zealand. BMC Infectious Diseases 13:114. URL: 
http://www.biomedcentral.com/1471-2334/13/114 (accessed April 2015). 
Singer A, Coppleson M, Canfell K, et al. 2003. A real time optoelectronic device as an adjunct to the 
Pap smear for cervical screening: a multicenter evaluation. International Journal of Gynecological 
Cancer 13(6): 804–11. 
Solomon D, Davey D, Kurman R, et al. 2002. The 2001 Bethesda System: terminology for reporting 
results of cervical cytology. Journal of the American Medical Association 287 (16): 2114–19. 
Soutter WP, Diakomanolis E, Lyons D, et al. 2009. Dynamic spectral imaging: improving colposcopy. 
Clinical Cancer Research 15(5): 1814–20. 
Stevens MP, Garland SM, Tan JH, et al. 2009. HPV genotype prevalence in women with abnormal 
pap smears in Melbourne, Australia. Journal of Medical Virology 81(7): 1283–91. 
Strauss S, Sastry P, Sonnex C, et al. 2002. Contamination of environmental surfaces by genital 
human papillomaviruses. Sexually Transmitted Infections 78(2): 135–8. 
Tan JHJ, Thompson LH, Howlett RI. 2011. Report of the Parliamentary Review Committee regarding 
the New Zealand Cervical Screening Programme. Wellington: Ministry of Health. 
Tan JHJ, Wrede CDH. 2011. New technologies and advances in colposcopic assessment. Best 
Practice and Research Clinical Obstetrics & Gynaecology 25(5): 667–77. 
Tang N, Huang S, Erickson B, et al. 2009. High-risk HPV detection and concurrent HPV 16 and 18 
typing with Abbott RealTime High Risk HPV test. Journal of Clinical Virology 45 (1): 25–8. 
Te Manawa Hauora. 1993. Hui Whakamarama: Report of a consensus hui concerning screening 
amongst Māori. Wellington: Te Manawa Hauora, Wellington School of Medicine, University of Otago. 
Thai H, Rangwala S, Gay T, et al. 2009. An HPV 16, 18, and 45 genotyping test based on Hybrid 
Capture® technology. Journal of Clinical Virology 45(1): 93–7. 
Tidy JA, Brown BH, Healey T, et al. 2013. Accuracy of detection of high-grade cervical intraepithelial 
neoplasia using electrical impedance spectroscopy with colposcopy. British Journal of Obstetrics 
and Gynaecology 120: 400–11. 
WHO (World Health Organization). 2002. National Cancer Control Programmes: Policies and 
managerial guidelines. 2nd edition. Geneva: World Health Organization. URL: 
http://www.who.int/cancer/media/en/408.pdf (accessed April 2015). 
  Report of the Parliamentary Review Committee 181 
 regarding the New Zealand Cervical Screening Programme 
WHO (World Health Organization). 2006a. Cancer Control: Knowledge into action. WHO Guide for 
Effective Programmes. URL: http://www.who.int/cancer/modules/Planning%20Module.pdf (accessed 
April 2015). 
WHO (World Health Organization). 2006b. Quality of Care. A process for making strategic choices in 
health systems. URL: http://www.who.int/management/quality/assurance/QualityCare_B.Def.pdf 
(accessed April 2015). 
WHO (World Health Organization). 2007. Community Health Workers: What do we know about 
them? The state of the evidence on programmes, activities, costs and impact on health outcomes of 
using community health workers. URL: 
http://www.who.int/hrh/documents/community_health_workers.pdf (accessed April 2015) 
WHO (World Health Organization). 2011. First Ministerial Conference on Healthy Lifestyles and 
Noncommunicable Disease Control. Moscow, 28–29 April 2011. Conference Proceedings. URL: 
http://www.who.int/nmh/events/moscow_ncds_2011/conference_documents/conference_report.pdf?
ua=1 (accessed April 2015). 
WHO (World Health Organization). 2013. WHO Guidelines for Screening and Treatment of 
Precancerous Lesions for Cervical Cancer Prevention. URL: 
http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf (accessed April 2015). 
WHO (World Health Organization). 2014. Comprehensive Cervical Cancer Control: A guide to 
essential practice. 2nd edition. URL: 
http://apps.who.int/iris/bitstream/10665/144785/1/9789241548953_eng.pdf (accessed April 2015). 
WHO (World Health Organization). 2015a. Health Statistics and Information Systems. Metrics: 
Disability-Adjusted Life Year (DALY). URL: 
http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/ (accessed April 2015). 
WHO (World Health Organization). 2015b. Health Systems Strengthening Glossary URL: 
http://www.who.int/healthsystems/hss_glossary/en/index7.html (accessed April 2015). 
WHO (World Health Organization), PAHO (Pan American Health Organization). 2013. Monitoring 
National Cervical Cancer Prevention and Control Programmes: Quality control and quality assurance 
for visual inspection with acetic acid (VIA)-based programmes. URL: 
http://www.who.int/reproductivehealth/publications/cancers/9789241505260/en/ (accessed April 
2015). 
Woodman CB, Collins S, Winter H, et al. 2001. Natural history of cervical human papillomavirus 
infection in young women: a longitudinal cohort study. The Lancet 357(9271): 1831–6. 
